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Abstract 
 
Various bioactive wound dressing materials exist on the market that are designed to aid 
recovery and comfort of patients with chronic wounds. However, one of the persistent issues is 
the control of bacterial activity in the wound, which can influence infection rates, efficacy of 
wound healing and odour generation. A key requirement of a wound dressing is to facilitate a 
moist wound-healing environment and simultaneously control the growth of bacteria using an 
antibacterial agent. Manuka honey is currently utilised in bioactive wound dressing materials as 
an antibacterial agent via the direct impregnation or coating of honey onto a suitable material. It 
provides a unique antibacterial potency, attributable to one of its constituents, methylglyoxal 
(MGO). Commercially, there have been relatively few examples of electrospun fabric 
components being integrated into advanced wound care products. However, many studies have 
explored the potential of electrospun webs as part of a novel wound dressing material, due to 
their inherent nano and micro-fibrous structure, which provides a high surface area available for 
active delivery. 
 
In this research, synthetic MGO was evaluated for its effectiveness as a novel antibacterial 
agent, when encapsulated into an electrospun poly(vinyl alcohol) (PVA) hydrogel forming web. 
In the first phase of this research, the antibacterial activity of both Manuka honey and synthetic 
MGO when applied as a topical coating to a nonwoven fabric was assessed via two British 
standard methods using Gram positive and Gram negative bacteria in-vitro. BS EN ISO 
20743:2007 was employed as a quantitative method to establish if Manuka honey and synthetic 
MGO provided an antibacterial effect at equivalent MGO concentrations. It was found that 
concentrations of 0.0054 mg cm
-2
 of MGO in the form of Manuka honey and synthetic MGO 
was sufficient to achieve 100% reduction in bacteria for both Gram positive and Gram negative 
strains. Further tests were then carried out using BS EN ISO 20645:2004, which assessed the 
zone of inhibition using a seeded bacteria agar plate. In this case, higher concentrations between 
0.0170 mg cm
 -2 
and 0.1 mg cm
-2
 were required to facilitate a good antibacterial effect. The 
minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) was 
also assessed for MGO in liquid form against the three most prevalent wound pathogens, 
Staphylococcus. aureus, Pseudomonas. aeruginosa and Enterococcus. faecalis. Concentrations 
similar to that found in the literature, between and 128 mg L
-1
 and 1024 mg L
-1
 were shown to 
provide either a bacteriostatic or bactericidal effect. Most importantly, the MIC and MBC of 
MGO against Enterococcus. faecalis was reported for the first time. 
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The encapsulation of synthetic MGO in electrospun PVA fibres was explored using both needle 
and free surface (needleless) electrospinning technologies, with a successful outcome. It was 
found that an 11.22 wt % MGO solution with 16% (w/v) PVA was most favourable for 
producing fibres free from beads when using needle electrospinning. A higher PVA 
concentration of 20% (w/v) was required to achieve bead free fibres using free surface 
electrospinning. Two different collector materials were utilised during free surface 
electrospinning, where an aluminium foil collector was found to produce a smaller mean fibre 
diameter when compared with a less conductive polypropylene spundbond substrate. 
Characterisation of the as-spun webs was determined via Fourier transform infrared 
spectroscopy (FTIR) and proton nuclear magnetic resonance (NMR), where the presence of 
MGO in the PVA webs was confirmed by the characteristic carbonyl groups associated with 
MGO’s keto-aldehyde groups. A continuation of the zone of inhibition method highlighted that 
concentrations of MGO between 1.14 mg cm
-2
 and 1.50 mg cm
-2
 were required to have an 
antibacterial effect in-vitro.   
 
Finally the release behaviour of MGO from the electrospun webs was investigated using high 
performance liquid chromatography (HPLC). Crosslinking of the PVA/MGO webs with 
glutaraldehyde (GA), in the form of a vapour and a novel plasma technique showed promising 
results for controlling the release rate of MGO from the fibres. Prior to crosslinking, 93.7% of 
the MGO was released from the PVA fibres within 30 minutes. After crosslinking the amount of 
MGO released was considerably reduced over a period of 24 h, with a maximum of 75% 
released. The novel plasma crosslinking technique was further confirmed using FTIR and it is 
believed this is the first time this technique has been employed. 
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Textile materials are commonly used as health care and medical products, in applications such 
as blood filtration, infection control, implantable materials, tissue regeneration, drug delivery 
and wound care. (1). With the global population set to rise to 9.6 billion by 2050 (2), and an 
increase in the number of people aged 65 and above (3), it is expected that demand for 
improved health care products will continue to grow. Owing to the ageing population, 
growing rates of diabetes and obesity, chronic wounds are an increasing problem. Such 
wounds are extremely burdensome to health care providers and to patients because they do not 
heal in a progressive manner and can persist for months or even years. Wound care is 
estimated to account for about 3% of the NHS expenditure, equivalent to £2.3 - £3.1 billion, 
largely because of the nursing staff costs. Chronic wounds in particular represent a large 
portion of the cost, and affect around 200,000 patients (4). Pressure ulcers, venous leg ulcers, 
diabetic foot ulcers and arterial insufficiency ulcers are all known as chronic wounds (5). They 
cause patients serious discomfort and delayed healing as a result of infection from numerous 
strains of bacteria and bacteria biofilms, including Methicillin-resistant Staphylococcus aureus 
(MRSA), Escherichia coli (E.Coli), Pseudomonos aeruginosa (P.aeruginosa) and 
Enterococcus faecalis (E.faecalis) (6). As bacteria start to show resistance to antibiotics (7, 8) 
the use of topical bioactive wound dressings are increasingly being used in the treatment of 
infected chronic wounds (9). The excessive use of silver-based antimicrobials, used for the 
treatment of infected wounds, has recently been highlighted as a potential concern owing to 
potential toxic effects within the human body (argyria) (10), cyctotoxic effects on cells 
required for wound healing (11, 12) and bacterial resistance (13, 14). As a result, despite the 
widespread use of silver in commercial dressings, alternatives are being actively sought, 
particularly by the large manufacturers in Europe. It is for this reason that the controlled 
delivery of new topical antimicrobials in wound care, is of interest in the development of new 
wound dressings (15, 16). 
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1.1 Bioactive wound dressing materials 
“Bioactive dressings are dressings which deliver substances active in wound healing; either 
by delivery of bioactive compounds or constructed from materials having endogenous 
activity”. This type of dressing belongs to the Food and Drugs Administration (FDA) category 
of interactive dressings (17). In 1962 and 1963 the work by George Winter contributed to a 
significant advancement in wound care. He demonstrated that when the wound surface of a 
pig was kept moist with a polythene film, healing was more rapid when compared to a wound 
left exposed to the air. This is because a moist wound environment encourages epithelisation 
to be twice as fast and reduces the formation of scarring (18, 19). Present theories of modern 
wound care are based on maintaining a moist wound environment, the ability to promote 
healing, absorb wound exudate, provide mechanical protection against microorganisms and 
the removal of a dressing without pain or trauma (20). The majority of current bioactive 
dressings are able to fulfil these requirements by the use of biopolymers. Hydrogels and 
hydrocolloids are two types of bioactive dressings, which fall into this category. 
Hydrocolloids contain gel-forming agents, such as carboxymethylcellulose, gelatin or pectin 
(21). These materials absorb the wound fluid (exudates) and transform into a jelly-like state, 
which keeps the wound hydrated and enables a low adherent wound contact layer. Normally 
these materials are combined with elastomers or adhesives in the form of a foam or film 
carrier material to produce an occlusive or semi-occlusive dressing (22). Hydrogels are semi-
occlusive and composed of hydrophilic synthetic and natural polymers, such as 
poly(methacrylates), polyvinylpyrrolidine and alginates. They contain large amounts of water 
(70-90%) and are able to absorb moderate amounts of wound exudates (21). Hydrogels are 
able to provide a soothing and cooling effect and can be useful in treatment of burns and 
painful wounds (22). As well as hydrating the wound, a bioactive dressing may incorporate 
agents active in wound healing, including cleansing or debriding agents for removing necrotic 
tissue, growth agents to aid tissue regeneration and antimicrobials to prevent or combat 
infection (21).  
1.2 Topical antimicrobials in wound care 
Antimicrobials in the form of systemic antibiotics or topical therapies are frequently used in 
the treatment of infected chronic wounds. Topical antimicrobials are chemicals which are used 
to either kill or inhibit the growth of microorganisms on the wounds surface (23). All wounds 
contain microorganisms, though not all microorganisms cause infection and healing can occur 
successfully without intervention. In this case the bioburden of the wound and the patient’s 
immune system are in balance. However, when the bioburden of the wound is impaired due to 
multiplication of microorganisms (24) resulting in ‘critical colonisation’ (25),  direct 
intervention is required. Systemic antibiotic treatment is usually prescribed as the first course 
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of treatment, however as the resistance to systemic antibiotic continues, topical antimicrobial 
(8) therapy is increasingly utilised in chronic wound care (25, 26). Traditionally topical 
antimicrobials have been formulated as ointments or creams (26), but recent advancements 
have seen the incorporation of antimicrobial agents into dressings (17) including 
chlorhexidine, iodine, silver, polyhexamethylenebiguanide (PHMB), honey and glucose 
oxidase enzyme systems (27). The ultimate goal of a topical antimicrobial agent is to control 
and prevent the growth of microorganisms to the stage of critical colonisation where infection 
prevails (28). It is important that a balance is found by reducing the bioburden while avoiding 
cytotoxicity to cells. An ideal topical antimicrobial should have broad spectrum activity 
against bacterial organisms, minimal systemic absorption, no impedance to wound healing, 
have good eschar penetration, be painless and inexpensive (29). Furthermore the dressing 
should be contained in contact with the wound for 12 hours or more allowing the 
antimicrobial agent to remain active for the duration of wear time (27). Silver, the 
predominant antimicrobial agent currently used in the treatment of chronic infections is 
available in many forms, including ionic, metallic and nanocrystalline (29). Silver has been 
proven to have antimicrobial activity against a broad range of microorganisms (30) and 
contribute towards the healing of infected chronic wounds (31). Durafiber (Smith and 
Newphew) is an example of a nonwoven product that combines gel forming fibres, in this case 
cellulose ethyl sulphonate, with ionic silver to create both cooling and antimicrobial effects 
when in contact with the wound. The silver ions start to kill bacteria after 30 minutes post 
application, with sustained release for up to 7 days (32). Although the benefits of silver have 
been extensively reported in the wound care community (33), some scepticism exists because 
of concerns about cytotoxicity and bacterial resistance (34). Consequently, alternative topical 
antimicrobial agents continue to be an active area of current research. 
1.3 Honey as a topical antimicrobial in wound care 
Natural products and remedies have been used for many years in wound care and recently 
there has been an increased interest in identifying appropriate antimicrobial compounds.  
Many natural products are known to provide antimicrobial, astringent, anti-inflammatory and 
bio stimulant properties (35). In 1999 an editorial in ‘Advances in Wound Care’, suggested 
that “unproven complementary and alternative medicine strategies and opinions provide us 
with a tremendous opportunity to re-examine old treatments and apply them in the current 
environment” (36). In the last two decades honey, which is an ancient wound treatment, has 
been reintroduced as a traditional and natural remedy in the treatment of chronic wounds (37, 
38). Honey is known to have antibacterial properties and an ability to assist in debridement 
and deodorisation of wounds as well as having anti-inflammatory properties and an ability to 
stimulate tissue growth (37).  Manuka honey in particular has received considerable attention 
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owing to its antibacterial properties compared to conventional honeys. This characteristic 
known as the Unique Manuka Factor (UMF) has been linked to the presence of methylglyoxal 
(MGO) (39). MGO or MG contains ketone and aldehyde functional groups and is present as a 
metabolite in the human body and various food and drink sources. Numerous studies have 
reported beneficial effects of MGO in the treatment of numerous pathogens and diseases 
including cancers (40-42), viruses (43, 44) and bacterial pathogens found in wounds (45-47). 
Currently Manuka honey dressings are manufactured by the direct impregnation of the honey 
onto fibres in preformed fabrics via processes such as coating. This can make the dressing 
very sticky and impractical for clinicians or patients to handle. When applied to exuding 
wounds the honey can also become unevenly liquefied, which can lead to it running off the 
wound (17). To overcome this problem, a potential alternative is to encapsulate MGO within 
the fibres during the spinning process. It is common practice to suspend or dissolve an 
antimicrobial compound or drug into a polymer solution, which is then used to produce fibres 
(48). Using such an approach, when the dressing is in contact with the wound exudates, the 
antimicrobial agent could be potentially released from the fibre at a controlled rate of delivery. 
1.4 Electrospun polymeric webs as delivery vehicles for 
antimicrobial compounds 
In the last decade electrospinning of sub-micron and nanofibres has attracted much attention 
for biomedical applications, including implantable scaffolds for tissue engineering (49, 50), 
controlled drug delivery (51, 52) and wound dressings (53-57). The properties of electrospun 
fibres make them desirable materials in the biomedical field. There is the ability to control the 
fibre diameter in the nanometre range, enabling fabrics to be produced with very large surface 
areas. Also when the diameter of fibres is in the nanometre range, there is the ability to closely 
mimic the scale of collagen fibres found in the extracellular matrix (ECM) of the skin (58). 
The topographical nature of electrospun matrices play an important role in cell proliferation 
and adhesion (59). The high surface to volume ratio allows for cell attachment and the 
tuneable porosity aids in nutrient support. The fibres also have a malleability to conform to 
various shapes and sizes (51). Another beneficial property includes the optimisation of fibre 
morphology for controlled drug delivery. Due to the high surface to volume ratio, nanofibres 
have the ability to overcome mass transfer limitations observed in other polymer drug delivery 
systems and can also offer greater drug loading (58).  
 
Electrospun polymeric webs provide a suitable matrix for the controlled release of 
antimicrobials and the inclusion within a composite wound dressing. The local delivery of an 
antimicrobial agent sustained for about one week, in a chronic wound, can help solve and 
minimise the problem of frequent dressing change  (21). The sustained release also improves 
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the effectiveness of drug targeting and optimum concentrations at the wound site. This avoids 
the need for high systemic dosages of antibiotics (21, 54, 60). 
 
Electrospinning offers great potential in selecting materials for wound dressings and drug 
delivery. Poly(vinyl alcohol) (PVA) is a well known polymer that is approved by the FDA for 
medical use in humans (61) It has many beneficial properties including biocompatibility with 
tissue and blood (62), non-carcinogenicity and biodegradability (54). It has received 
significant attention in the literature for use as a hydrogel material (61, 63, 64) and for use in 
wound care (65, 66). Numerous studies have reported on the electrospinning of PVA alone 
(67) or the combined effect with other polymers for controlled drug release (54, 66). 
Biodegradable or non-biodegradable polymers can be used to control drug release via 
diffusion alone or diffusion and the biodegradation of the polymeric webs (58). Drug release 
from polymeric materials for wound healing is also controlled by one or more physical 
processes, whereby the polymer is hydrated by the wound exudate, which in turn results in the 
formation of a gel and the swollen gel then facilitates the release of the antimicrobial into the 
wound bed (21). 
1.5 Aims and Objectives 
The purpose of this work is to evaluate a new wound contact layer in which methylglyoxal 
(MGO) found in manuka honey is incorporated as a novel antibacterial compound within a 
poly(vinyl alcohol) (PVA) hydrogel polymer matrix formed in to fibres. The aim of this 
research is to study the production and properties of electrospun polymeric webs made from 
PVA incorporating MGO within the polymer matrix. In this study, two different 
electrospinning techniques are investigated, needle electrospinning and free surface 
(needleless) electrospinning.  
 
The specific objectives of the study are: 
 To study the antibacterial efficiency of Manuka honey and synthetic methylglyoxal 
(MGO) with equivalent MGO concentrations. 
 To investigate the feasibility of incorporating MGO as an antimicrobial agent in PVA 
electrospun fibre webs. 
 To analyse the physical and antibacterial properties of polymeric webs containing 
MGO. 
 To determine the main effects and interactions of different manufacturing conditions 
on the properties of the experimental materials. 
 To study the kinetics of antimicrobial release from the new fabric and the influence 
of crosslinking. 
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It is intended that the outcome of the study may ultimately contribute towards the 
development of new topical antimicrobial dressings for wound care.  
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The purpose of this chapter is to critically review aspects of the science and technology relevant 
to the experimental work that follows. Accordingly, to provide contextual background, a brief 
review of wounds and wound healing is presented, including the role of antimicrobials, 
followed by a discussion of salient aspects of honey in relation to wound healing. Finally, 
aspects of electrospinning relevant to the experimental work are discussed.  
A wound is defined as “a break in the epidermis or dermis that can be related to trauma or to 
pathological changes within the skin or body” (68). A wound can be caused intentionally or 
accidentally or it may be part of a skin disease (69). Physical trauma will cause a tear, cut or 
puncture to the skin and surgical procedure may also contribute to these breaks in skin. Wounds 
may be classified as acute or chronic, open or closed and by the way in which the wound is 
closed, either primary or secondary intention.  
An acute wound was defined by the Wound Healing Society (WHS) as “one that proceeds 
through an orderly and timely reparative process to establish sustained anatomic and 
functional integrity” (70). A simpler definition is “a recent wound that has yet to progress 
through the sequential stages of wound healing” (71). An acute wound may be a result of 
surgery, such as an incision or excision and will usually heal faster than a chronic wound as a 
result of primary intention. 
The WHS defined a chronic wound as “one that has failed to proceed through an orderly and 
timely reparative process to produce anatomic and functional integrity or that has proceeded 
through the repair process without establishing a sustained anatomic and functional result” 
(70). A simpler definition is “a wound that has remained unhealed for more than six weeks”. 
Venous leg ulcers, pressure ulcers, diabetic foot ulcers and arterial ulcers are key examples of 
chronic wounds (5). Chronic wounds are typically healed by secondary intention.  
Wound healing is a very complex process, in which a series of independent and overlapping 
stages occur. It is important for medical professionals to understand each of these stages in 
order to recognise any abnormalities which may cause prolonged healing and to select and 
change the appropriate dressing during the different stages. Healing occurs either by; primary, 
2.1 Introduction  
2.1.1 Types of Wounds 
2.1.1.1 Acute wounds   
2.1.1.2 Chronic wounds 
2.1.2 Wound Healing  
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secondary or tertiary intention. These categories are based on the anticipated nature of the repair 
process or how the wound is closed (72).  
The wound healing process takes place in a series of stages (Fig. 2.1). There are some 
contradicting views on the number, duration and names of each stage (73-76), but for the 
purpose of this study four stages referred to below are briefly discussed: 
 Haemostasis 
 Inflammation 
 Proliferation 
 Maturation 
 
 
 
Haemostasis is the control or the arrest of bleeding (68, 77), and after wounding is the normal 
physiological response of the body. The injured surface of the skin and blood vessels expose 
connective tissue, and platelets are attracted to the site of injury. The platelets come into contact 
with the collagen present in the walls of the damaged blood vessels (77). Interaction between 
the platelets and damaged tissue generates cytokines and the biochemical cascade forms 
thrombin. Thrombin converts fibrinogen to fibrin, which activates the platelets to clot and this 
forms the physical plug that stops bleeding. Cytokines and growth factors such as, thromboxane 
A-2 and serotonin are released from the activated platelets causing vasoconstriction. The 
2.1.2.1 Stages in Wound Healing 
Figure 2.1: Time scale of stages in wound healing (77). 
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platelet derived growth factor (PDGF) and transforming growth factor (TGR) are activated (78) 
prompting clotting to begin. Blood flow is reduced to the damaged cells giving the skin 
surrounding the wound a pale appearance. In contradicting cases it is claimed that haemostasis 
is achieved within 10 minutes after injury (77), others suggest that this process may take 2 to 4 
hours (5).  
 
Inflammation is an emergency response reaction to damaged tissue and bacterial invasion (75) 
which will not show any obvious signs of healing for about twelve hours (79). The signs that 
inflammation is taking place include redness to the surrounding area of the wound, heat which 
is created by a large amount of warm blood and heat energy produced by metabolic reactions, 
swelling and pain (75). The inflammation stage may last 3 to 5 days in acute wounds (77, 79). 
However, it is also suggested that it may last between 5 to 7 days (5). In chronic wounds non-
resolving inflammation is a key characteristic. It is this unresolved process that significantly 
delays the healing process in chronic wounds and no time limit can be anticipated (76). There is 
evidence to show that the impaired inflammation stage is due to bacteria biofilms, which 
harbour on the surface on the wound and can show a resistance to antibiotic and chronic 
inflammation (80-84). The importance of biofilms is discussed later in section 2.2.3.  
 
After the second or third day, proliferation begins and continues for up to 3 to 4 weeks (5). 
Overlapping of phases takes part in this stage, including granulation tissue formation, 
angiogenesis and epithelialisation.  
Granulation Tissue Formation 
Fibroblasts are cells which are responsible for collagen and elastin synthesis (68). They are also 
responsible for the extra-cellular matrix (ECM), visually seen as granulation tissue (75). They 
start to appear in the wound within the third to the fourth day of injury and reach their peak 
numbers on the seventh day (85).  As the number of macrophages is reduced, fibroblasts begin 
to produce growth factors such as the fibroblast growth factor (FGF), the transforming growth 
factor (TGF) and the platelet derived growth factor (PDGF). Keratinocyte and insulin growth 
factors are also produced. The collagen produced gives the wound its tensile strength (77), 
where cells involved in angiogenesis and ECM attach to and grow (5). Granulation tissue that 
appears bright red in colour and moist to touch is classed as healthy. Unhealthy tissue may bleed 
easily and will appear darker in colour (77).  Fibroblasts are also involved in the process of 
contraction (73, 75). Specialist fibroblasts known as myofibroblasts, gather around the wound 
edge pulling them together (77).   
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Angiogenesis 
Defined as “the production of new blood vessels”, angiogenesis gives the skin a healthy red 
colour (68). Vascular endothelial cells are the major cells involved in this process. They arise 
from undamaged blood vessels, pushing through the ECM. New vessels develop and form 
capillary loops which are transformed into arteries and veins, establishing new blood flow in the 
wound (5, 73, 85). 
Epithelialisation 
This is the stage in which epithelial cells migrate across the wound forming new epithelial tissue 
that appear pink and pale in colour (68). This process occurs in the following way: 
Keratinocytes found at the wound edges are simulated by the epidermal growth factor (EGF) 
released by macrophages. They synthesise fibronectin, forming a temporary matrix, where 
epithelial cells can migrate along (75). The cells move over the surface in a leap frog motion, 
where one cell migrates over the top of another and provides a base for other cells to climb over. 
When the cells meet in the middle they stop and migration ceases. This is known as contact 
inhibition (68, 75). When the cells stop migrating the basement membrane is rebuilt, which is 
essential for the epidermis to fix with the dermis (75). Iocono et al. claims that epithelialisation 
may begin within the first 12 to 24 hours after injury (86). However, Dealy states that this will 
start in the second day (75). 
 
Maturation often termed the ‘remodelling’ stage (77), involves the remodelling of collagen into 
an organised structure, where it is laid down at right angles to the wound margins (75, 77). The 
newly organised collagen structure contributes to the increased tensile strength (85). The 
vascularity of the wound decreases owing to the paler colour of the scar tissue (77). This 
process of maturation may take up to 2 years, depending on the size and severity of the wound 
(5).  
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In 1962, Winter (18) discovered that wounds in a moist environment heal faster than those in a 
dry environment. He discovered that wounds covered with an occlusive vapour permeable film 
dressing, encouraged epithelialisation to be twice as fast. The moist environment allowed the 
epithelial cells to migrate freely across the wound surface. In contrast if the wound was left in 
the open air where a scab had formed, the epithelial cells would migrate deep under the dried 
exudate and cells to find an area of moisture to allow cell movement (18). The work by Winter 
was not taken into consideration until the 1980s, when Eaglestein (87), compared the healing 
rate of a wound covered with a gauze dressing and a wound in a moist environment. He found 
that the healing rate was reduced by 40% when using a gauze dressing in comparison to a 
wound in a moist environment (87).  The advantages of a moist wound environment are 
summarised as follows (88): 
 Assists epidermal migration 
 Promotes alterations in the pH and oxygen levels 
 Maintains an electrical gradient 
 Retains wound fluid on the wound surface 
 
It was also reported that the benefits of a moist wound environment reduce the pain for the 
patient, as the wound is submerged in the natural bodily fluids fewer bacteria may exist 
compared to dry scab and eschar tissue which harbours microorganisms. The removal of a 
dressing will also cause less distress to the patient, as it is unlikely that the dressing will adhere 
to moist tissue (89). Autolytic debridement (the skins ability to remove dead necrotic tissue 
through the use of enzymes) is more likely to occur in a moist wound environment (68).  
The nutrients required for healing and their advantages can be seen in Table 2.1. Water is not 
mentioned, but may be considered the most important of all. It aids in hydration to the wound 
site and in oxygen perfusion. Vitamins, minerals, glucose and amino acids all need water as a 
solvent  to enable diffusion into and out of cells. It also transports vital materials to cells and 
carries waste away (90). A patient’s nutritional balance must be monitored by a recognised 
nutritional screening tool, such as the Malnutritional Screening Tool (MUST) (British 
Association for Parenteral and Enteral Nutrition [BAPEN], 2005) to ensure they are receiving 
the correct nutritional balance (91).  
2.1.3 Factors Affecting Wound Healing 
2.1.3.1 Moist Environment 
2.1.3.2 Nutrition 
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Nutrient RDA Food Source Contribution 
Carbohydrates 
1600-
3350 
kcals 
Wholemeal bread, 
wholegrain cereals, potatoes 
(refined carbohydrates are 
seen as empty calories) 
Energy for leuocyte, macropahge 
and fibroblast function 
Proteins 42-84g 
Meat, fish, eggs, cheese, 
pulses, wholegrain cereals 
Immune response phagocytosis, 
angiogenesis, fibroblast 
proliferation, collagen sysnthesis 
and wound remodelling 
Fats 
1-2% 
kcals 
Dairy products, vegetable 
oil, oily fish, nuts 
Provision of energy, formation 
of new cells 
Vitamin A 750 μg 
Carrots, spinach, broccoli, 
apricots, melon 
Collagen synthesis and cross-
linking, tensile strength of 
wound 
B Complex 3 mg 
Meat (especially liver) diary 
products, fish 
Immune response, collagen 
cross-linking, tensile strength 
Vitamin C 30 mg 
Fruit and vegetables (but 
easily lost in cooking) 
Collagen synthesis, wound 
tensile strength, neutrophil 
function, macrophage migration, 
immune response 
Vitamin E n/a Vegetable oils, cereals, eggs 
Appears to reduce tissue damage 
from free radical formation 
Vitamin K n/a Green leafy vegetables Aids in haemostasis 
Copper n/a Shellfish, liver, meat, bread 
Collagen synthesis, leucocyte 
formation 
Iron 
10-12 
mg 
Meat (especially offal), 
eggs, dried fruit 
Collagen synthesis, oxygen 
delivery 
Zinc 
12-15 
mg 
Oysters, meat, whole 
cereals, cheese 
Enhance cell proliferation, 
increases epithelialisation 
Table 2.1: Nutrients required for healing (5, 92, 93). 
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Infection is the most common cause of delayed healing in wounds (5). Several definitions exist, 
including “the presence of multiplying organisms which overwhelm the body’s immune system 
resulting in spreading cellulitis” (inflammation of the tissues) (94). Two simpler definitions 
include “infection is the invasion of living tissue by microorganism”’ (95) and “the deposition 
and multiplication of organisms in a tissue with an associated host reaction” (96). The 
important thing for health care professionals to distinguish is the difference between wound 
colonisation and infection. All wounds are contaminated with microorganisms (91).  Wound 
contamination is the presence of organisms on the surface of a wound. Contamination can occur 
in many different ways, including the transference of normal body bacteria (97). The skin hosts 
resident bacteria such as Staphylococcus aureus (S.aureus) and Staphylococcus epidermidis 
(S.epidermidis). This bacteria, is also referred to as normal body flora and lives quite happily on 
the skin without causing any harm and may also protect against more harmful or pathogenic 
organisms (98). If, however, the skin becomes broken, perhaps during surgery or through 
accidental or intentional injury, the resident bacteria may enter the wound and begin to cause 
complications (91).  
 
Wound colonisation can be characterised by the multiplication of microorganisms on the wound 
surface with no immune response from the host. Similar to contamination, colonisation does not 
cause ill health, delayed healing or disease and does not imply wound infection (91, 99). It is 
only when the wound becomes ‘critically’ colonised (23) with microorganisms that infection 
prevails (88). At this point the microorganisms invade the tissue below the wound surface and 
attack viable tissue, triggering the host responses (99). Wound infection can be identified by the 
following characteristics (91, 99): 
 Increase in pain 
 Wound breakdown 
 Spreading cellulitis  
 
If the wound continues to look inflamed after the initial 3 to 5 day period of inflammation, then 
cellulitis may be assumed. However, distinguishing infection in acute wounds is often easier to 
identify when compared to chronic wounds (99).  
Ageing can cause a decrease in the  immune response (91), resulting in the prolonged infection 
of wounds. The collagen that is produced is weaker and more susceptible to trauma (73) and 
underlying health conditions are often associated with the elderly which may also affect the 
healing process (91). Medical conditions such as arthritis, renal disease, cancer, heart disease, 
immune disorder, blood disorders, lung disease and diabetes all affect the wound healing 
2.1.3.3 Infection 
2.1.3.4  Other factors 
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process (5). Poorly controlled glucose levels delays the wound healing rate of elderly diabetic 
patients up to three times that of non-diabetic elderly patients (100). Medication such as 
chemotherapy and long-term steroid therapy can lower the immune response, allowing bacteria 
to replicate in the wound, which will subsequently increase the potential for wound infection 
(101). Anti-inflammatory, immunosuppressive, anticoagulant and cytotoxic drugs interrupt cell 
division and clotting factors causing a reduction in the healing rate (5, 102). Obesity has shown 
some risks in the development of infection in surgical wounds (103). The deep layers of fat 
tissue can often make surgical procedures more technical and complicated, particularly when 
trying to avoid the tearing of blood vessels. If this does occur, reduced blood supply to the 
wound during the healing process may cause a delay (91, 104). A review on the effects of 
smoking on wound healing, found that nicotine inhibits the epithelisation, macrophage activity 
and wound contraction (105). Smoking was also found to reduce the synthesis of type 1 
collagen (106). Psychological factors such as stress and anxiety have also been shown to 
contribute to a delay in healing (107, 108). 
Bacteria are a type of microorganism, unicellular and prokaryotic in type, they exist in nearly all 
places in the environment (109, 110). Bacteria can be classified into two groups; domain 
bacteria and domain archaea. However, the domain archaea contain only a small number of 
organisms, including species that live in extreme habitats with elevated temperatures and high 
salinity (109). This type of bacteria does not apply to the bacteria found in common 
environments, such as hospitals and so does not apply to this study.  
 
Bacteria are responsible for some major and minor diseases and infection. However, bacteria 
can live on the human body without causing any harm and in most cases are useful to man. 
Some of these uses include: biological washing powders, crop pesticides/insecticides, the 
production of cheese, yoghurt and butter and biodegradable plastics (109), these are only a few 
of the processes bacteria are involved in. For the purpose of this study bacterial pathogens will 
be discussed.  
 
Any microorganism which initiates disease is known as a pathogen. Bacteria which live on the 
human body known as microflora, are not known as pathogens, but can sometimes cause 
disease when the host is disturbed and are referred to as opportunist pathogens (91, 109). This 
may be through injury or surgery when the microflora migrate to places in the body that are not 
usual. Table 2.2, represents the microflora found on the human body. The bacteria frequently 
found in wounds, which may lead to infection, are discussed in section 2.2.3.  
2.2 Bacteria  
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Location Species 
Colon Bacteroids, Clostridium, Escherichia, Proteus 
Ear (conjunctivia) Corynebacterium, Mycobacterium, Staphylococcus 
Eye 
Staphylococcus (coagulase-negative), Corynebacterium, 
Propionibacterium 
Mouth Actinomyces, Bacteroids, Streplococcus 
Nasal passages Staphylococcus, Corynebacterium 
Nasopharnyxn Streplococcus, Haemophilus (e.g. H. influenzae) 
Skin 
Propionibacterium, Staphylococcus, Others (according e.g. 
to personal hygiene and environment) 
Uretha Acinetobacter, Escherichia, Staphylococcus 
Vagina (adult pre-
menopausal) 
Acinetobater, Cornyebacterium, Lactobacillus, 
Staphylococcus 
 
Bacteria can be classified into gram negative and gram positive. The difference is determined by 
the structure of the cell wall. Gram negative bacteria possess an outer membrane (110) (Fig. 
2.2). Typical gram negative and Gram positive bacteria used commonly in testing are 
Escherichia Coli (E.Coli) and Staphylococcus aureus (S.aureus) respectively (91). Bacteria can 
also be classified via the reactions they employ to generate growth and other activities. They are 
classified as either; aerobic, anaerobic or facultative. Aerobic bacteria require oxygen and 
cannot grow in its absence. In contrast, oxygen is toxic to anaerobic bacteria and they cannot 
grow in its presence (112). Both aerobic and anaerobic bacteria reside in wounds which may 
lead to infection. S.aueus, E.coli and Klebsiella pneumoniae are some types of aerobic bacteria 
while Peptostreptococcus and Prevotella, Clostridium species are anaerobic, all of which may 
reside in wound environments (113).   
Table 2.2.: Microflora found on the human body (111). 
2.2.1 Types of Bacteria 
~ 18 ~ 
 
 
Wounds are host to an extensive range of bacterial species. A study published in 2006 examined 
the chronic wounds of 46 patients with venous leg ulcers (6). A total of 37 species of bacteria 
were found. All of the ulcers contained more than one bacterial species, with a mean number of 
6.3 species per ulcer. The most common species isolated was S.aureus, which was found in 
93.5% of ulcers. Enterococcus faecalis (E.faecalis) was found in 71.7% of all ulcers and 
Pseudomonos aeruginosa (P.aeruginosa) was found in 52.2% (6). An earlier study in 1999 
(113) investigated the aerobic and anaerobic bacteria of infected and non-infected leg ulcers. 57 
bacteria species were cultured from both infected and non-infected wounds, 24 aerobic and 33 
anaerobic. The mean number of aerobe and anaerobe species from infected wounds was 2.6 and 
2.5 respectively. In comparison the non-infected wounds had a lower mean number of 
anaerobes at 1.3 and aerobes at 2.3. Numerous anaerobic species were more prevalent in the 
infected ulcers compared with the non-infected wounds. Peptostreptococcus and Prevotella 
species accounted for 37% of the total microbial population in infected wounds compared with 
26% in non-infected wounds. S.aureus, an aerobic species, was more prominent in non-infected 
wounds at 53% compared with infected ulcers at 43% (113). Bacteria biofilms are particularly 
troublesome in chronic wounds and play a significant role in the delay of healing, this is 
discussed in section 2.2.3. 
Bacteria are present as free floating entities in a planktonic state (115). However in clinical and 
natural environments, bacteria can grow as sessile communities, where the bacteria group 
together on a surface or air/liquid interface and are embedded within a matrix of extracellular 
polymeric substances (EPS), this is known as a biofilm (115-117). The EPS are composed of 
proteins, lipids, polysaccharides and DNA (115, 118), which act as a scaffold for the biofilm to 
quarantine and preserve enzymes and metal ions, all of which are thought to support its stability, 
aiding in survival (117). Biofilms also differ from planktonic bacteria in that they have an 
Figure 2.2: A Gram negative bacteria cell (114). 
2.2.2 Bacteria involved in wound infections 
2.2.3 Bacteria Biofilms 
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altered phenotype with respect to growth rate and gene transcription (119). The control of gene 
expression is thought to support and prepare bacteria biofilms for prompt adaption during 
external hostile conditions (117). The defences of a biofilm make them resistant to antibiotics 
(120), antiseptics (121) and the human immune response (122). It was reported that up to 17 
million new biofilm infections arise in the US and 550 000 people die from these infections 
annually (123). 
 
Both acute and chronic wounds are susceptible to bacteria biofilms (115), however it is chronic 
wounds which make up a large percentage of this. James et al. used scanning electron 
microscopy to study the existence of biofilms in patients with chronic and acute wounds. The 
results showed that 30 out of 50 chronic wounds had a biofilm existence compared with only 1 
out of 16 acute wounds (124). A chronic wound environment encourages the spread and growth 
of key opportunist pathogens already living on the intact skin. It is therefore likely that a chronic 
wound environment will promote propagation and collection of opportunist bacteria populations 
which will lead to a delay in healing and increased risk of infection from biofilms (125). One of 
the main reasons postulated why chronic wounds such as diabetic foot ulcers, venous leg ulcers 
and pressure ulcers fail to heal is because of biofilms (82). The wound becomes stuck in the 
inflammatory stage, which is characterised by a persistent influx of polymorphonuclear 
neutrophils (PMNs), which release cytotoxic enzymes and oxygen free radicals causing 
prolonged and detrimental damage to the host tissue (82, 88). The importance for understanding 
biofilms in wounds, is their inherent tolerance to antimicrobials and inflammatory reactions to 
the host (118). This is discussed in section 2.3.1. 
An antibacterial refers to an agent that specifically targets bacteria and falls into two general 
categories, bacteriostatic and bactericidal. Bacteriostatic refers to an agent’s ability to prevent 
the growth of bacteria, it keeps the bacteria in a stationary phase. Bactericidal means that the 
agent will kill the bacteria (102, 126).  
 
Antimicrobial is as an ‘umbrella’ term that includes: disinfectants, antiseptics and antibiotics. 
Chemical agents or biocides, such as hyperchlorite or glutaraldehyde are used to inhibit or kill 
microbes on inanimate objects and are referred to as disinfectants. Antiseptics are biocides used 
on a wound or intact skin to inhibit or kill micro-organisms (127, 128). These may also be 
referred to as an antibacterial. Hospitals and other health care settings use antiseptics and 
disinfectants extensively to aid in infection control practices. In general antiseptics target a 
broader spectrum of bacteria with multiple target sites (128). Antibiotics act differently to 
antiseptics, in that they employ a toxic effect against selective bacteria (128, 129). They are 
2.3 Antimicrobials 
Antimicrobials are agents which may kill or inhibit microbes such as bacteria, fungi or viruses. 
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naturally occurring or synthetic organic substances that are used predominantly for the treatment 
of infections in humans and animals (129).  Antiseptics and antibiotics use different 
mechanisms of action to kill or inhibit bacteria. The mechanistic role of antibiotics are well 
documented, however the function of an antiseptic is less understood (130). Table 2.3 highlights 
the basic mechanisms employed in the bacteriostatic or bactericidal action of an antibiotic or an 
antiseptic. 
Antibiotic mechanisms against bacteria Antiseptic mechanisms against bacteria 
Act as inhibitors to peptidoglycan synthesis Interact with bacterial cell wall or envelopes 
Protein synthesis Produce changes in cytoplasm membrane integrity 
Nucleic acid synthesis by interrupting nucleotide 
metabolism 
Dissipate the proton-motive force 
Inhibiting RNA polymerase Inhibit membrane enzymes 
Inhibiting DNA gyrase 
Act as alkylating, crosslinking and intercalating 
agents 
Interfere with membrane integrity* Interact with identifiable groups within the cell 
*Only select antibiotics act in this way 
care 
Chronic wounds are polymeric in nature and this provides an appropriate environment for the 
genetic mutation of bacteria (8). The first two cases of vancomycin (an antibiotic) resistant 
S.aureus were first reported to have come from chronic wounds in the USA (131). An analysis 
of antibiotic susceptibilities of skin wound flora in hospitalised dermatology patients found that 
more than half of S.aureus isoltaes from leg ulcers were MRSA and more than one third of 
P.aeruginosa were resistant to ciprofloxacin. The ulcers also appeared to be significantly larger 
in terms of area than ulcers which were not infected (132). The polysaccharide (Psl) in 
P.aeruginosa biofilms has been shown to provide a physical barrier against various antibiotics 
at the beginning stages of biofilm development. Psl was found to sequester antibiotics to the 
matrix via electrochemical interaction, which therefore limited their effectiveness (120). 
Another study compared the antimicrobial effect of silver sulphadiazine and tobramycin against 
P.aeruginosa biofilms. It found that 340 µg ml
-1
 of tobramycin had no effect against mature 
biofilms. In contrast only 5 µg ml
-1
 of silver sulphadiazine was able to destroy the biofilm. 
However the amount of silver available in three commercial dressings via extraction, was found 
Table 2.3: Antibiotic and antiseptic mechanisms (130). 
2.3.1 Bacteria and biofilm resistance to antibiotics and antiseptics in wound 
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to be considerably lower, including 0.033 µg ml
-1
, 2.2 µg ml
-1
 and 0.93 µgml
-1
 and showed no 
effect towards the established biofilms (121).  
 
The emergence of silver resistant bacteria has been documented since the 1970s where it was 
first reported in Massachusetts General hospital in Boston, USA. Burn victims suffering from 
Salmonella typhimurium were treated with a standard 0.5% silver nitrate (AgNO3) solution. 
Resulting swab cultures reported persistent resistance to AgNO3 and was transmissible to 
susceptible strains of E.coli and Salmonella typhimurium (133). Following this, other studies 
reported that various strains of gram negative bacilli showed resistance to silver sulphadiazine 
(134). Similarly burn patients with bacteria infections from P.aeroginosa showed resistance to 
treatment by AgNO3 (135) and silver sulphadiazine (136). A Canadian burns unit also 
documented that isolates of Enterobacter cloacae (E.cloacae), Proteus mirabilis (P.mirabilis) 
and Klebsiella pneumonaie (K.pneumonaie) showed resistance to AgNO3 (137).  
 
Bacterial resistance to silver is thought to arise through mutation or acquisition of plasmids or 
transposons, as an intrinsic natural property or via epigenetic mechanisms (change not 
modulated by genetic expression) (14).  The silver resistant strain of Salmonella typhimurium 
has provided in depth insight into the mechanisms of silver resistance in bacteria. The following 
Sil gene products are said to be attributable for action of silver resistance to Salmonella 
typhimurium (138):  
 SilE, a small silver binding protein located on the bacterial cell surface 
 SilS, a regulatory kinase membrane receptor protein 
 SilR, a transcriptional responder protein that regulates mRNA transcription in silver 
resistance 
 SilCBA, a complex three protein membrane protein dependant silver and hydrogen ion 
anti-porter 
 SilP, a P-type efflux ATPase. 
 
Multi-species bacteria biofilms are now highly resistant to most antimicrobial agents, including 
silver. The mechanisms of biofilm resistance to silver have been documented and the principal 
features of resistance are anticipated to be  (13, 139): 
 Modified nutrient requirements and suppression of growth 
 Direct interactions between the polysaccharide and its constituents with the active 
moiety of the antibiotic, namely silver 
 Lack of penetration and diffusion of the antibiotic into the polysaccharide matrix 
 Development of specific biofilm/attachment phenotypes within the biofilm 
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With the growing rise in planktonic and bacteria biofilm resistance to antibiotics and topical 
silver treatment, biofilm based wound care (BBWC) strategies are being implemented, which 
involves the physical debridement of necrotic tissue and the use of topical treatments (122). The 
search for new and novel antiseptics are also being explored, including natural remedies like 
Manuka honey. Manuka honey dressings are in use, as there has been limited evidence to show 
biofilm resistance (140, 141). The role of Manuka honey in wound care is discussed in section 
2.4.3.2. 
Antimicrobial wound dressings contain an antiseptic agent which has been incorporated within 
the dressing, this does not include products which contain antibiotics. Antimicrobial dressings 
offer many benefits over antibiotics, which include (24): 
 Relatively easy to use  
 Widely available  
 Frequently cost less than antibiotics  
 Available without prescription 
 Have less risk of resistance 
 
Antimicrobial dressings are applied topically to the wound. They differ to antibiotics, in that 
they exert an extensive spectrum of non-selective antibacterial action and act at multiple sites 
within microbial cells, this reduces the likelihood of bacteria developing resistance. Antibiotics 
however, are selective against the bacteria they inhibit or kill and are usually administered 
systemically, although it is possible to apply them topically which is not recommended. Silver, 
honey, cadexomer iodine and polyhexamethyl biguanide (PHMB) are among the most common 
antiseptics utilised within a dressing (24). Silver and honey are traditional antiseptics which 
have been used throughout the centuries for the treatment of wounds (127). They are both 
highly regarded as being effective in the treatment of infected chronic wounds with numerous 
publications highlighting their antibacterial performance.  For the purpose of this study silver 
and honey will be discussed. 
In today’s medicine silver has received much attention and has been utilised in advanced wound 
care for the past 40 years (142). There are many papers reporting on the antibacterial efficiency 
against a range of bacteria, including both gram positive and gram negative (30) and its use in 
the treatment of patients suffering from chronic wound infections (31). The range of silver 
dressings is extensive, including film, foam (143), hydrocolloid (25), hydrogels (144) and 
dressings incorporating a Hydrofibre® technology (145). A variety of silver compounds are 
2.4 Topical antimicrobials in wound dressings 
2.4.1 Silver (Ag) 
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available within a dressing, as indicated in Table 2.4 and the methods for incorporating these 
consist mainly of the following (96): 
 Coating of the base fabric or fibres with metallic silver 
 Attachment of silver ions to the base material through ion exchange 
 Blending fine silver particles with the base layer 
 Blending silver containing fibres with other non-silver fibres 
 Incorporation into fibres 
Manufacturer Name of the Dressing Silver Compound  
Argentum Silverlon Metallic Silver 
Smith and Nephew Acticoat Metallic Silver 
Mediline SilvaSorb Silver Chloride 
Convatec Aquacel Ag Silver Chloride 
Mediline Arglase Silver Calcium Phosphate 
Coloplast Contreet Silver Annomium Complex 
Johnson and Johnson Actisorb Silver 220 Silver Carbon 
 
The amount of silver content within commercially available dressings have been found to be 
considerably different. These differences were highlighted in two studies in 2003 by Thomas 
and McGubbin (146, 147). Both of the studies compared the antimicrobial properties of 
commercially available silver containing wound dressings and reported the total extractable 
content observed by optical emission spectroscopy, as seen in Table 2.5.   
Table 2.4: Silver compounds used in dressings (96). 
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Dressing Silver content (mg 100 cm
-
²) 
Silverlon 546 
Calgitrol Ag 141 
Acticaot 101 
Contreet Ag 47 
Contreet H 32.4 
Aquacel Ag 8.3 
Silvasorb 5.3 
Actisorb Silver 220 2.9 
Avance 1.6 
Argyria is a non-life threatening condition, where a blue to grey discolouration of the skin has 
occurred in systemic or localised forms (10, 148). The condition is also referred to as 
Argyriasis, Argyrism and Argyrosis and is predominantly a condition affecting the skin and its 
limbs, attributable to minute particles of metallic silver, silver sulfide or silver selenide 
containing granules in the connective tissues of the dermis (149-151).  It can occur in a variety 
of circumstances and be localised via the implantation of silver-loaded acupuncture needles, or 
generalised throughout the body where discolouration to the eyes (Argyrosis) or the internal 
organs may occur (149, 150, 152). Argyria may be defined as “a permanent or long-lasting grey 
or blue-grey discolouration of the skin attributable to prolonged exposure to metallic silver or 
ionisable silver salts” (10). Fig. 2.3 depicts an image of a 65 year old woman’s chest ulcer, 
which was treated with silver sulfadiazine cream. A blue to grey discolouration of the non- 
healing ulcer can be seen. The patient reported that the discoloration did not change appreciably 
over a 3 year period (148). The increasing use of silver (metallic or Ag
+
) can be introduced 
directly into the circulation via a coating or impregnate on materials used in implantable or in-
dwelling devices such as catheters, bone cements and prostheses, dental materials, 
cardiovascular valve sewing cuffs and stents (10). Topical treatment with silver sulfadiazine in 
burn wound therapy has shown cases where side effects including hypersensitivity reactions, 
allergic contact dermatitis, erythema multiforme, and systemic Argyria have occurred (148). 
Although the condition is visually undesirable, it must be regarded as a cosmetic condition at 
most (10). There is minimal evidence that even in severe cases an overdose of silver is fatal. 
Where death has been recorded, pre-existing health problems unrelated to silver have been the 
cause (153).  
Table 2.5: Silver content in commercial dressings (146). 
2.4.1.1 Toxic and cytotoxic effects of silver  
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The cytotoxicity of silver in cells required for healing including fibroblasts and keratinocytes 
has been highlighted in few studies (11, 12). One study evaluated the cytotoxicity of six 
commercially available dressings, including Acticoat, Aquacels Ag, Contreet foam, PolyMem 
silver, Urgotuls SSD and Aquacel (a control sample with no silver available). The method of 
investigation involved the seeding of both keratinocytes and fibroblasts separately into six well 
plates at a density of 1 x 10
5
/well and 5 x 10
4
/well respectively. Upon three to four days culture, 
separate dressing pieces measuring 1 x 1 cm
2
, were soaked with 0.8 ml of deionized water, 
saline and fetal bovine serum (FBS) separately before being added to the plate well for culture. 
The three solutions were also tested separately as a control. It was found that Acticoat, Aquacels 
Ag, and Contreet foam, had the most cytotoxic effects on keratinocytes and fibroblasts after 24 
h, while PolyMem Silver and Urgotul SSD were found to be the least cytotoxic. All silver 
dressings resulted in a significant delay of reepithelialisation and Acticoat and Contreet foam 
indicated a strong inhibition of wound reepithelialisation (12). Table 2.6 and Table 2.7 show the 
percentage cell death for both the keratinocytes and fibroblasts, respectively after 24 h.   
 
 
 
  
Figure 2.3: Argyria on a non-healing ulcer, after treatment with silver sulfadiazine cream (148). 
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 Pre-treatment 
 Deionized water Saline FBS 
Dressing Percentage (%) of keratinocyte cell death after 24 h 
Aquacel (control) 12 25  
Comparable to 
control solutions 
Acticoat 80  80  50   
Aquacel Ag 47  91   80   
Contreet Foam 90  50   95   
Poly Mem silver Shown to enhance the cell proliferation in all cases 
Urgotul SSD Comparable to the control sample (Aquacel)  
 
 Pre-treatment 
 Deionized water Saline FBS 
Dressing Percentage (%) of keratinocyte cell death after 24 h 
Aquacel (control) Comparable to the control solutions 
Acticoat 75  < 50  < 30  
Aquacel Ag <25 <25 <25 
Contreet foam 50 25 30 
PolyMem silver 
Initially all pre-treatments showed a mild cytotoxic effect 
after 6 h. After 24 h, all cells began to proliferate 
Urgotul SSD Comparable to PolyMem silver  
  
Table 2.6:Percentage (%) of keratinocyte cell death after dressing treatments. 
Table 2.7: Percentage (%) of fibroblast cell death after dressing treatments. 
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Honey is produced in the hive, by bees who convert the natural sugars from nectar, a thin, sweet 
and spoiled solution to a highly viscous, high energy food (154). Honey was defined by the 
British Pharmacopoeia in 1993 as being “obtained by purification of the honey from the comb of 
the bee, Apis mellifera L, and other species of Apis” (155). The composition of honey is mainly 
80 wt % sugars and 17 wt % water (17). However, the plant source, season and production of 
honey will vary the chemical composition (156). The main constituents include carbohydrates, 
proteins, amino acids, vitamins, minerals and antioxidants (154, 157). The carbohydrates 
present are the monosaccharides, fructose (38%) and glucose (31%), (17, 157). The 
disaccharides include a smaller percentage of (~9%) sucrose, maltose, isomaltose, maltulose, 
turanose and kojibiose. There are also some oligosaccharides present approximately 4.0%, 
including erlose, theanderose and panose, which are formed from the incomplete breakdown of 
the higher saccharides present in nectar and honeydew (157).  
Honey has been used for thousands of years for its medicinal and nutritional effects.  It has been 
cited as far back as 2100-2000 BC, where honey was mentioned as a drug and ointment 
treatment on a clay tablet (158), and in Chinese literature dating back to 2000 BC (159).  There 
are Egyptian records from 1550 BC which include 147 prescriptions for the external application 
of honey, used for treating eyes. Honey treatment for wounds and diseases of the gut was used 
by the Ancient Egyptians, Assyrians, Chinese, Greeks and Romans (160). There are also reports 
that using cotton wool soaked in honey and lemon juice, was used as a contraceptive. Around 
300 BC a study by Herophilus, founder of the medical school in Alexandria, discovered 
techniques used by the Egyptians for treating wounds. This included applying a salve made of 
either honey and animal fat or honey and aromatic resins, with an adhesive linen tape (161). The 
therapeutic properties of honey are known to act as an antimicrobial and anti-inflammatory, as 
well as having the ability to debride, deodorise, simulate tissue growth, manage pain and 
minimise scarring (162).  
In 1937 the work by by Dold, Du and Dzaio (163), discovered that honey when diluted with 
water had superior antibacterial activity against certain bacteria. This discovery was later 
confirmed in 1962 when White, Subers and Schepartz concluded that hydrogen peroxide (H2O2) 
found in honey is responsible is for its antibacterial action. It was found that when honey is 
diluted, hydrogen peroxide is produced (164). Originally H2O2 is produced by the interaction of 
the honey bee when it releases an enzyme known as invertase, converting the sucrose found in 
pollen into glucose and fructose. A small amount of the glucose is then converted by a second 
enzyme known as glucose oxidase, which converts the glucose into gluconic acid and H2O2 
2.4.2 Honey 
2.4.2.1 History of Medicinal Use 
2.4.2.2 Antimicrobial action of honey 
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(165). It is believed that the function of H2O2 prevents the damage of unripe honey when the 
sugar concentration has not yet reached levels able to prevent microbial growth. The enzyme 
glucose oxidase is deactivated throughout the ripening of honey. However it reclaims its 
activation on dilution of honey (166). H2O2 is responsible for a broad range of activity against 
bacteria, in particular gram positive bacteria.  It serves as an oxidising agent, affecting the 
cellular elements of the bacteria by producing free radicals which react with lipids, proteins and 
nucleic acids. A 3% H2O2 solution is often used as an antiseptic and disinfectant (96, 167). H2O2 
has been reported as the main constituent responsible for the bacteriostatic effect of honey (168, 
169).  
 
The osmolarity has also been reported to play an important role in the biocidal activity of honey. 
Due to honeys super saturated sugar and low water content, it has very high osmolarity (170), 
with an osmotic pressure estimated to be 2000 mosm. This environment makes it very difficult 
for micro-organisms to grow in. The acidity of honey has also been shown to contribute to the 
resistance of spoilage by bacteria (171), with an average pH of 3.9. However, although the low 
acidity was presumed to have a relationship to honey’s antibacterial activity, it has since been 
reported that no correlation between the acidity and antibacterial activity has been found (170).  
Manuka honey is derived from the floral source ‘Leptospernum scoparium’, in New Zealand. It 
is known to possess a distinctive antibacterial characteristic known as the Unique Manuka 
Factor (UMF) (172). The UMF activity of Manuka honey was established by Molan and Russell 
in 1988 to test the non-peroxide antibacterial activity of Manuka honey (173). The method of 
assay was later altered by Allen et al. in 1991 (174) and is now used widely in honey 
laboratory’s in New Zealand to establish the UMF of Manuka honey for therapeutic use (175). 
 
The production of Manuka honey has grown over the last decade due to the desire for 
therapeutic use (175) and it is now widely recognised in wound management (37) where it has 
been accepted by regulatory health authorities in the European Union member states, Australia 
and Canada (38), Hong Kong and North America (127). In 2006 it was reported that the annual 
Manuka honey harvest was said to be approximately 1500-2000 tonnes. The geographical 
location of the plant is also known to affect the low or high levels of the UMF and the north and 
east of New Zealand’s north island are found to produce the most prominent UMF activity.   
The work by Russell et al. in 1983 highlighted Manuka’s enhanced antibacterial activity was 
unrelated to the osmolarity, acidity and H2O2 commonly found in all honeys (176). Following 
this discovery the properties of Manuka honey have been extensively researched by Professor 
2.4.3 Manuka Honey 
2.4.3.1 Non-peroxide antibacterial activity in Manuka honey 
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Molan and his team at the University of Waikato in New Zealand. In 1988 a study reported the 
antibacterial comparison of 19 honeys of differing floral sources from numerous geographical 
locations in New Zealand. They were tested against the common gram positive bacteria 
S.aureus and the zone of inhibition was measured for varying diluted concentrations of honey. 
The average results expressed in mean weighted sum (mm²) highlighted that three honeys, 
Kanuka, Manuka and Penny Royal were most active, with values of 28.24, 14.64 and 5.12 
respectively. However the small number of samples tested for Kanuka and Penny Royal cast 
doubt on the reliability of the results and so it was concluded that Manuka honey showed the 
most promising results for therapeutic treatments (177).  
 
Further studies by Molan and his team were conducted to determine if Manuka honey showed 
any signs of antibacterial activity on the removal of hydrogen peroxide. Upon dilution of the 
Manuka honey with an enzyme catalase to remove the hydrogen peroxide, zones of inhibition 
against S.aureus were still evident. However after dilution to the lone hydrogen peroxide 
solution with the enzyme catalase to resemble that of the Manuka honey dilutions, no zone of 
inhibition was observed. These results concluded that another compound must play a significant 
part in the antibacterial activity of Manuka honey (173).  
 
Several attempts have been made to distinguish the unique antibacterial compound in Manuka 
honey. Using thin layer chromatography Molans team was able to isolate a number of aromatic 
acid derivatives, including syringic acid and phenyllatic acid, which were found to have an 
antibiotic activity towards a range of bacteria (178). This was later confirmed by Wilkins et al. 
who found these aromatic acids to be the most abundant phytochemicals found in Manuka 
honey (179). However these acids are also plentiful in other honey from Europe (180). Weston 
et al. also confirmed the presence of syringic acid in over 45% of the total extract of Manuka 
honey, however after testing Manuka honey and inactive honeys against S.aureus, the degree of 
inhibition was found to be the same for both honeys and so syringic acid cannot be solely 
responsible for the antibacterial activity of Manuka honey (181).  
 
In 2004 Weigel et al. found that honey contains varying amounts 1,2-dicarbonyl compounds 
including glyoxal (GO), methylglyoxal (MGO), 3-deoxyglucosulose (3-DG) and 5-
hydroxymethylfurfural (HMF) (182). Following this work, Henle and his team at the University 
of Dresden conducted a study to determine if the 1,2-dicarbonyl compounds could be 
responsible for the unique antibacterial activity in Manuka honey.  The study looked at total of 
50 honeys from various origins, plus six Manuka honey samples labelled as ‘active’ or with 
increasing UMF. It was found that GO, MGO and 3-DG were present in all honey samples, 
however much higher concentrations of MGO were recorded in the Manuka honey samples, up 
to 100 fold higher when compared to conventional honeys. The antibacterial activity of GO, 
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MGO and 3-DG was also evaluated using minimum inhibitory concentration (MIC) values and 
compared with honey samples. An antibacterial effect was observed for all 1,2-dicarbonyl 
compounds and honeys, however 3-DG showed no antibacterial effect until a MIC 
concentration of 60 mM was achieved. GO showed much lower MIC values of 6.9 mM for E. 
coli and 4.3 mM for S. aureus. A pronounced antibacterial effect was found for MGO, with a 
low MIC value of 1.1 mM (79.3µg ml
-1
) (183) for both bacteria strains. No antibacterial activity 
was observed for the conventional honeys with dilutions below 80% (w/v), however Manuka 
honey samples showed an antibacterial effect with dilution to 15% (w/v). Henle and his team 
believe this work conclusively provided evidence that MGO is directly responsible for the 
unique antibacterial effect of Manuka honey (172). Following the work by Henle’s team, Molan 
conducted a study to determine the origin of MGO in Manuka honey. It was concluded that 
MGO is derived in New Zealand Manuka honey by the non-enzymatic conversion of 
dihydroxyacetone in the nectar. Although it is not yet understood why this occurs (184). 
The use of Manuka honey in wound healing is now widely accepted with numerous studies 
showing the benefits to heal various types of chronic wounds, including leg ulcers (185-189), 
diabetic foot ulcers (190, 191), burns (192) and forelimbs of horses (193). A study of particular 
interest reported the treatment of a surgical infected wound which had not responded to 
treatment for 36 months. Several treatment options were tried, including antibiotics and topical 
silver, sulphadiazine, silver nitrate and povidone-iodine.  After the failure of all these options, 
the patient requested to try a honey dressing. A noticeable improvement in the appearance of the 
wound was observed within 1 week. After four months following initial closure of the wound, 
the patient discontinued the honey dressing and experienced no further problems (194).  
 
With the growing rise in bacterial resistance to antibiotics (8, 129, 130) and concern to find 
alternative treatments (130, 195), the antibacterial activity of Manuka honey is of growing 
interest and well documented with reference made to the antibacterial potency. Manuka honey 
inhibits the growth of clinically important pathogens and biofilms found in wounds, including 
Methicillin-resistant Staphylococcus aureus (MRSA) (196, 197), E.coli (198), Proteus mirabilis 
and Enterobacter cloacae (199), P.aeruginosa (200, 201) and Streptococcus pyogenes (202). 
Gastrointestinal pathogens (203) and oral infections (204) have also shown susceptibility to 
Manuka honey. 
 
The anti-biofilm formation of Manuka honey was evaluated for its effectiveness to inhibit the 
in-vitro development of important gram negative bacteria. Activon Manuka honey, developed 
by Advancis Medical was used in a study and tested against methicillin-sensitive S.aureus 
(MSSA), MRSA and vancomycin-resistant Enterococcus faecalis (VRE). Concentrations of 
2.4.3.2 Manuka honeys antimicrobial effectiveness in wound care 
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honey ranging from 1% (w/v) to 20% (w/v) in increments of 1% (w/v) were evaluated. It was 
observed that for both MSSA and MRSA concentrations of honey from 2% (w/v) upwards began 
to show reduction in the biofilm formation. No depletion of VRE was seen below a 5% (w/v) 
concentration. At concentrations above 10% (w/v) the biofilm growth was completely inhibited 
for all three test organisms. A further experiment looked at the survival of each bacteria 
organism over a period of 24 h with a Manuka honey concentration of 40% (w/v) and compared 
this with a control. It was found that each biofilm mass was significantly reduced in comparison 
to the control, decreasing over the 24 h period (197).  
 
In comparison another study also investigated the effect of Activon Manuka honeys anti-biofilm 
properties against MRSA at different concentrations over a period of 24 h and compared this 
against a manmade artificial honey which was tested with and without the addition of 614 mg 
kg
-1
 of MGO. The concentration of MGO added to the artificial honey was thought appropriate 
for a 10% (w/v) sample of Manuka honey. The results showed that 10% (w/v) artificial honey, 
2.5% (w/v) Manuka honey and the control sample had a generation time of 30 min,  with colony 
forming units reaching up to 8.5 (log10 cfu ml
-1
) after 24 hours. The Manuka honey samples 
with a concentration of 5% (w/v) to 20% (w/v) and the artificial honey containing MGO showed 
a loss in the colony forming units after 30 min, which continued to fall to 3.5 (log10 cfu ml
-1
) 
after 24 h for all the Manuka honey samples. The extent of inhibition after 24 h was less for the 
artificial honey containing MGO, which fell to 5 (log10 cfu ml
-1
) (196). 
 
A very recent study used Woundcare
TM
 18+Active Manuka honey to establish the potency 
against Clostridium difficile biofilms. The results highlighted that there was a dose-response 
relationship between the concentration of Manuka honey and the depletion of the biofilm. 
Concentrations below 20% (w/v) had little or no effect against the established biofilm however, 
at concentrations between 20% (w/v) to 50% (w/v) the amount of biofilm decreased during a 24 
h period (205).  
 
There has been limited or no evidence to show biofilm resistance to Manuka honey until 
recently, when an experiment highlighted for the first time that P.aeruginosa strains were 
resistant to Manuka honey with a MIC of 30.6% (w/v) (206). This is not surprising, owing to 
P.aeruginosa reputation to provide a physical barrier to other antibiotics and antiseptics (120, 
121, 132).  
At present Manuka honey wound dressings are manufactured through the direct impregnation of 
honey into the fabric or as a hydrogel. Currently some of the medically approved honey 
dressings include Medihoney by Derma Science (207), the Advancis Medical range (208) and 
2.4.3.3 Manuka honey dressings 
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L-Mesitran (209). The Medihoney range includes Medihoney Calcuim Alginate dressing (a 
nonwoven fabric impregnated with 95% content of Manuka honey) and Medihoney 
Hydrocolloid dressing (80% content Manuka honey).  Within the Advancis Medical range are 
Activon Tulle (a knitted viscose mesh, impregnated with 100% Manuka honey), Algivon (a soft 
nonwoven alginate dressing impregnated with 100% Manuka honey) and Actilite (a light 
viscose net dressing coated with Manuka honey and Manuka oil). L-Mesitran offer two 
dressings types including a hydro active dressing (a thin honey hydrogel dressing) and a net 
dressing (a hydro-active hydrogel honey coated dressing with an open weave mesh).   
Methylglyoxal (MGO) also termed 2-oxopropanol, pyruvaldehyde, pyruvic aldehyde, 2-
ketoproinoaldehyde, acetylformaldehyde, propandendione or propioaldehyde is a yellow liquid 
found in Manuka honey (210). It has a strong distinctive odour (211). Chemically it is a keto-
aldehyde (Fig. 2 4), is hygroscopic and polymerises readily (210). MGO has been identified in a 
range of beverages and foods including wine, beer (212), bread (213), soya, coffee, teas (214) 
and Manuka honey (184).  MGO is also a metabolite found in the human body, where it is 
formed endogenously via enzymatic and non-enzymatic reactions (210). In water MGO is 
available in the mono and dehydrate forms, the non-hydrated form of MGO is available only in 
trace amounts (215). The reactivity of MGO in cells and tissues can be strongly influenced by 
the presence of some organic compounds which are dependent on temperature and amount of 
water (216).  
 
 
A number of studies have looked at the beneficial effects of MGO in the conquest of different 
diseases. As already discussed, MGO is present in Manuka honey and is thought to be the 
unique antibacterial compound responsible for killing or inhibiting bacteria in wounds (172). 
However the antiviral activities of glyoxals were first reported in 1957, where two of these 
studies looked at the antiviral effect of 95 glyoxals against influenza and Newcastle disease 
virus when administered to an embryotic egg (43, 44, 218). Following these studies the anti-
cancer properties of MGO were first reported in 1958 by French and Freelander, who 
investigated the carcinostatic action of polycarbonyl compounds. Although MGO was not the 
2.5 Methylglyoxal  
Figure 2.4: Chemical structure of Methylglyoxal (217). 
2.5.1 Methylglyoxal as a therapeutic agent  
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sole focus of the study it was reported that an effective response against leukaemia cells was 
apparent with MGO (219). 
 
A later report in 1993 concluded that MGO had the anti-proliferative effects on leukaemia cells 
in-vitro (41); however, a recent report has described the opposite effect in-vivo highlighting the 
activation of macrophages and lymphophocytes by MGO against tumour cells (220). It is 
thought that the apoptosis mechanisms of MGO responsible for cell death to include inhibition 
of DNA synthesis, RNA synthesis and protein synthesis (221). Two earlier reports also 
discovered the high success rate of MGO as an anti-cancer treatment against mice who were 
intraperitoneally injected with ascites cancers. In the first study mice were subjected to either 
lymphosarcoma or leukaemia. It was found that a five or six day dosage of 70 mg kg
-1
 to 80 mg 
kg
-1
 of MGO given once each day resulted in 90% to 99% inhibition of cancer growth (42). On 
the contrary, in the other study, mice were divided into four groups, where treatment began after 
1, 4, 24  and 48 h respectively. Over a ten month period mice were treated with 18 injections 
daily, which amounted to 22 mg of MGO. In the first group, 15 mice remained free from 
ascites, in the second group, 13 remained free, in the third group 7 and in the fourth group, 4 
(222).  
 
A clinical trial of MGO in cancer patients has been reported with significant results. The study 
evaluated the performance of MGO against different types of cancer in fourty-six patients over a 
period of four months to five years. The cancers included, but not limited to brain tumours, head 
and neck cancer, gastrointestinal, lung, gynecological, breast, urological, hematological, 
prostate, gall bladder, and pancreatic cancer. The treatment consisted of an 8 ml solution of 0.45 
M MGO diluted in 60 ml of water followed by a chewable tablet of vitamin C containing 400 
mg of sodium ascorbate. The treatment was administered four times a day at regular intervals. 
The results highlighted the positive effects of MGO treatment with 78% of patients greatly 
benefited. 39% of patients had complete remission, while another 39% were classed as having 
partial remission or stable, 17% of patients were progressive and 2% was not stated. Patients 
during the study who had no sign of the disease after treatment strongly desired to continue the 
treatment for fear of recurrence. The significant finding of this study is that MGO is effective 
against a wide variety of cancer, which is in sharp contrast to other anticancer drugs now widely 
used. It also highlighted no adverse effects on glucose levels, which have been reported in other 
studies (40).  
 
More recent studies have experimented with the idea of introducing MGO into hydrogel wound 
dressings (45, 46) and polymer based nano-formulations for drug administration (47). The 
former study investigated the liquid and hydrogel formulations of MGO against two bacteria 
pathogens found in wounds; S.aureus and S.epidermidis. The hydrogel was prepared using 
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Carbopol as a gelling agent with an MGO concentration of 0.5% (w/w). Liquid concentrations 
of MGO were also prepared at 0.5% (w/w) and 0.8% (w/w) in water. A 70 µM solution of 
Methicillin was also formulated for testing. 150 µL of the liquid solutions and hydrogel were 
deposited into 9 mm wells cut in agar plates which were inoculated with each bacteria species. 
The plates were incubated overnight at 37ºC and then examined for a zone of inhibition. The 
results highlighted that the average zone of inhibition diameters ranged from 18 mm to 40 mm 
with an increasing concentration of MGO from 1.25 mg mL
-1
 to 15 mg mL
-1
.  No zone of 
inhibition was observed against Methicillin, proving the resistance that the bacteria have to this 
drug. The hydrogel performed equally as well as MGO in liquid form, with average zones of 
inhibition of 29.3 mm ± 0.4 mm, using the gel, and 29.5 mm ± 0.3 mm when using the liquids 
(45). Following this study the development of a topical hydrogel formulation containing MGO 
and hyaluronan was developed to access the activity against various wound pathogens. 
Hyaluronan was chosen as it is a naturally occurring glycosaminoglycan of the extracellular 
matrix and has been shown to promote wound healing and tissue regeneration in a recent study 
(223). E. coli, S. aureus, P.aeruginosa, Proteus mirabilis and MRSE were all included for 
testing using standard agar diffusion and dilution tests. Gel formulations were prepared with 
varying amounts of MGO from 0.1 wt % to 1 wt %. The results showed that MGO was found to 
inhibit and kill bacteria for all bacteria species with the minimum inhibitory (MIC) values 
between 1.05 mM and 4.22 mM and minimum bactericidal (MBC) values between 2.11 mM 
and 4.22 mM (46).  
 
New developments for the use of MGO in drug delivery have recently been investigated using 
conjugated MGO based nano-formulations (47). MGO was successfully encapsulated in 
nanoparticles in an emulsification mediated crosslinking method using a chitosan polymer 
(NMG). A second process involved the physical loading within a dendrimer polymer matrix 
using an equilibrium dialysis method (DMG).  The diameters of the particles were found to be 
between 68 nm ± 10 nm and 45 nm ± 5 nm respectively. These diameters are found to be 
acceptable for an encapsulated drug delivery technique in-vivo. The release behaviour of the 
MGO was studied using a dialysis bag. After 12 h 75% of the MGO content was released from 
the DMG particles compared to 43% of the MGO content being release from NMG particles. 
This is thought to be due to the crosslinking of the NMG particles with glutaraldehyde and the 
hydrophobic and hydrogen bonding interactions between the MGO and chitosan. Both the NMG 
and DMG particles were tested for their antibacterial activity against four bacterial strains 
including both gram negative and gram positive species; E.coli, P.aeruginosa, S.aureus and 
Bacillus subtilis respectively. NMG showed antibacterial activity against both positive and gram 
negative bacteria. However, the DMG demonstrated antibacterial activity against gram negative 
bacteria only. The values for NMG particles against gram positive bacteria displayed a strong 
activity, ranging from 0.4 µg mL
-1 
to
 
0.8 µg mL
-1 
MIC and 1.6 µg mL
-1
 to
 
2 µg mL
-1
 MBC. In 
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contrast the MIC and MBC values against gram-negative bacteria were 2 µg mL
-1 
to 6 µg mL
-1
 
and 4 µg mL
-1  
to 8 µg mL
-1
 respectively. DMG particles exhibited a strong effect with MIC 
values of 0.8 µg mL
-1
 and MBC values of 1.6–2 µg mL-1 against gram negative bacteria; 
P.aeruginosa and E.coli, respectively in comparison to MIC values of NMG. The 
concentrations of MGO found to demonstrate a biocidal effect in this study, where nanoparticles 
are used, were shown be considerably lower when compared to another study which showed a 
concentration of 1.05mg mL
-1 
in a liquid form (172).   
MGO has the ability to induce irreversible modifications in proteins under physiological 
conditions (224). It was shown that MGO was a potent protein glycating agent able to form 
advanced glycation end products (AGEs) (225). Numerous studies have indicated that AGEs 
have a pathogenic role in the progression of different oxidative-based diseases including 
diabetes (226-228). MGO is thought to be elevated in diabetic patients which may cause a 
variety of complications including nephropathy, retinopathy and cardiovascular disease (229). 
There are also reports that irreversible AGEs can disrupt the matrix remodelling of collagen 
(230). The treatment of diabetic foot ulcers with a Manuka honey dressing is also the subject of  
debate due to the speculation MGO may put patients as risk (231). However no study to date 
has reported any direct complications in diabetic patients treated with a Manuka honey dressing. 
 
On the contrary one study which assessed the treatment of neuropathic diabetic ulcers with a 
Manuka honey dressing, showed that no complications arose during treatment. The results 
showed a comparison of healing time between a Medihoney tulle dressing and a saline soaked 
gauze dressing. An increased rate in healing was achieved with the Manuka honey, with a mean 
healing time of 31 ± 4 days compared with 43 ± 3 days for the saline dressing (191). 
delivery in wound care  
Recent attempts in the area of drug delivery in wound care, include targeted drug delivery, 
where the antibacterial agent or drug shows activity at the wound site and limits systemic 
absorption (232). Controlling the release of a drug to a specific target, involves prolonging the 
action of the active drug, while maintaining a continual release. The use of polymers, such as 
PVA (233) show promising advantages for controlling the delivery, when compared to drug 
administration via injection or oral ingestion. These advantages include; 1) continuously 
maintained plasma drug levels in a therapeutically desired range, 2) harmful side effects from 
systemic administration are eliminated or reduced, 3) a continuous release of a small amount of 
a drug may be less painful than several large doses, 4) delivery via this method is potentially 
2.5.2 Potential complications of Methylglyoxal in diabetic patients 
2.6 Polymeric materials as delivery vehicles for targeted drug 
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less wasteful and expensive (60), 5) many polymers are readily biodegradable and can be 
washed off the wound surface once the drug has exerted the desired effect, 6) improvement of 
patient compliance, as there is less need for frequent dressing change if the delivery can be 
maintained for up to one week (21). An ideal drug delivery system should follow zero-order 
kinetics, where the concentration of the drug or antibacterial agent in the blood remains constant 
throughout the delivery period. The controlled delivery is most suited for non-healing chronic 
wounds such as diabetic ulcers, venous leg ulcers and decubitus ulcers. In these cases a 
bioactive compound is incorporated into a carrier material and the release rate may be 
dependent on the physiochemical properties of the carrier material, as well as the bioactive 
compound. It may also rely on the environmental conditions of the wound, including pH, ionic 
strength, temperature, enzymic concentration and degree of infection. Some dressings require 
the influence of the inflammatory enzymes or microbial proteases in the wound, in order for the 
drug release to take place. The polymer in the dressing is degraded by the enzymes, thereby 
releasing the drug from the polymer matrix (232).  
 
In others systems, where hydrophilic polymers, such as hydrogels are used, the controlled 
release of a drug happens via one or more physical process, including; 1) hydration of the 
polymer by the wound exudate, 2) swelling of the polymer to form a gel, 3) diffusion of the 
drug through the gel matrix and 4) eventual biodegradation of the polymer gel (21). Hydrogels 
offer many unique characteristics as wound dressings for drug delivery systems, in that they can 
be easily tuned via crosslinking techniques to control the rate of swelling and subsequent 
diffusion of the drug into the wound. They are generally highly biocompatible since they 
provide a high water content and have similar physiochemical properties similar to the 
extracellular matrix of the skin (234). Hydrogels are discussed in more detail in section 2.7.1.1. 
Wound dressings can be classified into four main categories based on the required treatment, 
these include passive, interactive, advanced and bioactive. A passive dressing will provide 
protection to the wound from mechanical trauma and bacteria permeation. They are dry and will 
not control moisture levels in the wound. Examples of passive dressings include gauze, 
bandages and tulle materials (235). An interactive dressing will facilitate wound healing by 
alternating the environment and interacting with the wound surface to optimise the healing 
process (22). They are fabricated with polymeric films and foams which are permeable and 
transparent to water vapour and oxygen. They offer a protective environment from external 
organisms such as bacteria (235). An advanced dressing is capable of maintaining a moist 
environment around the wound. Hydrocolloids and alginates are classed as advanced dressings 
(235). However hydrocolloids and alginates have also been grouped into the class of bioactive 
dressings (17). A bioactive dressing  delivers substances active in wound healing; either by 
2.7 Wound dressing classification 
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delivery of bioactive compounds or constructed by materials having endogenous activity (17). 
For the purpose of this study, bioactive dressings are of importance when considering the 
delivery method of antibacterials into the wound environment. 
Bioactive dressings should be able to provide all or some of the following characteristics (17, 
235): 
 Maintain a moist wound environment, while absorbing small amounts of wound 
exudate.  
 Neutralise the wound alkalinity by restoring the natural pH of the wound and skin. 
 Act as a drug delivery system to the wound site, while maintaining a controlled release 
rate. 
 Act as a skin substitute to severe burns or chronic wounds, where a large portion of the 
skin is lost.  
Within the classification of bioactive dressings, are specific types and structures, including 
hydrocolloids, hydrogels, alginates, chitin and chitosan derivatives and antibacterial dressings, 
such as honey and silver (17). As the work in this thesis is concerned with the hydrogel forming 
polymer PVA, a further discussion of hydrogels is given below in section 2.7.1.1. PVA is 
discussed in section 2.7.1.2. 
A hydrogel is known as ‘a water absorbing gel substance of varying rigidity (17)’. They are 
three-dimensional hydrophilic polymer networks, which are soluble in water (234, 236). 
Synthetic polymers such as poly(methacrylates), poly(vinylpyrrolidine (21) and poly(vinyl 
alcohol) (PVA) (237-239) are some common polymers used in hydrogel dressings. If the 
hydrogel has low rigidity it can be applied onto a wound via a syringe as an amorphous gel. 
These gels may require a second covering to avoid any movement. However, the more rigid 
hydrogels in the form of an elastic, solid sheet or film (240) are enclosed in a sealed sterile 
sachet which is opened upon direct application to the wound. The main role of a hydrogel is to 
hydrate the wound environment. Hydrogel dressings contain between 70–90% water which 
allows only a limited amount of exudate to be absorbed. Therefore hydrogels are more suited to 
light moderately exuding wounds (21). A hydrogel dressing may be used on necrotic, sloughy, 
granulating (241) and epithelializing wounds. If the hydrogel is used on a heavily exuding 
infected wound, the hydrogel must be changed daily, as there is the possibility the hydrogel will 
donate fluid into the wound causing maceration (236). Hydrogels have recently attracted 
attention with the objective of use as a properly controlled system to deliver drugs. The high 
2.7.1 Bioactive wound dressings 
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water content of a hydrogel promotes similarities to the physical and mechanical properties of 
the extracellular matrix, making them favourable materials in drug delivery (234). 
Poly(vinyl alcohol) (PVA) is a semi crystalline, hydrophilic polymer. It is known to have good 
chemical and thermal resistance and good physical properties (242, 243). Recently, PVA has 
become attractive for its use as a hydrogel in biomedical applications (238). PVA has been 
approved for medical use in humans by the FDA (61), where it has been used for several 
medical applications including transdermal patches, oral drugs, contact lenses, ophthalmic 
solutions such as synthetic tears (244), implants of artificial organs, cardiovascular devices and 
cartilage skin (245) . It has been shown to provide biocompatibility with tissue and blood, when 
combined with sodium alginate into a gel matrix (246) and in a study where a PVA hydrogel 
was used for the controlled release of antibiotic gentamicin when in contact with wound fluid 
(247) and the slow release of antibiotics into rats (63). PVA is also valued for its 
biodegradability (248).  
 
Several studies have explored the potential of PVA as a hydrogel forming polymer when used 
alone or combined with other natural or synthetic materials. Of these studies, PVA and poly 
(acrylic acid) were blended with two biological polymers, collagen and hyaluronic acid to form 
a hydrogel which was loaded with growth hormones for drug delivery for bone and cartilage 
repair (245). Another study combined PVA with poly (N-vinyl prryolidone) and chitosan as 
medicated hydrogel dressings containing antibiotic ciprofloxacin (249). PVA/gelatin hydrogel 
membranes were also fabricated via esterification of the hydroxyl groups in PVA and the 
carboxyl group of gelatin. The hydrogel membranes were shown to be super absorbent and 
highly compatible with human blood (64). Another study investigated the controlled release of 
two antibiotics, tylosin and oxytetracycline via the use of a PVA hydrogel. The results indicated 
a slow release of up to five days with tylosin as detected in the kidneys and muscles (63). The 
preparation of PVA hydrogels via electrospinning has also been explored in many cases and is 
discussed in section 2.8.4.2.  
PVA has poor stability in water, resulting in the majority of studies crosslinking PVA via 
physical or chemical treatment in order to make PVA insoluble, improve the mechanical 
integrity and control the release of any additional agents (54). The different techniques 
previously used to crosslink PVA are discussed in detail in a review by Bolto et al. (250) and 
are shown in Table 2.8. One of most popular methods, glutaraldehyde crosslinking which has 
already been employed for potential hydrogel materials in wound care (66), is discussed below. 
 
2.7.1.2 Poly(vinyl alcohol) (PVA) as a hydrogel material 
2.7.1.3 Crosslinking of PVA  
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Freeze thaw treatment Maleic acid and anhydride 
Heat treatment Malic acid 
Acid catalysed dehydration Malonic acid 
Irradiation Fumaric acid 
Persulphate treatment Poly(acrylic acid) 
Formaldehyde Trimesic acid 
Gluataraldehyde Trimesoly chloride 
Glyoxal Toluene diisocyanate 
Teraphthaldehyde Glycidal acrylate 
Acrolein Divinly sulphone 
Urea formaldehyde/H2SO4 Boric acid 
Citric acid 1-2 Dibromoethane 
ɣ-Glycidoxypropyltrimethoxysilane Tetraethoxysilane 
ɣ-Mercaptopropyltrimethoxysilane  
 
Gluataraldehyde has been employed as a crosslinking agent to PVA and PVA composite 
membranes in the form of a vapour (66), or a solution, where an acid catalysis is sometimes 
used (251, 252). It may also be included within polymer solutions during electrospinning (253). 
The crosslinking reaction between PVA and GA can be seen in Fig. 2.5 and can be attributed to 
the formation of acetal bridges between the hydroxyl groups in the PVA and the difunctional 
aldehyde molecule in GA (254, 255).   
Table 2.8: Crosslinkers used on PVA (250). 
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A study by Wang and Hseih (251) prepared a GA crosslinking solution by dissolving 50 wt % 
aqueous GA with 0.5 M aqueous sodium sulphate or ethanol to achieve a 0.2 M GA solution. 
PVA fibrous membranes were immersed into either GA solution for various lengths of time 
between 20 min to 2 days. The PVA membranes were then dried in a vacuum oven at 80ºC for 
12 h. In both cases the crosslinking with both GA solutions proved successful in providing 
water stable hydrophilic PVA membranes.  
 
In another study, nanofibre mats fabricated from chitosan, silver nanoparticles and PVA were 
exposed to a 25 wt % GA vapour for various lengths of time between 30 min to 120 min. Any 
unreacted GA vapour was removed via the incubation of the nanofibre mats in a vacuum oven at 
70ºC for 24 h. The study showed that the cumulative amount of silver ions released over a 7 day 
period in distilled water at 32ºC, was greater after only 30 min crosslinking time when 
compared with 60 min and 120 min crosslinking time (66). Fig. 2.6 shows the release profile of 
the silver ions from the GA crosslinked PVA nanofibre mats.  
 
Figure 2.5: Chemical reaction of PVA polymer with Glutaraldehyde (256). 
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nanofibre mats for different crosslinking times (66). 
 
A similar study by Destaye, Lin and Lee (254), examined the crosslinking of PVA electrospun 
mats. Four different GA molar concentrations between 0.5 and 2.56 were prepared and the PVA 
mats were exposed to the GA vapour for differing lengths of time between 6 h and 48 h. It was 
reported that the non crosslinked PVA mats were instantly soluble in water. After crosslinking 
via GA vapour, the PVA mats were rendered water insoluble. The higher molar concentrations 
of 2.0 and 2.56 showed no change in fibre morphology. At the lower molar concentrations of 
0.5 and 1.0, with increasing crosslinking time, the fibres began to swell and flatten. This was 
explained by the higher water content at lower GA concentrations, which caused swelling in the 
fibres. 
 
Tang et al. (253) reported a single step process of crosslinking PVA during electrospinning, by 
incorporating GA and a hydrochloric acid in appropriate portions in the polymer solution. 
Another study also employed a similar technique, using hydrochloric acid. PVA electrospun 
substrates were immersed in GA concentrations prepared between 15 mM to 60 mM and 0.01 N 
hydrochloric acid in an acetone solution for 24 h. It was found that the water uptake of the 
electrospun PVA substrates was reduced by approximately 6 g in weight when the GA 
concentration was lowered from 15 mM to 30 mM. Between a GA concentration of 30 mM and 
60 mM a gradual decrease in the water uptake of 1.5 g in weight was observed (255). The 
release profile of raspberry ketone (RK) from a gelatin/PVA nanofibre matrix at concentrations 
of 2% and 5% after crosslinking with GA was also reported. The exact method of crosslinking 
was not given. GA crosslinking times of 0 h, 2 h and 5 h were employed. A weight of 0.2 g of 
fibre was placed into 80 ml of phosphate buffer solution at 37ºC and agitated at 100 rpm. 5 ml 
samples were taken from the buffer solution at times between 10 min and 300 min. The 
Figure 2.6: Cumulative release profile of silver ions released from the GA crosslinked PVA 
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cumulative amount of RK released in the buffer solution was detected using UV spectroscopy. 
The release profile can be seen in Fig. 2.7. In the first 2 h, a large initial burst between 70% and 
80% KR was detected, before the profile levelled out. With an increase in crosslinking time the 
release rate was slowed down and the degree of fibre swelling was decreased (64).  
 
 
gelatin/PVA nanofibres for different crosslinking times (64). 
 
The ability to create fibres using an electrostatic field has been known since 1934, when 
Formhals patent on artificial filaments using a high electric field was published (257). This 
technique described the effect of an electrostatic force on a liquid droplet. A cone shape was 
formed at the tip of a capillary where small jets were formed when the charge density was high 
enough (257). The cone shape at the needle tip was later described as a Taylor cone by Geoffrey 
Taylor, where the disintegration of water droplets in an electric field was explored (258). Since 
these discoveries the basics of solution electrospinning in many laboratories has followed the 
basic set-up shown in Fig. 2.8.  
Figure 2.7: Cumulative release profile of raspberry ketone released from GA crosslinked 
2.8 Electrospinning fundamentals 
2.8.1 The principles of needle electrospinning 
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The simple set-up consists of three major components, a high voltage power supply, a 
spinnerette (syringe and needle) and a grounded collector (260). A solution is held in the 
syringe, which is fed to the needle tip at a controlled rate. A high voltage, usually more than 5 
kV (259), is supplied to the needle, this electrifies the drop of solution at the needle tip by both 
electrostatic repulsion between the surface charges and the Coulombic force exerted by the 
electrical field. As a result the drop of solution at the needle tip transforms into a conical shape 
known as the Taylor cone (258). When the electrostatic charges are great enough to overcome 
the surface tension of the solution, the ejection of polymer jets from the needle tip are initiated. 
The electrified jet undergoes a whipping action, during which it is elongated and stretched into a 
long thin polymer thread attracted by the grounded collector. During this phase, the solvent is 
evaporated and the charged fibre landing upon the collector is arranged in a randomly orientated 
state (260). 
 
This basic electrospinning process where by only one electrospinning jet is formed, has some 
limitations when considering the productivity, with reports that one needle can only produce 
fibres up to 300 mg h
-1 
(261). Various other systems have since been explored, including multi-
jets from a single needle, multi-jets from multiple needles and free surface (needleless) systems. 
However, the multi-needle systems usually require a large operating space, and the optimisation 
of the relative locations of needles, has to be considered to avoid the strong charge-repulsion 
Figure 2.8: Basic solution electrospinning set-up (259). 
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between the neighbouring solution jets. Regular cleaning has to be employed to each needle to 
prevent the blockage of the nozzles during spinning (262).  
 
To solve these problems, several methods of free surface (needleless) electrospinning have been 
explored, where several polymer jets are launched from a free liquid surface.  In this method, 
several potential benefits are available, including simplicity of design, lower operating and 
equipment costs, higher production rate, higher fibre and web uniformity, and higher fibre 
packing density (262). Elmarco s.r.o in the Czech Republic, are the first company to develop 
and patent (263) laboratory and commercial free surface (needleless) electrospinning 
equipment. In this study an Elmarco NS Lab was employed during experimental work and for 
the purpose of this literature survey, the technology of this equipment will be discussed in 
section 2.8.2.  
In this process a rotating electrode drum is dipped into a bath containing a polymer solution. A 
thin layer of the polymer is carried on the surface of the drum, which is exposed to a high 
voltage electrical field. When the voltage applied exceeds a critical value, electrospinning jets 
are formed along the electrode (264). These jets then rise upwards towards the grounded 
electrode, covered by a supporting substrate. Fig. 2.9 shows a schematic illustration of the free 
surface needleless electrospinning set-up using an Elmarco Nanospider. Fig. 2.10 shows the 
formation of jets along a spinning electrode (265). Until recently the theoretical description of 
free surface needleless electrospinning was not formulated.  
 
In 2008, Lukas, Sarkar and Pokorny derived a hypothesis based on the process of multi-jet 
formation from a liquid surface in an electric field. The work showed that the process can be 
analysed based upon Euler’s equation for liquid surface waves (265). From this equation, they 
developed another which explained the critical field strength value which must be met in order 
to initiate jet formation from the rotating electrode and one which explains the critical spatial 
period (wavelength- the average distance between jets generated from the surface) (264, 265).   
 
2.8.2 Free surface (needleless) electrospinning - Nanospider 
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1 = support material, 2 = grounded electrode, 3 = support material with a layer of fibres, 4 = 
bottom rotating electrode drum, 5 = tray with polymer solution, 6 = power supply with a 
positive polarity from 0-75 kV & L = the distance between bottom rotating electrode and 
support material (265). 
 
 
  
Figure 2.9: Set-up of the free surface (needleless) electrospinning process using a Nanospider (266). 
Figure 2.10: Formation of polymer jets rising from the rotating electrode drum (265) 
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Polymer solution, processing conditions and ambient conditions are three factors which 
influence the morphology of electrospun fibres. Within each of these factors are numerous 
parameters which may be altered to achieve a desired fibrous structure. Table 2.9 refers to each 
of these parameters, some of which are discussed in further detail. 
 
Solution Parameters 
Processing Condition 
Parameters 
Ambient Condition 
Parameters 
Molecular weight Voltage Humidity 
Concentration Flow Rate* Atmosphere 
Viscosity Collector Pressure 
Surface Tension Diameter of Needle* Temperature 
Conductivity 
Distance between 
tip/electrode and collector 
 
* Applies only to needle electrospinning 
Molecular Weight/Viscosity/Concentration 
The molecular weight (Mw) has a direct influence on the viscosity of a solution. When the Mw of 
a solution is higher, there will be greater entanglement of the polymer chains within the 
solution, resulting in a higher viscosity. An increase in concentration of a polymer will also 
increase the viscosity for the same reason (267). As an example, a study looked at the effect of 
varying Mw between 9000 and 186,000 g mol
-1
, and solution concentrations between 6 wt % and 
31 wt %, when using PVA. It was found that by varying the Mw and solution concentration of 
PVA in water, a significant effect was had upon the fibre morphology. At a concentration of 21 
wt % and a Mw of 13,000-23,000 g mol
-1
, the fibres appeared circular. As the concentration is 
increased to 27 wt % for the same Mw, the fibres become less round and appeared flat. When the 
PVA concentration was relatively low, at 6 wt %, a higher Mw between 50,000 and 186,000 g 
mol
-1
 produced round fibres. During the experiment a voltage of 30 kV was supplied and 
aluminium foil was used as the collector. No mention was given to the flow rate used (242).  
 
Many studies have also shown that at low polymer concentrations and viscosities, beaded fibres 
are generally formed (268). A critical polymer chain entanglement is required in order to initiate 
the electrospinning jet and obtain fibres free from beads (269). If the viscosity becomes too 
high, in the case of needle electrospinning, the flow of polymer solution to the needle tip will be 
prohibited (270) and subsequent needle blockage may occur (268).   
2.8.3 Electrospinning Parameters 
Table 2.9: Electrospinning parameters. 
2.8.3.1 Polymer Solution Parameters 
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Surface Tension 
For the electrospinning process to occur, the charge of the polymer solution must be high 
enough to overcome the surface tension of the solution. If the polymer solution has a high 
concentration of free solvent molecules, there is a possibility that the molecules will group 
together and create a spherical bead shape due to the surface tension. To overcome this problem 
an increase in viscosity will help to create a greater interaction between the solvent and polymer 
molecules. When the solution is stretched during electrical charging the solvent and polymer 
molecules are less likely to congregate into a spherical shape. Instead the solvent molecules will 
spread over the entangled polymer molecules (267). Fig. 2.11 illustrates this occurrence.  
 
distributed over the entangled polymer at a relatively high viscosity and (B) shows how the 
solvent molecules tend to congregate under the action of surface tension at a relatively low 
viscosity (267). 
Conductivity  
The electrospinning process can only occur when a solution gains sufficient charge so that the 
repulsive forces within the solution can overcome the surface tension. The ability for a solution 
to incur stretching and drawing  also depends on how well the  solution can carry charges (267). 
A number of studies have reported that a high solution conductivity yielded fibres free from 
beads (271-273). One study reported that the addition of salts to the electospinning solution 
resulted in a higher charge density on the electrospinning jet surface, which in turn increases the 
charges carried by the jet, causing higher elongation and fibres with fewer beads (268). 
Voltage 
A high voltage is an essential element in the electrospinning process. A high voltage will induce 
the required charges on the polymer solution and together with the external electrical field an 
elctrospinning jet will emerge from the needle tip or rotating electrode when the electrostatic 
charge is high enough to overcome the surface tension of the solution (267). During the 
electrospinning process the viscoelastic solution will be stretched by the columbic repulsive 
2.8.3.2 Processing Condition Parameters 
Figure 2.11: Bead formation during electrospinning, where (A) shows the solvent molecules 
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force in the jet. A higher voltage will increase the acceleration of the jet and stretch the polymer 
solution due to the increase in electrical charges (268). This may result is fibres with a smaller 
mean diameter, due to the stretching of the polymer jet (274, 275). However, if the acceleration 
is too fast the solvent will have less time to evaporate and will result in wet polymer fibres 
composed of mainly beads landing upon the collector (276). 
Distance 
It can be assumed that by increasing the distance the polymer solution has to travel, the 
stretching of the solution will be increased, resulting in a smaller fibre diameter. Increasing the 
distance also allows time for the solvent to evaporate before it reaches the collector (267). When 
the distance is too low, it may cause the fibres to merge, forming junctions (275), as shown in 
Fig. 2.12. 
 
 
 
 
 
Flow Rate  
Flow rate refers to the amount of solution released from the needle tip. It can be assumed that if 
a greater volume is drawn away from the needle tip at a given voltage, the fibre diameter may 
be greater than a lower flow rate at the same voltage (268). However, a greater volume of 
solution will take longer for the solvent to evaporate and so the distance must be considered 
when finding optimum spinning conditions (277).  
The temperature, humidity, atmosphere and pressure may also have an influential effect on the 
polymer solution during electrospinning. The humidity is of particular importance as water 
drops may condense on the surface of the fibres, disrupting the fibre morphology (267). A study 
on the effect of relative humidity (RH) on the electrospinning of poly (acrylonitrile) (PAN) and 
polysulfone (PSU) showed great variation in the diameter and mechanical strength of the fibres 
with varying RH between 0% to 60%. For example the average fibre diameter of PAN increased 
distance of 0.5 cm from the collector (241). 
2.8.3.3 Ambient Condition Parameters 
Figure 2.12: Nylon 6,6 . Merging fibres deposited at a 
~ 49 ~ 
 
from 150 nm at 0% RH to 630 nm at 60% RH while the average diameter of PSU fibres 
increased from 1.15 µm at 0% RH to 3.58 µm at 50% RH, all other parameter remained 
constant. PAN fibres were also shown to shift from a smooth surface to a rougher one with 
increasing RH. PSU exhibited varying changes in the surface morphology with increasing RH, 
from smooth to elongated pores and creases in the fibres (278).  
 
A change in temperature is also known to affect the fibre morphology during electrospinning, 
due to the change in viscosity of the electrospinning solution and solvent evaporation (267). 
Polyurethane was shown to produce more uniform fibres, when electrospun at a higher 
temperature of approximately 70ºC, when compared with those spun at ambient room 
temperature. At the higher temperature several jets were produced from the tip of the needle, 
with a large angle between each jet. It was also observed that the deposition rate of the fibres 
was increased at a higher temperature, resulting in a thicker electrospun web (279).  
Electrospun materials as medical dressings are still in their infancy, with many research 
institutions exploring new possibilities. These materials meet the majority of the requirements 
outlined for wound healing polymer devices, as their microfibrous and nanofibrous structures 
provide the nonwoven textile with desirable properties (280). The fibres produced from 
electrospinning are exceptionally small, with typical fibre diameters ranging from 5 nm to 500 
nm (57). This offers many advantages including, a high surface area between 5 m
2
 g
-1
 to 100 m
2
 
g
-1 
(281) and a high aspect ratio, where the length of the fibres can be as long as several 
kilometres due to the continuous process (260). The size of the fibres also provides an 
environment which closely mimics the extracellular matrix (ECM) required in healing (260). 
They also have a high porosity but small pore size, with reports of 93.6% porosity (280) and  
pore throat diameters ranging between 0.1 µm to 0.8 µm (282). These unique properties of 
electrospun webs provide the following benefits for materials in wound care and can be seen 
below in section 2.8.4.1.   
2.8.4 Electrospun polymeric materials for wound care  
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Haemostatic effect:  Due to the small interfaces and effective high surface area, haemostasis is 
promoted via the physical nature of the nanofibrous material without the need of a haemostatic 
agent (283, 284).  
 
Absorption: The work by Dabney (285) showed that the water absorption of nanofibres of the 
same polymer, absorbed between 17.9% to 213% compared to a typical film dressing which 
only absorbed 2.3%. If a hydrophilic polymer is used, this will increase absorbability further, 
which is necessary for heavy exuding wounds. 
 
Semi-permeability: The porous structure provides excellent respiration for the cells (284) and 
does not lead to wound desiccation (286). The small pore size allows for protection against 
bacteria, while allowing gas permeation (286). 
 
Conformability: The ability of a dressing to conform to the contour of the wound is one of the 
parameters that needs to be clinically assessed. It is recognised that conformability of a textile 
material is closely related to the fineness of the fibres. In the case of electrospun fibres, the 
lower fibre diameter results in better coverage and protection from bacteria infection (284).   
 
Functionality: Antibacterial agents or growth factors for promoting fibroblast or epithelisation 
can be incorporated into the carrier polymer during the electrospinning process, making the 
fibrous membranes bioactive. Multi layers can also be achieved to provide different 
functionality in each layer to attain desired objectives in wound healing (285). This allows for 
the decreased frequency in dressing change and the disturbance of tissue regeneration. 
 
Reduction of Scar Tissue: Fibres produced via electrospinning can also provide a scaffold to 
promote cell growth, as the size of the fibres closely bio-mimics the proteins such as collagen 
found in the ECM (58). The topographical nature of the electrospun webs also plays an 
important role in cell attachment and proliferation (59). These features hope to aid in a wound 
free from scarring.   
Electrospun hydrophilic polymer webs provide a convenient way of incorporating antibacterial 
agents or drugs into fibres, via suspending or dissolving the agent into a polymer solution prior 
to spinning (48). These webs offer potential means of delivering a drug or antibacterial agent to 
the wound site via diffusion alone or diffusion and scaffold degradation (58). PVA has many 
beneficial properties which make it a desirable polymer for use in wound care and drug delivery 
systems, as discussed previously in section 2.7.1.2. Several studies have explored the use of 
2.8.4.1 Potential benefits of electrospun materials in wound care 
2.8.4.2 Electrospun poly(vinyl alcohol) webs for wound care 
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electrospun PVA webs for potential wound dressing materials or transdermal patches. Of these 
studies PVA has been used alone (67, 159, 287-291) or combined with other natural and 
synthetic polymers such as sodium alginate (292), calcium alginate (293), poly(vinyl acetate) 
(54), polyurethane (PU) (294), polyethylene (295), chitosan (66, 296), gelatin (233), and silk 
fibroin (297).  
 
Antibacterial agents or antibiotics, such as silver (67, 288, 292, 295), honey (287), gum 
tragacanth (298), ciprofloxacin HCL (54), gentamicin (294), ketoprofen (291), raspberry ketone 
(233) and non-steroidal anti-inflammatory drugs (289) have been incorporated within the PVA 
or copolymer matrix with the intention of providing a controlled delivery to the intended site or 
an antibacterial effect on bacterial organisms. In certain cases, the controlled release of the 
antibacterial agent or drug was achieved via crosslinking with GA (64, 66), as discussed in 
section 2.7.1.3. The release of antibacterials or drugs from PVA webs without crosslinking has 
also been reported. A study by Maleki et al. (287), assessed the release of dexamethasone 
sodium phosphate (Dex-P), an anti-inflammatory drug, from electrospun PVA/honey 
nanofibres, for the potential use in wound dressings. In this work, PVA/honey electrospun 
solutions were prepared at differing ratios in distilled water. Dex-P was added to the certain 
PVA/honey ratios at concentrations of 5, 10 and 15 wt %. PVA solutions without honey, 
containing Dex-P at equivalent concentrations were also prepared for electrospinning. The 
spinning solutions were electrospun using the syringe method at a voltage of 19 kV, a distance 
of 20 cm and flow rate of 1 ml h
-1
. The release of Dex-P from the as-spun webs was assessed 
via immersing pre-weighed webs of both PVA/honey (ratio of 80/20) and PVA in phosphate 
buffer solution (PBS) at 37ºC in a shaking incubator. At scheduled intervals, 1 ml of the 
solution was taken and replaced by 1ml of fresh PBS. The amount of Dex-P present in the 
solution was measured by a UV-visible spectrometer and related to the premade calibration 
curves of Dex-P in in PBS. Figure 2.13 shows the cumulative release profile of Dex-P from 
both PVA/honey (Fig. 2.13B) and PVA webs (Fig. 2.13A) was similar. A large initial burst was 
firstly observed in the first 40 min. After this the amount release amount plateaued. The effect 
of Dex-P concentration also showed a limited effect, with the higher concentration of 15 wt % 
showing a slightly increased release percentage (287). 
 
~ 52 ~ 
 
  
fibres (287). 
  
 
The antibacterial effect of the electrospun PVA fibres, in the majority of cases is assessed via a 
common zone of inhibition method (292, 294). One study reported the effect of gentamicin on 
bacteria S.aureus and P.aeruginosa from a multi-layered electrospun composites prepared by 
nanospider technology (294). PU and PVA were electrospun separately in a layering process to 
build a novel composite structure. Within the PVA layer, gentamicin was added to the PVA 
electrospun mixture at a 10 wt % concentration. Thermal crosslinking was employed to the 
PVA layer at 145ºC for 15 min. A non-crosslinked sample was also prepared. To determine the 
antibacterial performance from the multi-layered structure, 6 mm discs were cut from the 
electrospun samples and placed on agar plates seeded with either S.aureus or P.aeruginosa. The 
plates were incubated at 37ºC for 1, 2 and 6 days. Pure gentamicin disks containing the same 
concentration were used as a control, as well as a multi-layered electrospun structure free from 
the drug. Clear inhibitory zones were observed with both strains around all of the gentamicin 
loaded samples, as seen in Fig. 2.14. The control samples showed no zone. This experiment 
proves that gentamicin survives the high electric field during electrospinning and high 
temperatures during thermal crosslinking (294).  
 
Similarly two others studies also reported the antibacterial effect of sodium alginate/PVA/zinc 
fibres and PVA/silver fibres using the agar plate diffusion method, where zones of inhibition 
were reported in both cases (67, 292).  
A B 
Figure 2.13: Cumulative release of Dex-P from PVA (A) and PVA/honey 80/20 (B) electrospun 
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crosslinked PU/PVA samples (C&F) loaded with gentamicin for different bacterial strains. 
B&C = S.aureus and E&F = P.aeruginosa (294). 
 
The antibacterial activity of chitosan/PVA nanofibre mats loaded with silver nanoparticles (Ag-
NPs), was assessed using a different approach called a viable cell counting method (66). In 
brief, this system cultivated a known amount of E.coli colony forming units (CFU) per ml of 
nutrient broth. Several dilutions of this original solution were made to reach a desired 
concentration of bacteria. Electrospun PVA/chitosanAg-NPs and PVA/chitosan mats were 
prepared at varying ratios to determine the effect of chitosanAg-NPs or chitosan on the growth 
of E.coli. 100 g samples of the electrospun webs measuring 2.8 cm in diameter were added to 
10 ml of the cultured bacteria broth and incubated in a shaker at 37ºC for 24 h. After this time, 
100 µL of the bacterial solution was taken and spread onto nutrient agar containing plates. 
These plates were then incubated again at 37ºC for 24 h and the number of surviving bacteria 
colonies was counted. The results indicated that the PVA/chitosan webs were able to prevent the 
growth of E.coli at a ratio of 80:20, where the concentration of bacteria was at 7 x 10
5 
CFU ml
-1
. 
In comparison the PVA/chitosanAg-Nps at a ratio of 90:10 were able to prevent the growth of 
bacteria, as seen in Fig. 2.15.  
Figure 2.14: Zone of inhibition produced from non-crosslinked PU/PVA samples (B&E) and 
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ratios on the growth of E.coli at a concentration of 7 x 10
5 
CFU ml
-1
(66). 
There is substantial evidence to support the effective antibacterial properties of Manuka honey 
in chronic wound care, with several studies reporting on the improved healing of chronic 
wounds, after treatment with a Manuka honey dressing. In the majority of cases, MGO is 
reported to be the main constituent reason as to why these infected chronic wounds are healing. 
MGO as a lone compound was shown to inhibit the growth of S.aureus, E. coli, P.aeruginosa, 
Proteus mirabilis and MRSE when combined in hydrogel formulations in-vitro. The controlled 
delivery of MGO when encapsulated in nanoparticles was successfully demonstrated and the 
antibacterical effect against E.coli, P.aeruginosa, S.aureus and Bacillus subtilis was also 
reported in the same study. MGO has also shown ability to provide anti- carcinostatic activity, 
with successful outcomes both in-vivo and human trials.  
 
The production of nano and submicron fibres via electrospinning, shows many beneficial 
properties for novel materials in wound care, including the ability to incorporate antibacterial 
agents or drugs. PVA has been effectively used in a number of electrospinning studies as a 
potential carrier material for the release of antibacterial agents or drugs, owing to its hydrogel 
form and biocompatibility with human tissue and blood. The controlled delivery of antibacterial 
agents and drugs from PVA hydrogels has been demonstrated with and without the need for 
crosslinking mechanisms. 
 
The aim of the experimental study was therefore to determine the feasibility of producing a 
functional electrospun PVA hydrogel forming material, with the addition of MGO as 
antibacterial agent. Antibacterial studies were carried out to determine the minimum MGO 
B 
A 
Figure 2.15: Effect of PVA/chitosan (A) and PVA/chitosanAg-NPs (B) electrospun webs at varying 
2.9 Summary 
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concentrations required to have an antibacterial effect in-vitro. The effect of crosslinking was 
also explored to understand the release kinetics of MGO from the PVA webs.   
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Chapter 3 Experimental Materials and Methods 
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In this chapter a description of the raw materials, chemicals, experimental setup and the main 
experimental and characterisation techniques that were used in this research are discussed. 
Details of the experimental methodology are explained in the following chapters. 
Polymers and reagents used throughout this study and the individual suppliers are listed below 
in Table 3.1.  
Chemical Supplier 
Poly(vinyl alcohol) (31-50000 Mw, 98-99% hydrolysed) Sigma Aldrich 
Methylglyoxal (40% in H2O) Sigma Aldrich 
Manuka honey (MGO 550 mg kg-1) Wellbeing, UK 
Glutaraldehyde (25% in H2O) Sigma Aldrich 
Acetone (99.5%) Sigma Aldrich 
Distilled Water Distilled in house 
Deuterium Oxide (99.9% atom D) Sigma Aldrich 
Equipment and materials used throughout this study and the individual manufacturers are listed 
in Table 3.2.  
Equipment Model Make 
Optical Microscope  Watson Barnet 
Viscometer DV-E Viscometer Brookfield LV 
Conductivity meter CON 2700 EUTECH 
Tensiometer K100 KRUSS 
Fourier transform infra-red spectroscopy (FTIR) Spectrum BX Perkin Elmer 
High Performance Liquid Chromatography 
(HPLC) 
1290 Infinity Agilent 
HPLC column Eclipse XDB-C8 Agilent 
Plasma machine Electronic diener Pico 
Scanning Electron Microscope JSM-6610LV Jeol 
3.1 Introduction 
3.1.1 Stock Chemicals 
Table 3.1: Chemicals used in experiments. 
3.1.2 Equipment 
Table 3.2: Equipment for characterisation techniques. 
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Scanning Electron Microscope EVO MA15 Carl Zeiss 
Field Emission Gun Scanning Electron 
Microscope (FEGSEM) 
LEO 1530 Carl Zeiss 
Field Emission Gun Scanning Electron 
Microscope (FEGSEM) 
Quanta 200F FEI 
SEM Sample Coater 
High resolution sputter 
coater 
Agar 
SEM Sample Coater Model: SC500 Emscope 
Proton NMR Spectrometer 500 MHz 1H NMR Bruker Avance 
High voltage DCpower supplies EH series 100 watt 
Glassman High 
Voltage 
Syringe pump Model 200 series Kd Scientific 
Glass syringes Fortuna Optima, 10 ml 
Poulten & Graf, 
Barking 
Syringe needle 21 gauge stainless steel Sigma Aldrich Ltd 
Digital Temperature and Humidity meter N18FR Precision GOLD 
Free surface needleless electrospinning Nanospider NS LAB Elmarco 
Aluminium foil   
Polypropylene spunbond (SPB)  Elmarco 
Electronic scale Sartorius CP225D Sartorius AG 
Electronic scale EK -200G AND 
Hotplate/Magnetic stirrer PC-351 Corning 
Hotplate/Magnetic stirrer  Stuart Scientific 
Shaker/Incubator 
Orbital shaker-Incubator 
ES-20 
Grant-bio 
Shaker/Incubator Orbital Incubator; S1500 Stuart Scientific 
Incubator IGS 180 Thermo Scientific 
Water bath BB2 Grant 
Petri dishes 92x16 mm with cams Sarstedt (AG & Co) 
Desiccator   
Metal frame 10 cm diameter  
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The preparation of individual electrospinning solutions is discussed in following chapters. To 
avoid repetition the methods used to characterise these spinning solutions throughout the 
experimental work are detailed in this section. 
Electrospinning solutions were characterised by viscosity measurements to determine a 
relationship between the spin ability of the polymer solution and the viscosity. Details of the 
polymer solutions are provided in Table 3.3. 
 
measurements. 
Solvent 
MGO concentration 
(wt %) 
PVA concentration 
(% w/v) 
Distilled water 0 
8, 12, 14, 16, 18, 20 
40 wt % MGO 40 
40 wt % MGO diluted 
with distilled water 
21.57 
14.76 
11.22 
  
3.2 Materials and Methods 
3.2.1 Viscosity of electrospinning solutions and Manuka honey 
Table 3.3: Polymer solutions for viscosity, surface tension and electrical conductivity 
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Rheology is the science of flow which describes the deformation of a body against a certain 
strain or force (299). Viscosity is the measure of a liquid against a forced motion (300). There 
are two methods for measuring viscosity; kinematic and dynamic viscosity. In the present study 
dynamic viscosity measurements were taken, as most polymers solutions are non-Newtonian 
and dependent on the shear rate. Dynamic viscosity provides the ability to control the shear rate 
during testing. Dynamic viscosity (η) is a measure of the shear stress (τ) divided by the shear 
Eq. 3. 1 
η = τ/ɣ 
The shear stress (τ) is the force applied to a specified unit area. As a result of this shear stress on 
the liquid, a shear rate (ɣ) (flowing liquid) is created. The shear rate describes the flow gradient 
between the spindle and sample chamber wall. The unit of measurement of viscosity is the poise 
(P). A liquid requiring a shear stress of one dyne per square centimetre to produce a shear rate 
of one reciprocal second, has a viscosity of one poise of 100 centipoise (cP) (301). 
 
A Brookfield LV viscometer (DV-E) was used to measure the viscosity of the polymer solutions 
and Manuka honey (MGO 550). The viscosity measurements of all polymer solutions were 
measured using a removable sample chamber, at a temperature of 25ºC ± 2ºC. The Manuka 
honey was measured at a temperature of 25ºC ± 2ºC and 37 ºC ± 2ºC in order to determine the 
effect of temperature on the viscosity of Manuka honey. In order for the chamber and solution 
to reach the specific temperature required, 9.4 ml of the polymer solutions and 16.1 ml of the 
Manuka honey was decanted into the chamber and conditioned in an S1 500 Orbital Incubator at 
the required temperature for 24 h prior to testing. The spindle was also conditioned to the 
correct temperature. The speed (shear rate) and spindle were kept constant during all 
measurements (300, 302). For the polymer solutions, the speed was set at 6 r min
-1
 and a spindle 
size 34 was used. For the Manuka honey solutions a speed of 6 r min
-1
 and a spindle size of 18 
was used.  
Electrospinning solutions were characterised by surface tension measurements to determine a 
relationship between the spinning ability of the polymer solution and the surface tension. 
Details of the solvents and conditions used to prepare each polymer solution are provided in 
Table 3.3.  
 
Surface tension, also known as surface free energy is caused by the imbalance of liquid 
molecule forces at the surface of a liquid. In the bulk of a liquid each atom is surrounded by 
similar atoms, which are pulled equally in every direction by the neighbouring atom. This 
3.2.2 Surface tension of electrospinning solutions 
rate (ɣ) of a liquid, seen in the following equation: 
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results in a net zero force.  At the surface of the liquid, the atoms are exposed and do not have 
neighbouring atoms surrounding them to provide a balanced force in equal directions. These 
atoms are pulled inwards by the atoms below, creating an internal pressure, which results in the 
liquid voluntarily contracting its surface area to maintain the lowest surface free energy (303). 
 
The surface tension of electrospinning solutions was measured using the Wilhelmy plate 
method, using the KRUSS Tensiometer K100 (Fig. 3.1). The surface tension measurements of 
all polymer solutions were measured at 25ºC ± 2ºC. The polymer solution was contained in a 
sample vessel with a diameter of 66.5 mm and a depth of 35 mm, capable of holding 121.5 ml 
of solution. In order for the sample vessel and the solution to reach the specific temperature 
required, 100 ml of the polymer solution was decanted into the chamber and conditioned in a 
Grant bio ES-20 Orbital shaker incubator at 25ºC ± 2ºC for 24 hours prior to testing. A platinum 
plate of 19.9 mm in width, 0.2 mm thickness and 10 mm in height was used to carry out the 
measurements. The platinum plate was lowered vertically into the liquid solution. Upon contact 
with the surface a force (F) acts upon this plate and the surface tension (σ) can be calculated by 
the following equation: 
Eq. 3. 2      
     (      ) 
 
 
 
  
Figure 3.1: Wilhelmy plate method (304). 
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The conductivity of electrospinning solutions was determined to understand if there was a 
relationship between the spinning ability of the polymer solutions and conductivity. Details of 
the polymer solutions can be seen in Table 3.3.  
 
Conductivity is defined as “the ability of a substance to conduct electric current” (305). 
Electrical conductivity in a liquid occurs by the migration of positive and negative ions through 
the liquid. When two electrodes are placed in a liquid and an electromotive force is connected to 
them, a current is supplied. An electric field between the positive and negative terminals causes 
the ions in the liquid to drift. The drift velocity and number of ions per unit volume influences 
the electrical conductivity of a liquid. The electric field intensity, the mass of the ion and other 
factors influences drift velocity of the ions. This means that the electrical conductivity of 
various liquids may be expected to have different values (306). Water molecules even at low 
temperatures tend to be in continuous motion. When two water molecules collide, the transfer of 
a hydrogen ion from one molecule to another occurs. The molecule that loses a hydrogen ion 
will become negatively charged hydroxide ion (OH
-
) and the molecule that gains a hydrogen ion 
becomes positively charged hydrogen ion (H
+
). This is a process known as self ionisation of 
water (307). At a room temperature of 25ºC the conductivity of water is around 0.05 µS cm
-1
. 
The amount of H
+
 and OH
-
 ions are approximately the same. However, in other solutions the 
concentrations of these ions will be unequal (306).  
 
The conductivity of the prepared electrospinning solutions was measured using a EUTECH 
CON 2700 conductivity meter, fitted with a probe capable of measuring conductivity in the 
range of 0-500 µS cm
-1
. The conductivity measurements of all polymer solutions were measured 
at 25ºC ± 2ºC. Each solution was contained in a 40 ml measuring vessel in an incubator at 25ºC 
± 2ºC for 24 hours prior to testing. The conductivity probe was also conditioned to the required 
temperature. During testing the conductivity probe was positioned in the centre of this solution 
and left until a stable reading could be taken.   
3.2.3 Electrical conductivity of electrospinning solutions 
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Preparation of electrospinning solutions is discussed in detail in following chapters. The general 
procedures are described in this section.  
Electrospinning solutions were contained in a 10 ml syringe, fitted with a 21 gauge blunt needle. 
The syringe was connected to a dual head syringe pump set to run at a feed rate of 0.1 ml hr
-1
. 
Details of the time spun are explained in the relevant experimental chapters. The voltage was 
supplied to the needle at its base via a copper electrode. A voltage between 7 kV and 18 kV and 
a distance between 5 cm to 15 cm from the tip of the needle to the collector was used. An 
aluminuium foil collector measuring 10 cm x 10 cm was secured on a non-conducting board 
opposite the needle and connected to a grounded cable. The electrospinning procedure was 
carried out inside a fume cupboard where continuous suction was available to evacuate any 
fumes. The ambient temperature was 25ºC ± 2ºC and the humidity was 49% ± 2%. Fig. 3.2 
displays the needle electrospinning setup. 
 
 
  
High voltage 
power supply 
Syringe containing 
the polymer solution 
Needle 
Grounded 
collector 
Electrically 
charged 
polymer jet 
3.2.4 Electrospinning Procedures  
3.2.4.1 Needle electrospinning  
Figure 3.2: Needle electrospinning setup. 
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An Elmarco Nanospider NS LAB was used to carry out free surface electrospinning. A spinning 
bath capable of holding quantities of liquid between 15 ml to 25 ml was fitted with a cylindrical 
wire roller electrode measuring 300 mm in length. The voltage was supplied to the electrode by 
means of internal wiring contained within the machine. A voltage between 65 kV to 75 kV and 
a distance between 163 mm to 183 mm from the electrode to the collector was used. The 
electrode speed was set to run at 6.0 r min
-1
.  Fig. 3.3 displays the free surface electrospinning 
setup. Fig. 3.4 shows an image of the spinning bath and cylindrical wire electrode. Both 
aluminium foil and polypropylene spunbond (SPB) collectors were utilised during the 
experiments. The following experimental chapters make reference to these where necessary. 
 
 
 
 
 
Polymer 
jets 
Motor device for electrode 
Grounded electrode 
Rotating electrode 
High 
voltage 
distribution 
Collector base material 
Polymer solution in spinning bath 
3.2.4.2 Free surface (needleless) electrospinning  
Figure 3.3: Free surface electrospinning set up using the Elmarco Nanospider NS Lab. 
Figure 3.4: Free surface electrospinning bath with wire cylindrical electrode.  
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SEM was employed to elucidate details of fibre morphology, fibre diameter and the degree of 
bead formation. SEM has the advantage over optical microscopy, in that it is able to produce 
images with an increased depth of field and greater resolution. Prior to imaging, all samples 
were cut and mounted onto 25 mm aluminium stubs and sputter coated with gold in a vacuum of 
0.05 torr for 4 minutes at 20 mA. Four different scanning electron microscopes were used 
during the course of this study, an EVO MA15 SEM, a LEO 1530 FEGSEM, a Jeol JSM 
6610LV SEM and a Quanta 200F FEGSEM. A voltage between 5 kV and 15 kV and a vacuum 
pressure in the order of 10
-6
 mbar was achieved in the chamber. Magnifications between x200 
and x6000 were used in order to record morphological features of individual fibres. 
FTIR is used for identifying the major functional groups in a compound (308). When a polymer 
sample is placed inside the IR machine wavelengths are passed through an interferometer and 
onto the sample. The sample absorbs all the different wavelength characteristics of its spectrum 
and this subtracts specific wavelengths from the interferogram. The atoms and bonds inside the 
molecule will vibrate and at different frequencies depending on the type of bond. A detector in 
the machine records the variation in energy versus time for all wavelengths simultaneously. 
Fourier transform analysis allows the conversion of the intensity vs. time spectrum into an 
intensity vs. frequency spectrum (309).   
 
An FTIR Perkin Elmer Spectrum BX spotlight spectroscope was used in this study to detect the 
presence of specific compounds within the fibres. Solid polymer particles and solutions were 
measured with a diamond ATR attachment. Measurements of polymeric fibres were measured 
using a KBR disk. Fibres were cut into small pieces measuring approximately 1 cm² and ground 
with potassium bromide (KBr) granules to make sample pellets. Measurements were taken in 
the range between 4000 – 400 cm-1 with a resolution of 4 cm-1. 64 scans were taken for each 
sample with the diamond ATR and 16 scans were performed for samples with the KBr pellets. 
1
To quantify the presence of antibacterial compounds within electrospun fibres, nuclear magnetic 
resonance spectroscopy was utilised. NMR spectroscopy is frequently used as one of the most 
popular methods for characterisation of polymers in both solution and solid states. Solution 
NMR is regularly used due to its high resolution and sensitivity (310).   
3.2.5 Scanning Electron Microscopy (SEM) 
3.2.6 Fourier Transform Infra-Red (FTIR) Spectroscopy 
3.2.7 H- Nuclear Magnetic Resonance (NMR) Spectroscopy 
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Nuclear magnetic resonance spectroscopy involves the absorption and emission of 
electromagnetic radiation by the nuclei in certain atoms when they are subjected to a magnetic 
field (311). The nuclei of an atom must possess a non-zero magnetic moment in order to absorb 
electromagnetic radiation. This is possible if the spin quantum number (I) is non-zero (311). If 
the atomic number and atomic mass are even, the nucleus will have no magnetic properties and 
a spin quantum number of I = 0. When the atomic number or atomic mass is odd or both are 
odd, the nucleus is said to be spinning.  Hydrogen (
1
H), the simplest atom found in most organic 
compounds is composed of a single proton and a single electron. Because the atomic number of 
hydrogen is odd, the nucleus of the hydrogen atom is spinning. 
 
When a sample, typically liquid, is placed into a magnetic field (B0) whose units are tesla or T, 
the atoms have a preferred orientation as a compass needle has in the earth’s magnetic field.  
Energy, supplied to the system along a direction designated as the z axis, will move the nuclei to 
a less preferred energy orientation. Nuclei with a spin of 
 
 
, such as hydrogen atoms, can assume 
two orientations; lower energy, with the external magnetic field (+z) and higher energy (-z), 
against the magnetic field (312, 313). The nuclei will not align perfectly horizontally along the z 
axis and instead will move in a circular motion about the z axis called precession. The two 
directions of precession are referred to as + 
 
 
 and - 
  
  
.  The precession motion of the magnetic 
moment occurs by angular frequency known as Larmor frequency ( 0). A second magnetic 
field (B1) is supplied in order to interconvert the two orientations. When the radio frequency of 
the B1 field is the same as the Larmor frequency of the nucleus, energy will flow between the 
newly applied field as absorption and emission. Absorption occurs as + 
 
 
 nuclei become - 
  
  
 
nuclei and emission occurs as - 
  
  
 nuclei become + 
 
 
 nuclei. At the beginning of the experiment 
there is an excess of + 
 
 
 nuclei and there is a net absorption of energy. This process is known as 
resonance and the absorption is detected electronically and displayed as frequency vs amount of 
energy absorbed (312, 313). 
 
In this study a Bruker Avance spectrometer 500 MHz 
1
H NMR was used to characterise and 
detect the presence of a compound. Prior to testing, 10 mg of each sample was dissolved in 1 ml 
of Deuterium oxide (99.9%) solvent which contains deuterons instead of protons. There are two 
reasons for this, firstly a protonated solvent would overwhelm the proton signal from the 
sample, secondly the deuterated solvent can be used for frequency locking to ensure magnetic 
field stability (310). H-NMR spectra were recorded with 1024 repetitions.  
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Three methods of testing were used to assess the antibacterial properties of the experimental 
fabrics or solutions. BS EN ISO 20743:2007 Textiles - Determination of antibacterial activity of 
antibacterial finished products (314),  was carried out at Shirley Technology Ltd. BS EN ISO 
20645:2004, Textile fabrics - Determination of antibacterial activity, agar diffusion plate test 
(315), was carried out at the Leeds Pathology and Microbiology department. The minimum 
inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were carried 
out at the Research and Development Laboratory of the Health Care Associated Infections 
group, Leeds Institute of Biomedical And Clinical Sciences (LIBACS), University of Leeds. 
Details of each test are described in the following sections.  
antibacterial finished products 
A brief summary of the method of test performed at Shirley Technology is given below. 
Preparation of bacterial culture 
The bacterial cultures were prepared to concentrations between 1-3 x 10
5 
per 10 ml in 1 in 20 
nutrient
 
broth. 
 Preparation of test specimens 
Test pieces with a mass of 0.40 g ± 0.05 g were cut into suitable sizes for testing. Six control 
specimens and six antibacterial specimens were prepared. 
Inoculation  
The test specimens were placed in sterile jars and inoculated with 0.2 ml of bacterial suspension 
on several areas of the sample, taking care to prevent contact of the suspension with the jar 
surface. Immediately after inoculation, 20 ml of SCDLP medium (simulated wound exudate) 
was added to three of the control jars and three of the antibacterial sample jars. The jars were 
sealed with caps and shaken in an arc of approximately 30 cm by hand for 30 sec. 
 
The number of bacteria recovered from the samples was then determined using a standard serial 
dilution and pour plate technique using peptone salt solution as the dilutant and enumeration 
agar. The remaining jars were incubated at 37ºC for 24 h.  
3.2.8 Antibacterial Testing 
3.2.8.1 BS EN ISO 20743:2007 Textiles - Determination of antibacterial activity of 
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Calculation of results 
After the incubation period, the number of bacteria that could be recovered was determined 
Eq.3.3   
     M = 20 cB 
where  
M   is the number of bacteria per specimen 
cB  is the bacteria concentration obtained  
20  is the volume of shake out solution in ml 
Calculation of percentage reduction 
In this thesis, the average percentage reduction of bacteria after incubation for 24 h was 
calculated using the following equation. 
Eq.3.4 
   100 (CFUb – CFUa) / CFUb 
where 
CFUb    is the average number of colony forming units before incubation  
CFUa    is the average number of colony forming units after incubation  
activity agar diffusion plate test 
In this study, two bacterial strains were used, including one gram positive and one gram 
negative; Staphylococcus aureus (S.aureus) and Escherichia.coli (E.coli) respectively. The 
selection of both strains are in accordance with the standard and are common pathogens found 
3.2.8.2 BS EN ISO 20645:2004, Textile fabrics Determination of antibacterial 
in infected wounds.  
using the following equation: 
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Preparation of bacteria inoculated agar plates 
Separate agar plates were inoculated with S.aureus and E.coli bacterial species via streaking the 
plates with an inoculation loop from a solution containing 1-5 x 10
8
 colony forming units per 
ml.  
Preparation of Test Specimens 
A circular specimen of fabric with a diameter of 25 ± 5 mm was cut from the test sample. Two 
specimens of the antibacterial fabric and two control specimens without addition of antibacterial 
treatment were prepared. The specimens were stored between 12 h to 24 h in sterilized petri 
dishes at room temperature. 
Test Procedure  
The test specimen was placed onto the bacterial inoculated agar surface using a sterilized pair of 
tweezers until the texture of the specimen was uniformly imprinted onto the agar. The petri 
dishes were placed in the incubator for 24 h at 37°C ± 1°C. Immediately after this period the 
petri dishes were examined for bacterial growth. If any zone of inhibition was formed around 
the test specimens, the diameter of the zone was measured using a pair of calibrated callipers. 
The microbial zone of inhibition was calculated using the following equation: 
  (    )   
Where 
H  is the inhibition zone (mm) 
D  is the total diameter of specimen and inhibition zone (mm) 
d  is the diameter of specimen (mm) 
 
After calculating the inhibition zone, the specimen was removed from the agar with a pair of 
tweezers. The contact zone under the specimen was examined for bacterial growth using a 
Watson Barnet x20 magnification optical microscope. Referring to Table 1 in section 10.4 of 
the test method, the antibacterial effect of the specimens was evaluated. 
Concentrations (MBC) 
The MICs of synthetic MGO were determined against S.aureus, Pseudomonas aeruginosa (P. 
aeruginosa) and Entrocuccus faecalis (E. faecalis) isolates using a broth microdilution method. 
The method was based on the procedures recommended for broth microdilution determination 
of MICs by the Clinical and Laboratories Standards Institute (CLSI) (316). 
3.2.8.3 Minimum Inhibitory Concentrations (MIC) and Minimum Bactericidal 
Eq.3.5 
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The bacterial isolates used in MIC testing are listed in Table 3.4 and consisted of reference 
strains from the National Type Culture Collection (NTCC) (Public Health England) and clinical 
isolates obtained by the Leeds General Infirmary (LGI), following ethical approval. 
Bacterial isolate Source 
S. aureus NTCC29213 NTCC 
S. aureus patient 1 LGI 
S. aureus patient 2 LGI 
P. aeruginosa NTCC27853 NTCC 
P. aeruginosa patient 1 LGI 
P. aeruginosa patient 2 LGI 
E. faecalis NTCC29213 NTCC 
E. faecium patient 1 LGI 
E. faecium patient 2 LGI 
 
Media and Diluents 
The media and diltuents used in this method are listed in Table 3.5. All media and diluents were 
prepared according to the manufacturer’s instructions, unless otherwise stated. 
 
Medium/diluent Supplier 
Mueller Hinton Broth Oxoid 
0.9% saline Sigma Aldrich 
 
Preparation of MGO MIC broths 
MGO 40 wt % from Sigma Aldrich was diluted in sterile distilled water to achieve a working 
stock solution of 4096 mg L
-1
. A double strength dilution series was then prepared by diluting 
the working stock solution in Mueller Hinton broth to achieve a doubling dilution series from 2 
Table 3.4: Bacterial isolates. 
Table 3.5: Media and dilutents. 
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mg L
-1
 to 2048 mg L
-1
.  The dilution series was dispensed across all rows of a 96-well microtitre 
tray (Fisher Scientific) in 50 µl amounts, as seen in Fig. 3.5. 
Preparation of bacterial inocula 
Each bacterial isolate was inoculated on to fresh blood agar (FBA) plates and incubated at 37
o
C 
for 24 h. Single colonies of each bacterial isolate were removed from the FBA and resuspended 
in 5 ml Mueller Hinton Broth to a 0.5 MacFarland turbidity equivalent. 
Test procedure  
Starting with the non-MGO-containing growth control, and then working from the lowest to the 
highest MGO containing broth, duplicate rows of the 96 well MGO MIC plate were inoculated 
with each bacterial isolate. Inoculation of the MGO MIC plates occurred within 15 minutes of 
inoculum preparation. Lids were placed on each MGO MIC 96-well plate, and these were then 
incubated at 37
o
C for 24 h. 
Reading and interpretation of MIC results 
The MIC was defined as the lowest concentration of MGO that completely inhibited the growth 
of the bacterial isolates, as detected by the unaided eye. This is assessed by placing a clear black 
line underneath the wells in the microtitre tray. If the black line is visible under the well, the 
concentration of MGO in that well shows an inhibitory effect. If the black line is not visible, this 
is due to the growth of bacteria in that well, creating a turbid solution. An example of this can 
be seen in Fig. 3.6A.  
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the highest concentration starting at the left and finishing with the lowest concentration at 
the right. The final well is left blank as the control. 
 
In order to determine whether the growth inhibition at any particular dilution was bactericidal or 
bacteriostatic, triplicate 20 µl aliquots were inoculated onto each of four quarters of a FBA plate 
and spread over the surface of the agar quarter with a sterile inoculating loop. Inoculated FBA 
plates were then incubated at 37
o
C for 24 h. The MBC was defined as the lowest concentration 
at which there was no visible bacterial growth upon FBA. Fig. 3.6B shows an example of this. 
                   
 
(A) and determination of  MBC via the regrowth of bacteria on FBA plates (B). 
MGO concentration
 
Highest 
 
Lowest  
Growth 
control 
(no MGO) 
B A 
Figure 3.6: Determination of MIC via visibility of black line under the well  in the microtitre tray 
Figure 3.5: Preparation of the 96-well microtitre tray showing the placement of 50 µl of MGO, with 
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High performance liquid chromatography was used in this study to determine the release profile 
of MGO from the electrospun fibres.  
 
High performance liquid chromatography (HPLC) is a physical technique used to separate a 
liquid sample into individual components (317, 318). The separation occurs by the interaction of 
the sample with a mobile and stationary phase. The mobile phase is the phase that moves in a 
definite direction and consists of the liquid sample in a solvent. When the mobile phase passes 
through the column the sample interacts with the stationary phase and is separated. There are 
many combinations of stationary and mobile phases that can be employed when separating a 
mixture. Based on each components affinity in the mobile phase, the components will migrate 
through the column at different rates. For example, if the components in the mobile phase are of 
different polarities, one component will migrate through the column faster than the other based 
on that component’s affinity for either the mobile or stationary phase (317). Several modes of 
liquid chromatography exist. In this study reversed-phase liquid chromatography (RPLC) was 
employed. In RPLC the column is non-polar and the mobile phase is polar; this is the opposite 
to normal phase chromatography (319).  
 
To detect the presence of MGO after the dispersion of the PVA/MGO fibres in a distilled water 
solution, an Agilent 1290 Infinity with a Diode UV Array detector was used. The machine was 
fitted with an Agilent Eclipse XDB-C8 column, measuring 150 mm x 4.6 mm and having a 5 
um particle size. The flow rate was set at 0.5 ml min
-1
. A binary pumping system allowed the 
mixing of two solvents as the mobile phase. Acetonitrile (solvent A) and water (solvent B) both 
containing 0.1% Trifluroacetic acid (TFA) were used. The acetonitrile and water were mixed by 
the pump in a linear gradient starting with 5% solvent A and 95% solvent B, increasing to 95% 
solvent A and 5% solvent B over 15 minutes. Peaks were detected by UV-absorbance at 280 
nm.   
3.2.9  High Performance Liquid Chromatography (HPLC) 
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Plasma is a collection of particles, including positive ions and electrons, ultraviolet radiation, 
free radicals and neutral species, which are created by supplying a high voltage to a gas or 
vapour. This is carried out at atmospheric pressure or in closed vessel at low pressure (low 
pressure temperature plasma technology) (320, 321). In this study, experiments were carried out 
with a low pressure low temperature plasma (LPLT). In LPLT systems the plasma state can be 
reached when the gas or vapour are subjected to a sufficiently low pressure, dependent on the 
frequency of the electromagnetic energy supplied (322, 323). 
 
Textile materials that are subjected to plasma treatments undergo chemical changes in surface 
layers, changes in surface layer structure and changes in physical properties of the surface 
layers. Five major effects on the textile surfaces can occur, including surface cleaning, ablation 
or etching, activation of specific sites on the surface to give rise to chemical reactions, 
polymerisation and grafting (321, 323). In this study plasma technology was used with the 
intention of producing crosslinks between the hydroxyl groups on the surface of the electrospun 
PVA/MGO material and the aldehyde molecules of the GA when in a plasma state.  
 
A Diener, PICO LPLT plasma system was employed for experiments in this study. Prior to 
plasma treatment, 100ml of 25 wt % GA solution was placed in a sealed bottle connected with a 
metal pipe to the machine (vaporiser). The electrospun samples were attached to a metal frame 
and placed inside the plasma chamber. A vacuum was created in the machine and allowed to 
reach a pressure of 0.5 mbar. At this point the GA vapour was supplied into the machine, where 
an electromagnetic energy was provided to convert the vapour to a plasma state. The valve 
connecting the vaporiser to the plasma chamber operates in a 10s time cycle where the opening 
time of the vaporiser could be varied. In this work, the opening time was varied from 20% (2s) 
to 80% (8s). 
3.2.10 Plasma treatment with GA as a crosslinking agent 
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Honey and Synthetic Methylglyoxal 
Coated Nonwovens 
 
  
Chapter 4 Antibacterial Properties of Manuka 
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As previously reported in sections 2.4.3.1 and 2.4.3.2, the antibacterial behaviour of Manuka 
honey is well documented with several studies reporting its effectiveness against numerous 
types of bacteria (196, 199, 200, 202, 204, 324) as well as its use in the treatment of wound 
infections (187, 191, 193, 194, 325). Methylglyoxal (MGO), the non-peroxide antibacterial 
compound found in Manuka honey (172), has also received significant attention because of 
its ability to act as a lone compound for the inhibition of bacterial growth. In these previous 
studies synthetic MGO has been studied in the form of a solution (45, 172), a hydrogel (45) 
and a polymer based formulation (47). All studies evaluated the effectiveness of MGO using 
an agar well diffusion method where the MIC (minimum inhibitory concentration) was 
reported. Comparison of the antibacterial performance of both Manuka honey and MGO was 
studied by Henle’s team (172), where six different Manuka honeys were first analysed to 
determine the concentrations of MGO. The MGO concentrations were found to range 
between 38 to 761 mg kg
-1
. Each of the honeys was diluted to concentrations ranging 
between 15% (w/v) and 80% (w/v). Synthetic MGO solutions were also prepared that 
corresponded to the MGO concentrations within the diluted Manuka honey solutions. It was 
established that five out of six of the Manuka honeys with concentrations ranging between 
15% (w/v) to 30% (w/v) exhibited an antibacterial effect. The MGO concentration in these 
honeys ranged from 347 ± 20 mg kg
-1
 to 761 ± 25 mg kg
-1
. These results correspond to 
synthetic MGO concentrations with a MIC value of 1.1 mM (79.3 µg ml
-1
) (183) to 1.8 mM. 
To the author’s knowledge no published work has evaluated and compared the antibacterial 
effects of Manuka honey and synthetic MGO when applied as a coating to a nonwoven 
fabric or reported the concentration per unit area. It was of interest to understand the degree 
to which synthetic MGO has an equivalent antibacterial effect to Manuka honey and could 
be used as an alternative to Manuka honey in an antibacterial dressing.  
 
Accordingly, the aim of this chapter was firstly to compare and evaluate the antibacterial 
efficiency of both Manuka honey and synthetic MGO when applied as a coating to a 
nonwoven fabric at equivalent MGO concentrations. Two standard methods to determine the 
antibacterial effect of textile products were utilised in this study, including BS EN ISO 
20743:2007 (314) and BS EN ISO 20645:2004 (315), outlined in sections 3.2.8.1 and 3.2.8.2 
respectively. Previous studies that have reviewed the concentration of antibacterial 
compounds in a dressing have expressed the values in terms of mass per unit area (mg cm
-2
) 
(146), therefore the concentration of MGO on the nonwoven fabric was determined in the 
same manner. Secondly, it was of interest to determine the antibacterial effect of MGO 
against three of the most common wound pathogens including Staphylococcus aureus 
4.1 Introduction 
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(S.aureus), Peudomonas aeruginosa (P. aeruginosa) and Enterococcus faecalis (E. faecalis) 
(6). The minimum inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC) of synthetic MGO in liquid form was evaluated against these three bacterial wound 
pathogens using a common laboratory protocol outlined in section 3.2.8.3.   
for coating 
Given that the work by Henle’s team (172), in which five honeys with varying 
concentrations of MGO between 347 ± 20 mg kg
-1
 to 761 ± 25 mg kg
-1
 exhibited an 
antibacterial effect, a Manuka honey certified by the University of Dresden as having 550 
mg kg
-1
 of MGO (Manuka honey MGO 550+) was used in the following experiments. 
 
Solutions of Manuka honey and synthetic MGO were prepared to contain final equivalent 
concentrations of MGO in mg g
-1
. A 20% (w/w) and a 60% (w/w) aqueous solution of 
Manuka honey was made by dissolving 100 g and 300 g of Manuka honey (MGO 550+) in 
distilled water made up to 500 g. The concentration of MGO within these two solutions was 
0.11 mg g
-1
 and 0.33 mg g
-1
 respectively. The equivalent concentrations of synthetic MGO 
were made by diluting a 40 wt % MGO solution with distilled water.  
Airlaid webs were produced from 100% lyocell (TENCEL®) fibre (short cut, 1.7 dtex/10 
mm) using a sifting airlaying machine of the Kroyer type, to give a basis weight of 120 g m
-
2
. Webs were bonded by hydroentanglement (STL Hydrolace) with a 110 - 120 jet strip and 
a jet pressure of 50 bar on one side and 50 bar on the reverse. The hydroentangled webs 
were washed with warm water and fabric detergent to ensure any finish on the fabric was 
removed. The samples were then air dried at room temperature. The coatings were applied 
by immersing a pre-weighed sample into the prepared Manuka honey and synthetic MGO 
coating solutions for 10 min. A sample liquor ratio of 1:50 was used. The samples were then 
passed through a pad mangle at a pressure of 10 kg cm
-2
, weighed and left to air dry at room 
temperature. A sample without coating was also prepared and used as a control. The amount 
of MGO per unit area (mg cm
-2
) assumed to be absorbed onto the nonwoven coated samples 
was calculated using the MGO concentration in the coating solutions (mg g
-1
), the amount of 
solution absorbed (g) and the area of the sample (cm
2
). Conditions are summarised in Table 
4.1.   
4.2 Preparation of coatings and nonwoven samples 
4.2.1 Formulation of the Manuka honey and synthetic MGO solutions 
4.2.2 Manufacture of nonwoven coated samples 
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synthetic MGO solutions and the calculated concentration of MGO on the coated samples 
(mg cm
-2
). 
 
Coating on the 
nonwoven 
sample and 
concentration 
of MGO 
(mg g
-1
) 
 
Original 
sample 
weight  
(g) 
Sample 
area  
(cm
2
) 
Sample 
weight 
after 
coating 
 (g) 
Amount of 
solution 
absorbed  
(g) 
Amount of 
MGO 
absorbed 
 (mg) 
Concentration 
of MGO per 
unit area 
(mg cm
-2
) 
Nonwoven 
control 
10.00 833 n/a n/a 0 0 
Manuka 
honey coating 
0.11 
10.00 833 53.02 43.02 4.73 0.0057 
Manuka 
honey coating 
0.33  
10.03 836 52.74 42.72 14.09 0.0169 
Synthetic 
MGO coating 
0.11  
9.97 831 50.56 40.58 4.46 0.0054 
Synthetic 
MGO coating 
0.33  
9.95 829 52.75 42.80 14.12 0.0170 
The antibacterial activity of the nonwoven coated samples was firstly evaluated using BS 
EN ISO 20743:2007 Textiles - Determination of antibacterial activity of antibacterial 
finished products, as outlined in section 3.2.8.1. This method has been previously used to 
evaluate commercial dressings containing silver where it is intended to simulate 
contaminated wound exudate that comes into contact with a dressing in a clinical situation 
(147). A quantitative result is obtained as a result of this test protocol. This method was 
initially used to give a reliable indication that Manuka honey and synthetic MGO had an 
antibacterial effect at equivalent MGO concentrations. In this method, the Manuka honey 
and synthetic MGO coated nonwovens, plus a nonwoven control (Table 4.1) were tested 
against Gram positive bacteria S. aureus and Gram negative bacteria Klebsiella pneumonia 
(K. pneumonia), according to standard requirements. The antibacterial effect was determined 
by determining the average count of bacteria colony forming units, immediately after 
inoculation and after 24 h in incubation. A percentage reduction of bacteria based on the 
difference between these two counts was calculated. Following the initial evaluation to 
Table 4.1: Nonwoven sample weight (g) before and after coating with Manuka honey and 
4.2.3 Antibacterial evaluation of the nonwoven coated samples 
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determine the antibacterial effect of Manuka honey and synthetic MGO as coatings on a 
nonwoven fabric, further experiments were carried out using BS EN ISO 20645:2004 
Textile fabrics, determination of antibacterial activity, agar diffusion plate test, as outlined in 
section 3.2.8.2. Firstly the coated nonwoven samples tested using BS EN ISO 20743:2007 
(Table 4.1), having MGO concentrations between 0.0054 mg cm
-
² and 0.0170 mg cm
-
² were 
assessed. Following tests at these concentrations, additional coated nonwoven test samples 
were prepared to give six new MGO concentrations between 0.1 mg cm
-
² and 1.2 mg cm
-
² 
using both Manuka honey and synthetic MGO. A 7 cm
2
 circular sample of the pre-made 
nonwoven was placed in a weighing boat, put upon a balance and the reading was zeroed. 
The addition of Manuka honey or synthetic MGO was added to the nonwoven sample to 
equate to the required weight needed to give the new range of MGO concentrations between 
0.1 mg cm
-
² and 1.2 mg cm
-
². Prior to adding the Manuka honey 550+, the honey was heated 
in an incubator to 40ºC to allow it to soften and enable a homogeneous distribution over the 
nonwoven sample. The Manuka honey and synthetic MGO coated nonwovens, plus a 
nonwoven control were tested against Gram negative bacteria Escherichia coli (E.coli) and 
Gram positive bacteria S. aureus in accordance with standard requirement. The number of 
samples tested at each concentration was three. The antibacterial activity of the samples was 
assessed by the absence or presence of bacterial growth in the contact zone between the agar 
and the specimen and the appearance of an inhibition zone around the specimen. The 
calculated width of the inhibition zone was recorded based on Eq. 3.5 outlined in section 
3.2.8.2. 
EN ISO 20743:2007   
Table 4.2 and 4.3 give the results obtained from the BS EN ISO 20743:2007. The results 
indicate the average reduction of bacteria in colony forming units (CFU). Interestingly, a 
99% reduction in bacteria was reported for the nonwoven control against S.aureus. A 
considerably reduced count of bacteria, (-252%) was also reported for the nonwoven control 
against K.pneumonia. The woven polyester control showed a high negative percentage 
reduction in both cases (-22438% and -5635%), which corresponds to heavy growth of 
bacteria in contact with the sample. For the Manuka honey coated and synthetic MGO 
coated nonwoven samples, 100% reduction in bacteria was achieved for all samples where 
the calculated concentration of MGO ranged from 0.0054 mg cm
-
² to 0.0170 mg cm
-
². The 
99% reduction in bacteria for the control samples may be attributed to cross contamination 
from the Manuka honey or synthetic MGO coatings. However, the lyocell fibres may also 
4.2.4 Results and Discussion  
4.2.4.1 Antibacterial performance of the nonwoven coated samples using BS 
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have had some inherent antibacterial effect. A study by Lenzing, compared the bacterial 
growth of S.aureus against cellulosic and synthetic materials including polypropylene, 
polyester and polyacrylate. Using a similar method to BS EN ISO 20743:2007, S.aureus was 
cultured in a medium to simulate perspiration and a known number of bacteria were then 
transferred to the textile samples in a dilution where a moisture content of 50% was obtained 
and incubated at 37 ºC for 24 h. The results revealed that the synthetic samples exhibited 
100 to 1000 times higher bacteria growth when compared with lyocell. The reduced growth 
on lyocell was attributed to the behaviour of the fibres in water. In the case of the synthetic 
fibres, the water has limited penetration into the fibres and sits mainly on the surface which 
is fully accessible to bacteria organisms. However, because of the nano-fibrillar structure of 
lyocell fibres, the water was absorbed into the micro capillaries inside the fibre, offering a 
reduced life sustaining environment for the bacteria to thrive (326).  
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Concentration of MGO per 
unit area of the sample  
(mg cm
-2
) 
Average CFU 
immediately 
after inoculation 
Average CFU 
after 24 h in 
incubation 
Average 
percentage 
reduction (%) 
Nonwoven control 2.64 x 104 8.60 x 102 96.7 
Woven polyester control 1.30 x 105 2.93 x 107 -22438 
Manuka honey coating 
(0.0054) 
3.15 x 10
4
 0 100 
Manuka honey coating 
(0.0169) 
3.90 x 10
4
 0 100 
Synthetic MGO coating 
(0.0054) 
3.20 x 10
4
 0 100 
Synthetic MGO coating 
(0.0170) 
3.05 x 10
4
 0 100 
 
 
Concentration of MGO per 
unit area of the sample  
(mg cm
-2
) 
Average CFU 
immediately 
after inoculation 
Average CFU 
after 24 h in 
incubation 
Average 
percentage 
reduction (%) 
Nonwoven control 8.53 x 104 2.40 x 105 -181 
Woven polyester control 6.80 x 104 3.90 x 106 -5635 
Manuka honey coating 
(0.0054) 
7.07 x 10
4
 0 100 
Manuka honey coating 
(0.0169) 
8.60 x 10
4
 0 100 
Synthetic MGO coating 
(0.0054) 
7.20 x 10
4
 0 100 
Synthetic MGO coating 
(0.0170) 
9.93 x 10
4
 0 
100 
  
Table 4.2: Average reduction in colony forming units (CFU) for S.aureus. 
Table 4.3: Average reduction in colony forming units (CFU) for K.pneumonia. 
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EN ISO 20645:2004    
Table 4.4 and 4.5 display the results achieved for the nonwoven controls and nonwoven 
coated samples against E.coli and S.aureus respectively. The average zones of inhibition and 
standard deviations are shown, as well as the effect of the sample on the growth of each 
bacteria species and the assessment of the antibacterial activity in accordance with standard 
requirements. Fig. 4.1 and 4.2 give a visual representation of the effect of the nonwoven 
control samples and the nonwoven coated sample initial tests at MGO concentrations of 
0.0054 mg cm
-
² and 0.0170 mg cm
-
². Fig. 4.5 and 4.6 show a visual representation of the 
Manuka honey coated nonwoven samples and the synthetic MGO coated nonwoven samples 
where an inhibition zone was produced, respectively.  
 
 
Manuka honey coatings Synthetic MGO coatings 
MGO 
concentration 
(mg cm
-
²) 
Mean 
inhibition 
zone 
(standard 
deviation) 
(mm) 
Growth 
under 
sample 
Assessment 
Mean 
inhibition 
zone 
(standard 
deviation) 
(mm) 
Growth 
under 
sample 
Assessment 
Control 0 (0) Heavy Insufficient 
 
0 (0) 
 
Complete Insufficient 
0.0054 0 (0) Heavy Insufficient 0 (0) Moderate Insufficient 
0.0170 0 (0) Slight 
Limited 
efficiency 
0 (0)*1 No growth Good effect 
0.10 0.42 (0.31) No growth Good effect 0 (0)*1 No growth Good effect 
0.15 0.75 (0.54) No growth Good effect 0 (0)*1 No growth Good effect 
0.20 1.58 (0.42) No growth Good effect 0 (0)*1 No growth Good effect 
0.40 n/a*2 n/a n/a 1.00 (0.41) No growth Good effect 
0.80 n/a*2 n/a n/a 2.17 (1.30) No growth Good effect 
1.20 n/a*2 n/a n/a 4.50 (0.94) No growth Good effect 
*
1
 The absence of growth, even without an inhibition zone, may be regarded as a good effect, as the 
formation of such an inhibition zone may have been prevented by a low diffusion of the active 
substance (314). 
*2 It was not possible to prepare Manuka honey samples at concentrations above 0.2 mg cm-² because 
nonwoven samples became heavily saturated. 
 
 
4.2.4.2 Antibacterial performance of the nonwoven coated samples using BS 
Table 4.4: Effect of MGO concentration on the growth of E.coli when applied as a coating. 
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Manuka honey coatings Synthetic MGO coatings 
MGO 
concentration 
(mg cm
-
²) 
Mean 
inhibition 
zone 
(standard 
deviation) 
(mm) 
Growth 
under 
sample 
Assessment 
Mean 
inhibition 
zone 
(standard 
deviation) 
(mm) 
Growth 
under 
sample 
Assessment 
Control 0 (0) Heavy Insufficient 0 (0) Heavy Insufficient 
0.0054 0 (0) Heavy Insufficient 0 (0) Moderate Insufficient 
0.0170 0 (0) Heavy Insufficient 0 (0) Slight 
Limit of 
efficiency 
0.10 0.17 (0.24) No growth Good effect 0 (0)*1 No growth Good effect 
0.15 1.58 (0.82) No growth Good effect 0 (0)*1 No growth Good effect 
0.20 3.08 (0.24) No growth Good effect 0 (0)*1 No growth Good effect 
0.40 n/a*2 n/a n/a 0 (0)*1 No growth Good effect 
0.80 n/a*2 n/a n/a 3.08 (0.62) No growth Good effect 
1.20 n/a*2 n/a n/a 4.50 (0.35) No growth Good effect 
*
1
 The absence of growth, even without an inhibition zone, may be regarded as a good effect, as the 
formation of such an inhibition zone may have been prevented by a low diffusibility of the active 
substance (314). 
*2 It was not possible to prepare Manuka honey samples at a concentration above 0.2 mg cm-² because 
nonwoven samples became heavily saturated. 
 
The results in Table 4.4 and 4.5 indicate that for the control samples, no zone of inhibition 
was achieved for E.coli and S.aureus. This is evident in Fig. 4.1A & 4.1C. Upon removal of 
the control samples from the surface of the agar, the contact zone between the sample and 
the agar presented heavy bacterial growth (Fig. 4.1B & 4.1D). This confirms that the control 
samples did not exhibit any antibacterial activity. The effect of equivalent MGO 
concentrations in the Manuka honey coatings and synthetic MGO coatings between 0.0054 
mg cm
-
² and 0.0170 mg cm
-
² showed no zone of inhibition for E.coli and S.aureus, as is 
evident in Fig. 4.2. Upon removal of the Manuka honey coated samples from the agar, heavy 
growth was apparent at an MGO concentration of 0.0054 mg cm
-
² for both E.coli and 
S.aureus (Fig. 4.2E2 & 4.2G2). At the equivalent MGO concentration in the synthetic MGO 
coatings, moderate growth was achieved for both E.coli and S.aureus (Fig. 4.2A2 & 4.2C2). 
With an MGO concentration of 0.0170 mg cm
-
² for the Manuka honey coated samples (Fig. 
4.2F2 & 4.2H2), moderate and heavy growth was observed for E.coli and S.aureus 
Table 4.5: Effect of MGO concentration on the growth of S. aureus when applied as a coating. 
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respectively. However, for the synthetic MGO coatings with an equivalent MGO 
concentration of 0.0170 mg cm
-
², no growth and slight growth was evident against E.coli and 
S.aureus respectively (Fig. 4.2B2 & 4.2D2). These initial evaluations at a concentration of 
0.0054 mg cm
-
², suggest an insufficient antibacterial effect was achieved for both Manuka 
honey and synthetic MGO coatings. At a concentration of 0.0170 mg cm
-
², limited efficacy 
was observed for the Manuka honey coatings. However, for the synthetic MGO coatings 
with an MGO concentration of 0.0170 mg cm
-
², the antibacterial effect was shown to 
improve slightly and a good antibacterial effect and a limit of efficiency was achieved for 
E.coli and S.aureus respectively.  
 
Where no growth is seen and no zone is apparent, a good antibacterial effect is still regarded. 
This may be due to a low diffusion of the active compound from the fabric (315) and may be 
attributed to the affinity of the lyocell fibres for moisture. Lyocell fibres are hygroscopic in 
nature with a high water absorption capacity. This is influenced by the hydrophilic, 
crystalline nano-fibrils, which are arranged in a very regular manner. Water is absorbed in 
the capillaries between the fibrils, not into the fibres themselves (327). A single lyocell fibre 
will act as a wetting bundle of micro and nano-fibrils with pores in the nanometer range 
(327, 328). Fig. 4.3 shows images of the different cellulosic fibres and their ability to absorb 
water using a transmission electron microscope. The dark areas, which were stained with a 
dye, show the water containing pores in the fibres. It can clearly be discerned that 
TENCEL® (lyocell) has a large affinity for water, as the whole fibre appears dark. A higher 
resolution image of lyocell can be seen in Fig. 4.4, where the pore clusters within the fibre 
cross-section are revealed. Thus, in the present study the lyocell fibres may retain the 
synthetic MGO and honey coating within their structure thereby restricting the diffusion of 
MGO into the agar at these relatively low MGO concentrations (329). 
 
 
under sample & S.aureus; C = no zone and D = heavy growth under sample. 
S.aureus E.coli 
A D C B 
Figure 4.1: Effect of control samples on the growth of E.coli; A = no zone, B = heavy growth 
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2
mg m
2
 on the growth of E.coli and S.aureus). A to D show the effect of the synthetic MGO 
coatings. For E. coli, A1 & A2 = 0.0054 mg cm
2
 (no zone and moderate growth 
respectively), B1 and B2 = 0.0170 mg cm
2
 (no zone and no growth respectively). For S. 
aureus, C1 & C2 = 0.0054 mg cm
2
 (no zone and moderate growth respectively), D1 & D2 
= 0.0170 mg cm
2
 (no zone and slight growth respectively). E to H show the effect of the 
Manuka honey coatings.  For E. coli, E1 & E2 = 0.0054 mg cm
2
 (no zone and heavy 
growth respectively), F1 & F2 = 0.0170 mg cm
2
 (no zone and moderate growth 
respectively). For S.aureus, G1 & G2 = 0.0054 mg cm
2
 (no zone and heavy growth 
respectively), H1 & H2 = 0.0170 mg cm
2
 (no zone and heavy growth respectively). 
E.coli 
E.coli 
C1 
A1 B1A2 B2 
C2 D1 D2 
S.aureus 
S
y
n
th
et
ic
 M
G
O
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o
a
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n
g
s 
S.aureus 
E1 F2 F1 E2 
G1 G2 H1 H2 
M
a
n
u
k
a
 h
o
n
ey
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o
a
ti
n
g
s 
0.0054 mg cm
2
 0.0170 mg cm
2
 
0.0170 mg cm
2
 0.0054 mg cm
2
 
Figure 4.2: Effect of initial coated nonwoven MGO concentrations (0.0054 mg cm  and 0.0170 
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for water. The water containing pores show up as dark areas (327, 328). 
 
 
 
 
In Table 4.4 and 4.5 the effect of MGO concentrations between 0.1 mg cm
-
² and 1.2 mg cm
-
² 
on the growth of E.coli and S.aureus in contact with both Manuka honey and synthetic MGO 
shows a good antibacterial effect in all cases. Note it was not possible to prepare Manuka 
honey samples at concentrations above 0.2 mg cm
-
² as the nonwoven samples became 
heavily saturated, due to the high density and viscose nature of the honey. However at these 
relatively low concentrations between 0.1 mg cm
-
² and 0.2 mg cm
-
² for the Manuka honey 
coatings, mean zones of inhibition were apparent against both E.coli and S.aureus, as seen in 
Fig. 4.5. A small mean zone of inhibition of 0.17 mm and 0.42 mm with a standard deviation 
of 0.31 mm and 0.24 mm was achieved against E.coli and S.aureus at a concentration of 0.1 
mg cm
-
², respectively. Examples of this are shown in Fig. 4.5A and 4.5D. As the 
concentration of MGO doubled to 0.2 mg cm
-
², the mean zone of inhibition for E.coli 
increased by a factor of about four times to 1.58 mm with a standard deviation of 0.42 mm, 
Figure 4.3: Transmission electron micrographs of different cellulosic fibres and their affinity 
Figure 4.4: High resolution image of TENCEL® (lyocell) (328). 
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Fig. 4.5C shows an example of this. The mean zone of inhibition for S.aureus increased to a 
far greater level by an approximate factor of eighteen to 3.08 mm, with a standard deviation 
of 0.42 mm, see Fig. 4.5F.  
           
(0.1 mg cm
-2
 to 0.2 mg cm
-2
) in Manuka honey coatings against E.coli (A, B & C) and S. 
aureus (D, E & F). 
 
Conversely, for the synthetic MGO coatings, no zone of inhibition was apparent below a 
concentration of 0.2 mg cm
-
² for E.coli and 0.4 mg cm
-
² for S.aureus, as seen in Fig. 4.6. 
However, upon removal of the samples from the agar, no growth was observed at a 
concentration of 0.1 mg cm
-
² for both E.coli and S.aureus, which corresponds to a good 
antibacterial effect. It was observed that an unclear zone was formed for synthetic MGO 
concentrations of 0.2 mg cm
-
² for and E.coli (Fig. 4.6A) and 1.5 mg cm
-
² to 0.4 mg cm
-
² for 
S.aureus (Fig. 4.6E-6G). Repeating the experiment at the same concentrations, led to the 
same observations. As reported previously, limited diffusion of the Manuka honey and 
synthetic MGO from the lyocell nonwovens was achieved at the lower concentrations of 
A B C 
F E D 
E. coli 
S. aureus 
0.1 mg cm
2
 0.15 mg cm
2
 0.2 mg cm
2
 
Figure 4.5: Examples of mean zones of inhibition produced (mm) from MGO concentrations 
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0.0054 mg cm
-
² to 0.0170 mg cm
-
² (Fig. 4.2). The Manuka honey coatings produced a clear 
zone of inhibition at concentrations between 0.1 mg cm
-
² to 0.2 mg cm
-
² (Fig. 4.5). At these 
concentrations, the Manuka honey coatings became extremely viscous when compared with 
the synthetic MGO coatings at the same MGO concentration. The synthetic MGO coatings 
still maintained a viscous nature, similar to water, which was likely to be absorbed and 
retained by the lyocell fibres. Fig. 4.7 shows images of the dry lyocell fibres (Fig. 4.7A), 
MGO coated lyocell fibres (Fig. 4.7B) and the Manuka coated lyocell fibres (Fig. 4.7C&D), 
obtained by an FEI Quanta 200F Field Emission Scanning Electron Microscope (FEGSEM). 
It can be seen that the MGO coated lyocell fibres (Fig 4.7B) retain a similar nature to the dry 
lyocell fibres as seen in Fig. 4.7A, with no obvious sign of any coating, confirming that the 
coating has been absorbed and retained by the fibres. However, the Manuka honey coated 
lyocell fibres, appear mainly occluded by the honey coating (Fig 4.7C&D), and some 
protruding fibres with a globular like structure, assumed to be the honey coating. This image 
provided further evidence that the Manuka honey coating is more freely available on the 
surface of the lyocell fibres to permit contact with the bacteria agar.  
 
Upon incubation of the Manuka honey samples at 37ºC during testing, the Manuka honey 
coating is likely to soften and allow greater diffusion into the bacteria seeded agar from the 
fibres. Previous studies have shown that temperature has a direct influence on the viscosity 
of honey (330-332), as the temperature increases the viscosity falls due to reduced 
hydrodynamic forces and a lesser amount of molecular friction (332). A viscosity 
measurement of Manuka honey at 37ºC ± 2ºC and ambient room temperature of 25 ± 2ºC 
using the procedure outlined in section 3.2.1, found that a relatively low viscosity of 17800 
cP was obtained at 37ºC ± 2ºC when compared with a higher measurement of 21800 cP at 25 
± 2ºC. This confirms that the Manuka honey coating is likely to migrate more freely into the 
bacteria seeded agar due to the reduced viscosity at 37ºC.  
 
In contrast, the synthetic MGO coatings did not show a clear zone of inhibition until a 
concentration of 0.4 mg cm
-
² was reached for E.coli (Fig. 4.6B) and 0.8 mg cm
-
² for S.aureus 
(Fig. 4.6H). Below these concentrations an unclear zone was observed and it is likely the 
lyocell fibres retained much of the synthetic MGO and subsequently only partial inhibition 
of the bacteria could be achieved. As the addition of synthetic MGO solution became 
greater, the lyocell fibres approach their absorbent capacity and their ability to retain the 
synthetic MGO solution may be reduced. This would encourage greater diffusion of MGO 
into the agar to create a clear zone of inhibition. Due to the calibration limits of the 
viscometer, a viscosity measurement of the synthetic MGO coatings was not possible.
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E. coli 
S. aureus 
A B C D 
E F G 
H I 
0.15 mg cm
2
 0.2 mg cm
2
 0.4 mg cm
2
 0.8 mg cm
2
 1.2 mg cm
2
 
2 2
F = 0.2 mg cm
2
, B & G = 0.4 mg cm
2
, C & H = 0.8 mg cm
2
, D and I = 1.2 mg cm
2
 and E = 0.15 mg cm
2
. 
Figure 4.6: Zones of inhibition produced from MGO concentrations (0.15 mg cm  to 1.2 mg cm ) in the synthetic MGO coatings against E.coli and S.aureus. A & 
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honey coated fibres (C&D). Taken at a magnification of 500 (A, B & C) and 1000 (D). 
 
Another study which explored the antibacterial activity of Manuka honey and MGO in a 
liquid form reported that higher levels of MGO alone were required to inhibit the growth of 
P.aeroginosa when compared with Manuka honey, which contained equivalent MGO 
concentrations. It was proposed that MGO may be enhanced when in the Manuka honey 
solution (183). There is also the probability that the hydrogen peroxide present in the 
Manuka honey may heighten the antibacterial effect (164, 168, 169). 
  
Comparing the results obtained using BS EN ISO 20743:2007, where quantitative results 
were obtained, and BS EN ISO 20645:2004, the concentration of MGO required to produce 
an antibacterial effect was found to be slightly different. For BS EN ISO 20743:2007, a low 
concentration of 0.0054 mg cm
-
² for both Manuka honey and synthetic MGO showed 100% 
reduction in bacteria for both S.aureus and K. pneumonia. For BS EN ISO 20645:2004, a 
good antibacterial effect was achieved at slightly higher concentrations between 0.0170 mg 
cm
-
² and 0.1 mg cm
-
² for E.coli and S.aureus. In the results from BS EN ISO 20743:2007, a 
likely explanation for the antibacterial effect at a concentration of 0.0054 mg cm
-
² may be 
attributed to the addition of 20 ml of SCDLP (used to simulate wound exudate) solution to 
the test specimens in the jars (314). In this case, the lyocell fibres were exposed to a high 
moisture content, which would encourage hydration of the fibres and facilitate extraction of 
the MGO from the fibres, allowing 100% reduction in bacteria. In the case of BS EN ISO 
20645:2004, an insufficient moisture content was available to initiate the diffusion of the 
A B 
C D 
Figure 4.7: FEGSEM of dry lyocell fibres (A), synthetic MGO coated fibres (B) and Manuka 
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MGO from the fibres (329). It is only when the nonwoven samples became increasingly 
saturated that the moisture content during the test heightened and allowed for the diffusion 
of MGO into the agar. 
pathogens 
To determine the MIC and MBC of MGO against three common wound pathogens, a 
standard laboratory assay was carried out in the Leeds Pathology Microbiology department 
according to 3.2.8.3. A 40 wt % MGO solution was diluted to concentrations between 1 mg 
L
-1
 to 1026 mg L
-1
 based on similar concentrations reviewed in the current literature (183) 
and tested against three bacterial strains including S.aureus, P.aeruginosa and E.faecalis. 
Two separate strains were collected from patients following ethical approval, and an 
American type culture collection (ATCC) standard of each was also used. The MIC was 
determined as the lowest concentration of MGO that was found to completely inhibit the 
growth of the organism in the microdilutions, as detected by the unaided eye. The MBC was 
determined as the lowest MGO concentration at which there was no growth upon subculture.  
Table 4.6 shows the results of the MIC and MBC of MGO in liquid form against each 
bacterial strain. For P.aeruginosa the MIC against the ATCC strain and patient 1 strain was 
found to be 512 mg L
-1
. The patient 2 strain required twice the concentration (1024 mg L
-1
) 
to inhibit the growth. Upon subculture of all three isolates, the MBC required to kill 
P.aeruginosa ATCC strain was doubled to 1024 mg L
-1
, while the two patient strains 
remained the same as the MIC. These concentrations were the highest among each 
bacterium species tested, as the MIC and MBC for S.aureus and E. faecalis did not reach 
above 512 mg L
-1
. The relatively high concentrations required to inhibit or kill P.aeroginosa 
are not surprising, given that P.aeruginosa is one of the most problematic multidrug-
resistant strains that is increasingly being isolated in clinical environments (183). It is 
important because P.aeroginosa is now showing resistance to common antibiotics, including 
ciprofloxacin (132), amikacin and imipenem (333). Limited work has been previously 
published on the MBC of MGO against P.aeruginosa. One previous study reported the MBC 
of both MRSA and P.aeruginosa in a planktonic and biofilm state. The MBC for 
P.aeruginosa in a planktonic state was found to range between 600 mg L
-1 
to 1200 mg L
-1
, 
while in the biofilm state the MBC was much higher ranging from 1800 mg L
-1 
to 7600 mg 
L
-1
(334). It can be expected that a raised concentration of MGO would be required in a 
biofilm state, as the polysaccharide (Psl) in P.aeruginosa biofilms has been shown to 
4.3 MIC and MBC of MGO against common wound 
4.3.1 Results and Discussion  
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provide a physical barrier against various antibiotics at the beginning stages of biofilm 
development (120).
 
 In the current study, the MBC was only tested in the planktonic state 
and shows a slightly lower MBC between 512 mg L
-1 
and 1024 mg L
-1
 than in the previous 
study.  
 
S.aureus, reportedly the most common bacterium species found in a chronic wound 
environment (6), showed the lowest MIC and MBC for all three bacteria species. The ATCC 
strain showed the lowest MIC of 128 mg L
-1
, while the two patient strains did not exceed 
256 mg L
-1
 for both the MIC and MBC. A previous study (172) reported a lower MIC of 
79.3 mg L
-1
 (1.1mM) for S.aureus while another reported a biocidal effect of MGO in 
Manuka honey with an MGO concentration of 530 mg L against biofilms
-1 
(335). In the 
same study, the concentration of MGO alone required to achieve a biocidal effect against 
biofilms was >1050 mg L
-1
, which is four times higher than the concentration reported in the 
current study (256 mg L
-1
).   
  
The effect of MGO concentration on E.faecalis has, to the author’s knowledge not been 
previously reported. One study has reported the effect of Activon Manuka honey dressing 
against vancomycin-resistant Enterococcus faecalis (VRE), stating that that a 5% (w/v) 
concentration was needed to initiate an antibacterial effect against the biofilm. No reference 
was made throughout the study in relation to MGO. Therefore, it was of interest to 
understand the MIC and MBC of MGO concentration against E.faecalis, as the literature has 
previously revealed (section 2.2.2) it is the second most prevalent bacteria to be found in a 
chronic wound environment (6). In the current study, equivalent MIC and MBC were shown 
to be effective for the ATCC strain at a concentration of 256 mg L
-1
 and the two patient 
strains with a concentration of 512 mg L
-1
.   
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-1
pathogens. 
Test organism MIC (mg L
-1
) MBC (mg L
-1
) 
Pseudomonas aeruginosa ATCC27853 512 1024 
Pseudomonas aeruginosa patient 1 512 512 
Pseudomonas aeruginosa patient 2 1024 1024 
Staphylococcus aureus ATCC29213 128 256 
Staphylococcus aureus patient 1 256 256 
Staphylococcus aureus patient 2 256 256 
Enterococcus faecalis ATCC21292 256 256 
Enterococcus faecium (VRE) patient 1 512 512 
Enterococcus faecium (VRE) patient 2 512 512 
 
The results of this experiment were particularly important because they provided an 
indication of the bactericidal concentration or the MBC of MGO when compared with the 
bacteriostatic concentration or the MIC (336). The previously conducted antibacterial test 
BS EN ISO 20743:2007 could not indicate if the antibacterial effect was attributed to a 
bactericidal or bacteriostatic effect. The results from BS EN ISO 20645:2004, showed only 
an inhibitory (bacteriostatic) effect. In this experiment the bactericidal concentration of 
MGO has been successfully identified for the three most prevalent chronic wound 
pathogens, and for the first time the effect of MGO on E.faecalis has been established. 
In accordance with BS EN ISO 20743:2007, it was found that when Manuka honey or 
synthetic MGO are applied as a coating to a nonwoven fabric, a concentration of 0.0054 mg 
cm
-2
 of MGO was sufficient to achieve 100% reduction in bacteria using S.aureus and 
K.peunomia. Further experiments, using BS EN ISO 20645:2004 and the same nonwoven 
coated fabrics, revealed that higher concentrations of MGO between 0.0170 mg cm
-2
 and 0.1 
mg cm
-2
 were required to produce a good antibacterial effect against E.coli and S.aureus. 
Zones of inhibition were apparent at relatively low MGO concentrations between 0.1 mg cm
-
2 
and 0.2 mg cm
-2
 for the Manuka honey coated nonwovens and were shown to increase with 
an increasing MGO concentration. However, clear zones of inhibition were not achieved 
with the synthetic MGO coated nonwovens until a concentration of 0.4 mg cm
-2
 of MGO 
Table 4.6: MIC and MBC (mg L ) of MGO in liquid form against three common wound 
4.4 Summary 
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was achieved for E.coli and 0.8 mg cm
-2 
of MGO for S.aureus. The moisture content that 
was present during the BS EN ISO 20743:2007 and BS EN ISO 20645:2004 methods and 
the affinity of the lyocell fibres for water may account for the differing antibacterial 
concentrations in both tests. The MIC and MBC results revealed the concentrations of MGO 
in liquid form to have bacteriostatic and bactericidal effects on three of the most common 
chronic wound pathogens. Most importantly the bactericidal concentration of MGO, 
required to provide a functional effect has been established.  
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Containing Poly(vinyl alcohol) and 
Synthetic Methylglyoxal 
  
Chapter 5 Evaluation of Needle Electrospun Fibres 
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In section 4.2.4.1, it was found that nonwoven webs containing 0.0054 mg cm
-
² of synthetic 
methylglyoxal (MGO) had an antibacterial effect against both Gram positive S.aureus and Gram 
negative K.pneumonia when assessed in accordance with BS EN ISO 20743:2007. A 100% 
reduction in bacteria was observed comparable in performance to the equivalent concentration 
of MGO in the coated nonwoven Manuka honey samples. Further experiments using BS EN 
ISO 20645:2004 found that the synthetic MGO coated nonwovens, required a concentration 
between 0.0170 mg cm
-
² and 0.1 mg cm
-
² for E.coli and S.aureus respectively, to inhibit the 
bacteria and achieve a good antibacterial effect (section 4.2.4.2). The results from the minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) tests for MGO 
in liquid form against three bacterial wound pathogens also confirmed low antimicrobial 
efficiency results against three common chronic wound pathogens (section 4.3.1).  
 
As reported in section 2.8.4.2, electrospinning of inherently antibacterial materials for wound 
care is an area of new interest. Electrospun polymeric materials have been shown to mimic the 
extracellular matrix of the (ECM) of tissues (58) as well as to provide a suitable matrix for the 
controlled release of antimicrobials and their inclusion within a composite wound dressing. 
Hydrogel forming polymers are particularly useful in wound care as they provide a moist 
environment at the wound bed, which is essential for healing (18, 19). In a wound contact layer 
they also facilitate a low adherent surface that is less likely to disturb new tissue when removed. 
Poly(vinyl alcohol) (PVA) is a hydrogel-forming polymer that has received significant attention 
in the literature and in particular electrospinning studies for medical applications (54, 65, 66).  
 
Given the antibacterial efficacy of MGO and the hydrogel formation properties of PVA, the aim 
of this chapter was to investigate the feasibility of combining MGO with PVA in a one-step 
manufacturing process to produce fibres and webs via needle electrospinning. This was 
explored using aqueous solutions of PVA doped with synthetic MGO. To determine the 
presence of MGO in the electrospun webs, Fourier transform infra-red spectroscopy (FTIR) and 
proton nuclear magnetic resonance (
1
H-NMR) were employed. The antibacterial activity of the 
webs was then determined by means of the protocol set out in BS EN ISO 20645: 2004. Firstly, 
suitable concentrations of PVA in aqueous solutions of synthetic MGO and distilled water were 
investigated to determine the optimum spinning solution, providing fibres free from defects. 
The degree of PVA hydrolysis, molecular weight (274) and concentration (337) can all be 
expected to contribute to the morphological features of the fibres. For PVA, previous studies 
have reported the use of molecular weights between 9,000-10,000 and 58,000-85,000 and a 
degree of hydrolysis between 97-99% contribute to fibres free from beads. At a lower molecular 
weight of 13,000 - 23,000 a concentration of at least 21 wt % was required to electrospin fibres 
free from beads. In contrast, at higher molecular weights of 58,000 - 85,000, a reduced 
5.1 Introduction 
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concentration of only 9 wt % was required to facilitate spinning (242). Other studies have 
reported electrospinning with concentrations of PVA between 5 wt % and 20 wt % (272, 274, 
338, 339). At concentrations between 5 wt % and 8 wt % the morphology of the fibres consists 
mainly of beads, merging areas or fibres that form junctions. As the concentration is increased 
to 10 wt % beads and defects become less frequent and elongated fibres are observed (274). A 
study by Santos et al. (338) reported that at concentrations below 10% (w/w), electrospraying 
was observed without fibre formation. At concentrations of 12% (w/w) and 20% (w/w) fibres 
free from defects were produced due to the viscous and conductive properties. An increase in 
the viscosity enabled the solution to withstand the columbic stretching force in the charged jet 
resulting in the formation of uniform fibres (338). 
electrospinning.  
Prior to electrospinning with PVA/MGO solutions, initial trials were carried out to check the 
spinning ability of PVA with a molecular weight of 31,000-50,000 in distilled water at 
concentrations of 8% (w/v), 12% (w/v) and 16% (w/v). To evaluate and determine if 
PVA/MGO solutions could form fibres using needle electrospinning, PVA concentrations of 8% 
(w/v), 12% (w/v) and 16% (w/v) were prepared in a 40 wt % MGO solution and in a further 
three aqueous dilutions of the 40 wt % MGO solution. The concentrations of MGO in each 
solution were calculated to be 40 wt %, 21.57 wt %, 14.76 wt % and 11.22 wt %.The prepared 
solutions were kept under constant agitation at 80ºC ± 2ºC for 24 h in a glass conical flask, 
sealed with a glass stopper. After 24 h all the PVA had dissolved and the solutions appeared 
clear.   
The prepared PVA/MGO solutions were electrospun to determine the spinning ability of each 
solution using needle electrospinning. The method of electrospinning was described in section 
3.2.4.1. Needle electrospinning was performed inside a fume cupboard using a Glassman high 
voltage power supply and a Kd Scientific syringe pump. The syringe pump flow rate was set to 
run at 0.1 ml h
-1
. Initial results revealed that a voltage below 7 kV was insufficient to maintain a 
continuous electrospinning jet and a voltage above 18 kV gave rise to electrostatic sparks, 
which again interrupted the process. A previous study has also reported that using a voltage 
below 5.5kV leads to difficulties in initiating a polymer jet (276). A higher voltage is required 
to induce the necessary charges on the polymer solution enabling the columbic repulsive force 
in the solution to overcome the surface tension and stretch the viscoelastic solution (267). For 
this reason a series of voltages between 7 kV to 18 kV was applied. Aluminium foil measuring 
10 cm x 10 cm was used as the web collector and tip to collector distances from 5 cm to 15 cm 
were employed following the initial trials.  
5.1.1 Preparation of PVA and PVA/MGO solutions for needle 
5.1.2  Needle Electrospinning  
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conductivity 
As previously reported in section 2.8.3.1, the viscosity (272, 276) is known to have an influence 
on electrospinning performance and the morphological features of the resultant webs. To 
determine any correlations between the solution properties and the spinning ability, 
measurements of viscosity, surface tension and conductivity of each prepared spinning solution 
were made. Measurements were taken according to the procedures outlined in section 3.2.1. 
Prior to recording the measurements, all spinning solutions were initially incubated at 25ºC for 
24 h. This temperature was chosen, to reflect the average ambient room temperature recorded 
during needle electrospinning of 25ºC ± 2ºC. 
 
Initial tests on the prepared spinning solutions confirmed that because of the variation in the 
viscosity of the prepared solutions, it was not possible to measure the viscosity of all the 
solutions with the same spindle and speed. Therefore direct comparisons were not always 
possible. It was therefore decided that extra solutions should be prepared for polymer 
concentrations between the experimental range of 8% (w/v), 12% (w/v) and 16% (w/v). 
Accordingly, additional solution concentrations of 10% (w/v), 14% (w/v), 18% (w/v) and 20% 
(w/v) were prepared and measured to determine their viscosity where possible with the same 
spindle and speed. The surface tension and conductivity of the additional solution 
concentrations was also measured. This provided an indication of the relative differences 
between the experimental solutions.  
5.1.3 Spinning solution properties: Viscosity, surface tension and 
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A summary of the needle electrospinning performance of each polymer solution is given in 
Table 5.1. Visual observations were also recorded as shown in Fig. 5.1.  
Solvent  
MGO 
concentrations 
(wt %) 
PVA 
concentration 
(% w/v) 
Electrospinning 
performance 
Behaviour of polymer 
solutions 
Distilled water 
0 8 &12 
Merging fibres that 
form junctions 
Wet polymer on the 
collector 
0 16 Fibres Steady jet stream 
40 wt % MGO 40 8, 12 & 16 
Solution not 
spinnable 
Formed a gel after 24 
hours stirring 
40 wt % MGO 
(aqueous 
solution) 
diluted  with 
distilled water 
21.57 8 & 16 
Merging fibres that 
form junctions or 
solution not spinnable 
Wet polymer on the 
collector or polymer 
dried at needle tip 
21.57 12 Beads 
Intermittent stream or a 
bowing Taylor cone 
14.76 8, 12 &16 
Merging fibres that 
form junctions or 
solution not spinnable 
Wet polymer on the 
collector or polymer 
dried at needle tip 
11.22 8 & 12 
Merging fibres that 
form junctions 
Wet polymer on the 
collector 
11.22 16 Fibres Steady jet stream 
  
5.1.4 Results and Discussion 
5.1.4.1 Needle Electrospinning performance  
Table 5.1: Needle electrospinning performance of each spinning solution. 
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at the needle tip, B = wet spots on the aluminium foil collector, C = bowing Taylor cone & D 
= gel formation 
 
The viscosity of the spinning solutions was found to greatly influence the needle electrospinning 
ability. Fig. 5.2 displays the viscosity results obtained for the experimental solutions and 
additional concentrations as described in section 5.1.3. With an MGO concentration of 21.57 wt 
% and polymer concentrations between 8% (w/v) and 12% (w/v), the viscosity was found to be 
relatively low between 260 cP and 435 cP. At an MGO concentration of 14.76 wt % and a 
polymer concentration of 12% (w/v) the viscosity was also relatively low at 374 cP. 
Concentrations below 12% (w/v) for an MGO concentration of 14.76 wt % were not measurable 
using the same spindle and speed. Similarly for an MGO concentration of 11.22 wt %, polymer 
concentrations below 14% (w/v) were not measurable. However, it is apparent from the points 
on the curves that the viscosity of the unmeasurable PVA concentrations would have been lower 
than the recorded measurements with a 21.57 wt % MGO concentration and PVA 
concentrations between 8% (w/v) to 12% (w/v). At these low polymer concentrations between 
8% (w/v) and 12% (w/v), the chain entanglement in the polymer solution was insufficient to 
A 
C 
B 
D 
5 mm 
5 mm 20 mm 
10 mm 
Figure 5.1: Observations of polymer solutions before & during electrospinning. A = polymer drying 
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sustain and stabilise an electrospinning jet, resulting in the breakup of the electrically driven jet 
into droplets (275, 340) that formed upon the collector, as observed in Fig. 5.1B.  
 
SEM micrographs were taken using a Carl Zeis EVO MA15 at a magnification of 11.00 K to 
provide an initial examination of the morphological characteristics of the spun webs as shown in 
Fig. 5.3. At the relatively low viscosities between 260 cP and 374 cP, wet polymer droplets 
formed upon the collector resulting in merging fibres that formed junctions or flat ribbon-like 
fibres (Fig. 5.3A to 5.3D). A previous study reported that for an 8.1 wt % concentration of 
Nylon 6,6 in formic acid, the fibre formation changed from elongated fibres to fibres that 
formed junctions when the distance from the tip of the needle to the collector was reduced from 
2 cm to 0.5 cm. At the shorter distance of 0.5 cm, wet polymer landing upon the substrate was 
observed (275) and can be attributed to the solvent having insufficient time to evaporate. 
However, in the present study an increase in distance from 5 cm to 15 cm made no difference to 
the deposition of wet polymer accumulating on the collector and subsequently resulting in flat 
ribbon like fibres. Another study reported that PVA with a lower degree of hydrolysis (80%) 
also gave rise to flat ribbon-like fibres (272). However, in the present study the degree of 
hydrolysis remained constant at a relatively high magnitude of 98-99% and therefore results did 
not follow the same trend.  
 
Many previous studies have also reported that low viscosities contribute to the formation of 
beads (268, 270, 272, 273, 276, 341-343). At a low viscosity, a greater number of free solvent 
molecules are available as well as fewer chain entanglements, which results in the surface 
tension of the solution having a dominant influence on the electrospinning jet causing beads to 
form along the fibre (267). 
 
Beads were observed in the present study (Fig. 5.3E) at relatively low viscosity of 435 cP, as 
seen in Fig. 5.2. At a higher polymer concentration of 16% (w/v) in an MGO concentration of 
11.22 wt %, the viscosity increased to 605 cP, as seen in Fig. 5.2, and fibres free from beads and 
defects were observed (Fig. 5.3F). At this concentration sufficient chain entanglement in the 
polymer solution was apparent to prevent the breakup of the electrically charged jet, allowing 
the electrostatic charges to elongate the jet (275) and create fibres free from beads.  
 
Comparatively, for a polymer concentration of 16% (w/v) in distilled water, a viscosity of a 
similar order of 635 cP was recorded and elongated fibres free from beads and defects were 
observed (Fig. 5.3G). Conversely at a polymer concentration of 16% (w/v) in an MGO 
concentration of 14.76 wt % and 21.57 wt %, the viscosity was shown to increase to 1421 cP 
and 3864 cP respectively. At these relatively high viscosities the polymer was found to dry at 
the needle tip, as seen in Fig. 5.1A, and subsequently an electrospinning jet was not formed. 
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Zong et al. also reported this observation for poly(D,L-lactic acid) at a concentration higher than 
40 wt % in dimethyl formamide (268). 
 
 
viscosity (cP) of the needle electrospinning and additional solutions. Measured using a 
Brookfield LV DV- E viscometer with a spindle size of 31 and a speed of 6 r min
-1
 at a 
temperature of 25˚C ± 2˚C. 
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Figure 5.2: The effect of MGO concentration (wt %) and PVA concentration (% w/v) on the 
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(w/v) PVA concentration respectively, C = 14.76 wt % MGO  with 8% (w/v) PVA, D = 11.22 
wt % MGO  with 8% (w/v) PVA, E = 14.76 wt % MGO  with 12% (w/v) PVA, F = 11.22 wt 
% MGO with 16% (w/v) PVA and G = distilled water with 16% (w/v) PVA. 
 
A B 
D C 
E F 
G 
Figure 5.3: SEM micrographs produced from: A & B = 21.57 wt % MGO with an 8% and 12% 
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The surface tension and conductivity of the polymer solutions are also known to have an effect 
on the electrospinning ability and have a strong link to the viscosity. Fig. 5.4 displays the 
surface tension and conductivity results obtained for the experimental solutions and additional 
concentrations as described in section 5.1.3. The surface tension of the solutions with a 
relatively low viscosity (260 cP to 435 cP), which were shown to create merging fibres or beads 
(Fig. 5.3D to 3E), was found to be at the highest range between 50.2 mN m
-1
 and 48.4 mN m
-1
 
(Fig. 5.4A).  
 
A higher solution surface tension is generally known to suppress the electrospinning process 
because of instability in the electrospinning jet causing the creation of sprayed droplets on the 
collector (344), as was observed in the present study. In the case of bead formation as seen in 
Fig. 5.3E, when there is a high concentration of free solvent molecules in the polymer solution, 
there is a greater tendency for the solvent molecules to group together and create spherical bead 
shapes along the electrospinning jet (267). When the polymer concentration was increased to 
16% (w/v) in a 11.22 wt % MGO concentration, the surface tension decreased to 45.96 mN m
-1
 
as seen in Fig. 5.4A, and fibres free from beads were produced (Fig. 5.3F and 3G). This is not 
surprising given that the main solvent in the solution is distilled water, which is known to have a 
high surface tension of 72.8 mN m
-1
. As the polymer concentration in the solutions is increased, 
the ratio of water molecules to polymer decreases, resulting in a decreasing surface tension. 
Other studies have also reported that reducing the surface tension results in smoother fibres 
(267, 341).  
 
The conductivity of the electrospinning solutions also correlates with the transformation from 
merging areas that form fibres or beads to elongated fibres. The concentration of PVA in each 
MGO solution has minimum effect on the conductivity values. For example at a 21.57 wt % 
MGO concentration for any given concentration of PVA (% w/v), the conductivity is shown to 
stay at relatively low values between 0.364 mS cm
-1
 and 0.465 mS cm
-1
 (Fig. 5.4B). However, 
as the MGO concentration was decreased to 11.22 wt %, the conductivity rises to values 
between 1.033 mS cm
-1 
and 1.260 mS cm
-1
. At a value of 1.234 mS cm
-1
 smooth fibres are 
achieved (Fig. 5.3F). Previous studies, have also reported that solutions with a higher 
conductivity yielded fibres free from beads (271-273). At a higher conductivity the charges in 
the solution will be greater which in turn increases the stretching of the polymer jet resulting in 
fibres free from beads (267).  
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surface tension (mN m
-1
) (A) and the conductivity (mS cm
-1
) (B) of the needle electrospinning 
and additional solutions, at a temperature of 25ºC ± 2ºC. 
8 10 12 14 16 18 20
36
38
40
42
44
46
48
50
52
S
u
rf
a
c
e
 T
e
n
si
o
n
 (
m
N
 m
-1
)
PVA concentration (% w/v)
 21.57 wt % MGO
 14.76 wt % MGO
 11.22 wt % MGO
 Water
A 
 21.57 wt % MGO
 14.76 wt % MGO
 11.22 wt % MGO
 Water
8 10 12 14 16 18 20
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
C
o
n
d
u
c
ti
v
it
y
 (
m
S
 c
m
-1
)
PVA concentration (% w/v)
B 
Figure 5.4: The effect of MGO concentration (wt %) and PVA concentration (% w/v) on the 
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SEM micrographs over the full range of voltages from 7 kV to 18 kV and distances from 5 cm 
to 15 cm can be seen in Fig. 5.5 and 5.6 for a 21.57 wt % MGO concentration with a 12% (w/v) 
PVA concentration and a 11.22 wt % MGO concentration with a 16% (w/v) PVA concentration 
respectively. The initial SEM images revealed that bead formation (Fig. 5.3E) occured for a 
21.57 wt % MGO concentration with a 12% (w/v) PVA concentration. However it was of 
interest to understand if the bead formation transformed to smooth fibres with increasing 
distance and voltage, as this solution showed no evidence of wet polymer landing upon the 
collector during electrospinning.  
 
Images were taken using a Jeol JSM-6610LV at a magnification of 2500. Fig. 5.5 shows that for 
a 21.57 wt % MGO concentration and a 12% (w/v) PVA concentration only 14 out of a possible 
25 combinations of voltages and distances achieved web formation upon the collector. It was 
noted that as the distance increased a higher voltage was needed to initiate a polymer jet. At a 
greater distance there will be a decrease in the electrostatic field strength at the same voltage 
and so a greater voltage is required to initiate the polymer jet (274). The varied distances and 
voltages had no effect on the transformation from beads to fibres and no fibres were observed. 
However the size of the beads was shown to grow in size at a short distance of 5 cm and 
increasing voltage from 7 kV to 15 kV. Previous studies have also observed bead formation 
with an increasing voltage from 5 kV to 9 kV for a polymer concentration of 7 wt % 
polyethylene oxide in water (276). A receding electrospinning solution droplet to within the 
needle can explain this observation. As the voltage is increased the size of the droplet will 
decrease as the droplet resides within the needle and around the needle edge (276). In the 
present study an intermittent jet stream occurred, which resulted in short repellent bursts of the 
polymer jet towards the collector. 
.
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MGO concentration with a 12% (w/v) PVA concentration 
Figure 5.5: SEM micrographs of webs produced using needle electrospinning at different combinations of tip to collector distance and voltage, using a 21.57 wt % 
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Figure 5.6: SEM micrographs of webs produced using needle electrospinning, from an 11.22 wt % MGO concentration with a 16% (w/v) PVA concentration 
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For the SEM micrographs shown in Fig. 5.6, for an 11.22 wt % MGO concentration with a 16% 
(w/v) PVA concentration, 19 out of 25 possible combinations between voltage and distance 
achieved web formation.  The range of fibre diameters was recorded for each distance and 
voltage and the mean fibre diameter was calculated and can be seen in Table 5.2. In general, as 
the distance and voltage increased, the average fibre diameter decreased. A higher voltage will 
initiate a greater stretching of the solution due to the strong columbic forces in the 
electrospinning jet and a higher electric field (267). This also encourages faster solvent 
evaporation, which in turn yields drier fibres upon the collector (345).  
 
A larger mean fibre diameter between 237 nm and 314 nm was associated with a short distance 
of 5 cm and an increasing voltage from 7 kV to 13 kV. The merging of fibres and fibres that 
form junctions was also evident using these parameters. Previous studies have also observed 
merging of fibres at short distances, which can be attributed to the solvent having less time to 
evaporate before arriving at the collector (275, 343). As the distance and voltage are increased, 
the average fibre diameter is shown to decrease. A study by Lee et al, also confirmed that a 
decrease in PVA fibre diameter is observed with an increase in voltage (274). Similarly Buchko 
et al. also reported a decrease in fibre diameter as the applied electric field was increased (275).  
 
For each applied voltage and distance, the standard deviation of the fibre diameter from the 
mean was also calculated and is shown in Table 5.3. Examination of these results shows that the 
smallest mean fibre diameter (157 nm) is achieved at a distance of 15 cm and a voltage of 15 
kV, which also coincides with the lowest standard deviation of 31 nm. At a smaller distance of 5 
cm and a voltage of 10 kV the highest standard deviation was observed (141 nm), which 
corresponds with a relatively large mean fibre diameter of 291 nm, nearly double that of the 
smallest mean fibre diameter. The fibre distribution for the smallest and largest mean fibre 
diameters can be seen in Fig. 5.7.   
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(w/v) PVA concentration at different voltages (kV) and distances (cm). *n/s = not spinnable. 
 
Distance (cm) 
 
5 7 10 13 15 
Voltage (kV) Mean Fibre diameter (nm) 
7 n/s* 241 188 n/s* n/s* 
10 238 244 205 192 192 
13 291 196 201 193 212 
15 314 300 209 170 157 
18 n/s* n/s* 240 192 166 
 
 
with a 16% (w/v) PVA concentration at different voltages (kV) and distances (cm). *n/s = not 
spinnable. 
 
Distance (cm) 
 
5 7 10 13 15 
Voltage 
(kV) 
Standard deviation (nm) 
7 n/s 86 38 n/s n/s 
10 83 107 65 56 56 
13 141 66 60 59 76 
15 90 117 77 47 31 
18 
  
52 77 66 
Table 5.2: Mean fibre diameters (nm) achieved for a 11.22 wt % MGO concentration with a 16% 
Table 5.3: Standard deviation (nm) of the fibre diameters for a 11.22 wt % MGO concentration 
~ 111 ~ 
 
 
PVA concentration: A = sample spun at a distance of 15 cm and a voltage of 15 kV, B = 
sample spun at distance of 5 cm and voltage of 10 kV. 
 
Both Fourier transform infra-red spectroscopy (FTIR) and proton nuclear magnetic resonance 
(¹H-NMR) were employed to determine the presence of MGO within the as-spun PVA/MGO 
fibres, as described in sections 3.2.6 and 3.2.7 respectively. Electrospun fibres produced from a 
spinning solution with a concentration of 11.22 wt % MGO with 16% (w/v) PVA, were 
assessed to verify if the MGO was present within the fibres after needle electrospinning. Prior to 
the analysis of the PVA/MGO fibres, FTIR spectra’s of a 40% wt MGO solution and PVA 
granules (31-50,000Mw) were obtained to decipher the characteristic absorption bands found in 
both compounds. Similar to the FTIR analysis, measurements of both compounds were also 
taken using 
1
H-NMR to establish the characteristic resonance peaks. 
Fig. 5.8 displays the FTIR results obtained for all three separate samples. As reported in section 
2.5, MGO has two distinct carbonyl groups, a ketone and an aldehyde which are possible to 
detect using an FTIR system. A spectra of 40 wt % MGO solution (Fig. 5.8A) shows a 
characteristic vibrational absorption peak at 1728 cm
-1
, which is attributed to the C=O stretching 
vibration in the aldehyde carbonyl. A peak at 1386 cm
-1
 was also observed and can be assigned 
to CH3 bending in the methyl group of MGO (275). In Fig. 5.8B the spectra of PVA is 
displayed, the broad band centred at 3282 cm
-1
 is due to hydrogen-bonded O–H stretching 
vibration and the peak at 2905 cm
-1
 is attributed to C–H stretching in the polymer backbone. The 
peak at 1419 cm
-1
 is the result of in-plane O–H bending, while the peak at 1089 cm-1 is 
indicative of C–O stretching. Fig. 5.8C shows the spectra obtained for the PVA/MGO fibres. 
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Figure 5.7: Fibre diameter distributions for an 11.22 wt % MGO concentration with a 16% (w/v) 
5.2 Identification of MGO in the PVA/MGO fibres  
5.2.1 Results of Fourier Transform Infra-Red spectroscopy (FTIR)  
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Two small peaks were detected at 1720 cm
-1
 and 1379 cm
-1
 and coincide with similar peaks 
detected for the pure MGO. It can be assumed that the peak at 1720 cm
-1
 is attributed to the 
ketone carbonyl, while the small peak at 1379 cm
-1 
is indicative of the CH3 bending.  
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diamond ATR attachment with 64 repeat scans & PVA/MGO fibres in KBR pellets 
measured with 16 repeat scans(C). 
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Figure 5.8: FTIR spectra of 40 wt % MGO solution (A), PVA powder (B) measured using the 
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1
NMR) 
Similar to the FTIR analysis, a 40 wt % MGO solution and PVA granules (31-50,000Mw) were 
measured using 
1
H-NMR to establish the characteristic resonance peaks of both compounds. 
The PVA/MGO fibres were then measured to establish if the MGO was detectable. Fig. 5.9 
displays the 
1
H-NMR spectra’s obtained for all samples. In Fig. 5.9A the chemical formulas of 
MGO, MGO mono-hydrate and di-hydrate are shown. The hydrogen protons that are detectable 
for each chemical formula are indicated. Two singlet peaks at 1.403 ppm and 2.338 ppm can be 
assigned to the methyl protons present in the MGO di-hydrate and monohydrate respectively. 
The peak seen at 5.309 ppm is attributed to the alkyl proton of MGO monohydrate. These three 
peaks are in agreement with a previous study, which reported singlet peaks at 1.378 ppm, 2.306 
ppm and 5.287 ppm for MGO (346). In Fig. 5.9B the spectra of dissolved PVA granules is 
displayed. The chemical formula of PVA and the hydrogen atoms, which are detectable, are 
shown.  The resonance peaks observed at 1.751 ppm and 4.075 ppm can be assigned to the 
protons of CH2 and the CH proton of the PVA, respectively (347). The spectra for the 
PVA/MGO fibres is seen in Fig. 5.9C.  Resonance peaks for both MGO and PVA are detectable 
and coincide with the peaks detected in the pure compounds found in Fig. 5.9A and 5.9B. This 
data gives further confirmation that MGO is encapsulated within the resulting needle 
electrospun PVA fibres, with solvent evaporation having a limited effect.  
5.2.2 Identification of MGO using proton nuclear magnetic resonance ( H-
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1, 2 and 3 indicate the chemical formulas of MGO, MGO mono-hydrate and MGO di-hydrate 
respectively. 
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1
all dissolved in 1ml of deuterium oxide (99.9 % atom). 
1
H-NMR spectra were recorded with 
1024 repetitions. 
 
Figure 5.9: H-NMR spectra’s of 40 wt % MGO (A), PVA granules (B) and PVA/MGO fibres (C) 
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To evaluate the antibacterial behaviour of the fibres produced from needle electrospinning, BS 
EN ISO 20645:2004, Textile fabrics, determination of antibacterial activity, agar diffusion plate 
test, described in section 3.2.8.2 was followed. The electrospun fibres which were spun onto an 
inert nonwoven polypropylene spunbond substrate (SPB) were tested against two types of 
common wound pathogens: S.aureus and E.coli. As control specimens, PVA was electrospun 
onto SPB and SPB alone was used. The antibacterial activity of the samples was assessed by the 
absence or presence of bacterial growth in the contact zone between the agar and the specimen 
and the appearance of an inhibition zone around the specimen. The calculated width of the 
inhibition zone was recorded.   
PVA/MGO fibres were prepared for antibacterial testing via needle electrospinning. An 
electrospinning solution made from an 11.22 wt % MGO concentration with 16% (w/v) PVA 
was prepared. For the control sample a 16% (w/v) concentration of PVA in distilled water was 
also prepared. SPB measuring 4 cm x 4 cm was used as the collector for the fibres to form a 
composite material. The SPB was placed over a piece of aluminium foil measuring 4 cm x 4 cm, 
to enable the attraction of the fibres to the SPB substrate. Based on the previous findings, a flow 
rate of 0.1 ml h
-1
, a distance of 15 cm and voltage of 15 kV was utilised. The concentration of 
MGO in this solution was calculated to be 105 mg ml
-1
. To determine the minimum 
concentration of MGO in the spun sample (mg cm
-
²) required to have an antibacterial effect, 
electrospinning was carried out for various lengths of time between 0.5 h to 4 h. As the spinning 
time increased it was expected that there would be an increase in MGO concentration. 
Assuming that all of the MGO in the spun solution is in the spun fibres, the concentration of 
MGO in the spun sample (mg cm
-2
) is given by the following equation: 
Eq.5.1 
Concentration of MGO in the spun sample  =           / Sa 
where, 
MGOc is the calculated concentration of MGO in the prepared spinning solution (105 mg 
ml
-1
) 
Fr is flow rate of 0.1 ml h-1  
T is the spinning time (h) 
Sa is the area of the spun sample (cm2) 
5.3  Antibacterial evaluation of PVA/MGO fibres 
5.3.1 Preparation of PVA/MGO fibres for antibacterial testing 
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Note: The spun sample was normally a circle of approximately 3 cm in diameter. An area of 7 
cm
2
 (Sa) was therefore used. 
Table 5.4 shows the calculated concentrations of MGO in the spun samples for each spinning 
time based on Eq.5.1. 
-
Time spun (h) 
MGO concentration 
(mg cm
-²) 
0.5 0.75 
1 1.50 
2 3.00 
3 4.50 
4 6.00 
 
Table 5.5 displays the results achieved for the needle electrospun PVA/MGO against E.coli and 
S.aureus. Fig. 5.10 and 5.11 show a visual representation of the effect of the control samples 
(PVA/SPB and SPB) and the PVA/MGO electrospun samples on the growth of S.aureus and 
E.coli after 24 h in-vitro, respectively. In Fig. 5.10, for the control samples, no zone of 
inhibition was present. Upon removal of the control samples from the surface of the agar, the 
contact zone between the sample and the agar presented heavy bacterial growth. This would be 
expected, given that no MGO was present.  
 
The effect of MGO concentration on the growth of each bacterial species can clearly be seen in 
Fig. 5.11 and further confirms that MGO is the sole agent responsible for antibacterial activity. 
No zone of inhibition was apparent for an MGO concentration at 0.75 mg cm
-
² for both S.aureus 
and E.coli, and slight bacterial growth was observed under the sample, showing a limited 
antibacterial efficiency (Table 5.5). At a concentration of 1.50 mg cm
-
² a small mean zone of 
inhibition measuring 1 mm for both S.aureus and E.coli was apparent. Upon removal of the 
sample from the agar no growth was observed, showing a good antibacterial effect. In this case 
it can be assumed that the minimum concentration required to have an antibacterial effect 
against S.aureus and E.coli is 1.50 mg cm
-
². However, there may be a point between a spinning 
time of 0.5 h and 1 h, where the concentration of MGO (mg cm
-
²) becomes great enough to 
initiate the development of a zone of inhibition or all bacteria is inhibited under the sample, 
further work would need to be carried out to determine this.  
Table 5.4: Calculated concentration of MGO in the electrospun samples (mg cm ²). 
5.3.2 Results for antibacterial testing 
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A previous study which evaluated the antibacterial activity of MGO in liquid and hydrogel form 
reported concentrations between 1.25 mg ml
-1
 (0.14 mg cm
-2
) and 15 mg ml
-1
 (1.72 mg cm
-2
) 
were found to have an antibacterial effect against S.aureus and multi-resistant S. epidermidis 
(MRSE) respectively. At the lower concentration of 0.14 mg cm
-2
 a zone of inhibition measuring 
approximately 20 mm for S.aureus and 16 mm for MRSE were recorded. While at the higher 
concentration of 1.72 mg cm
-2
 a larger zone of inhibition was observed at 40 mm for both 
strains (45). The concentration of MGO in the liquid or gels shows that for a concentration of 
approximately one-tenth (0.14 mg cm
-2
) than that present in the PVA/MGO fibre webs (1.50 mg 
cm
-2
) a zone of inhibition 16 to 20 times the size can be achieved. This difference can be 
attributed to the initial encapsulation of MGO within the fibre, which is not freely available on 
direct contact with the bacteria, as it is in a liquid or gel state.  
 
On contact with the agar, the PVA fibres are shown to form a gel, which then prompts the 
diffusion of MGO from the fibres into the surrounding bacterial strain, preventing bacterial 
growth (290). In accordance with a previous study in which the concentration of MGO in liquid 
form required to inhibit S.aureus was found to be 0.14 mg cm
-2 
(45), the concentration of MGO 
identified in section 4.2.4.2 on the coated nonwoven samples was similar with a concentration 
of 0.1 mg cm
-2 
for S.aureus. In both these cases the synthetic MGO is not restricted by the initial 
encapsulation within a fibre, as it is in the needle electrospun PVA fibres, and as such a 
relatively lower concentration of MGO is required to inhibit the bacteria.   
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-2
the growth of E.coli and S.aureus. 
MGO 
concentration 
(mg cm
-
²) 
 
Mean inhibition 
zone (mm) 
 
Growth under 
sample 
Assessment 
E.coli 
0.75 
0.00 Slight  
Limit of 
efficiency 
1.50 
1.00 No growth Good effect 
3.00 
2.75 No growth Good effect 
4.50 
6.50 No growth Good effect 
6.00 
9.00 No growth Good effect 
S.aureus 
0.75 
0.00 Slight 
Limit of 
efficiency 
1.50 
1.00 No growth Good effect 
3.00 
4.25 No growth Good effect 
4.50 
6.25 No growth Good effect 
6.00 
7.75 No growth Good effect 
 
 
& S.aureus; C = PVA/SPB and D = SPB. 
A B C D 
E.coli S.aureus 
Table 5.5:Effect of MGO concentration (mg cm ), in the PVA/MGO needle electrospun webs, on 
Figure 5.10: Effect of control samples on the growth of E.coli; A = PVA/SPB, B = SPB 
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(C & H), 3 h (D & I) and 4 h (E & J). 
A B E D C 
F G H I J 
E.coli 
S.aureus 
Figure 5.11: The effect of MGO concentration in the PVA/MGO fibres on the growth of E.coli and S.aureus after electrospinning for 0.5 h (A & F), 1 h (B & G), 2 h 
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It has been established that an 11.22 wt % MGO concentration with a 16% (w/v) PVA concentration 
was most favourable for producing smooth fibres free from defects. The smallest mean fibre diameter 
of 157 nm with the lowest standard deviation of 31 nm was achieved with a distance of 15 cm and a 
voltage of 15 kV on an aluminium foil collector. The successful encapsulation of MGO within the 
PVA fibres was confirmed using both FTIR and 
1
H-NMR, which highlighted the carbonyl groups 
associated with MGO’s keto-aldeyde groups. The presence of MGO was further confirmed by the 
evident antibacterial performance when compared with two control samples free from MGO, which 
showed no antibacterial effect. The antibacterial evaluations also confirmed that a minimum MGO 
concentration of 1.50 mg cm
-2
 was required to provide a bactericidal effect against both S.aureus and 
E.coli in-vitro. This concentration was substantially higher than that required on coated nonwovens to 
produce an antibacterial effect, where concentrations between 0.0170 mg cm
-2 
and 0.1 mg cm
-2
 of 
MGO were needed to inhibit E.coli and S.aureus respectively. The higher concentration of 1.50 mg 
cm
-2 
can be attributed to the encapsulation of MGO within the PVA fibres and the slower diffusion 
rate into the agar.  
 
5.4 Summary  
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Electrospun Fibres Containing Poly(vinyl 
alcohol) and Synthetic Methylglyoxal 
  
Chapter 6 Properties of Free Surface (Needleless) 
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In Chapter 5 the production of poly(vinyl alcohol) (PVA)/ methylglyoxal (MGO) fibres was 
successfully carried out via needle electrospinning. However, this method of electrospinning has 
some limitations if the intended purpose is to upscale the production of electrospun webs for 
commercial use. As reported in sections 2.8.1 and 2.8.2, free surface (needleless) 
electrospinning is available on an industrial scale. In this form of spinning, no needles are 
required and multiple electrostatic jets are produced along the surface of a rotating electrode 
immersed within a polymer bath (264). The advantage of this method is the continuous 
production of electrospun webs, potentially up to 50 million m² per year using PVA (348).  
 
Although both needle and free surface (needleless) electrospinning exploit the same mechanism 
for stretching the jet, the mode of spinning is quite different and it cannot be assumed that 
spinning solutions can be easily interchanged between the two methods. Accordingly, the aim of 
this chapter was to explore and determine the feasibility of electrospinning commixed PVA and 
synthetic MGO using free surface electrospinning. As previously identified in Chapter 5, the 
optimisation and development of PVA/MGO fibres, via needle electrospinning was successfully 
established with a spinning solution containing 16% (w/v) PVA in a synthetic MGO aqueous 
solution (11.22 wt %). At these concentrations, fibres free from defects were obtained and the 
antibacterial properties of the PVA/MGO fibres were confirmed using BS EN ISO 20645:2004. 
Previous studies, which have explored the spinning ability of PVA in distilled water using free 
surface needle electrospinning have found that lower polymer concentrations between 6% (w/v) 
and 11% (w/v) have successfully produced fibres free from beads (266, 349). It was therefore of 
interest to determine if an 8% (w/v) PVA solution in 11.22 wt % MGO could form fibres free 
from defects, when using free surface electrospinning. Higher PVA concentrations of 16% (w/v) 
and 20% (w/v) in an 11.22 wt % aqueous MGO solution were also considered. The machine 
employed during these experiments was an Elmarco NS Lab (section 3.2.4.2). Two different 
collector substrates, an aluminium foil and a polypropylene spunbond (SPB) were used to 
collect the electrospun webs; this is to determine if the collector had any effect on the fibre 
morphology. Fourier transform infra-red spectroscopy (FTIR) and proton nuclear magnetic 
resonance (
1
H-NMR) were employed to determine the presence of MGO within the spun webs. 
The antibacterial activity of the spun webs was determined by means of BS EN ISO 20645: 
2004.   
6.1 Introduction 
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electrospinning 
8% (w/v), 16% (w/v) and 20% (w/v) PVA (31-50,000 Mw) solutions in synthetic MGO (11.22 
wt % aqueous solution) were prepared for spinning. Thus, a wide range of PVA concentrations 
were studied. The prepared solutions were kept under constant agitation, at 80ºC ± 2ºC for 24 h 
in a glass conical flask, sealed with a glass stopper. After 24 h all the PVA had dissolved and 
the solutions appeared clear. 
Free surface electrospinning was performed using an Elmarco Nanospider NS LAB. A detailed 
description of this procedure is outlined in section 3.2.4.2. After initial investigation with both 
the roller and wire cylindrical electrode, it was found that the wire cylindrical electrode 
produced an even distribution of electrospinning jets, when compared to the roller electrode 
where, limited jet formation was observed. Therefore the wire cylindrical electrode was chosen 
for the following experiments and set to run at a speed of 6.0 r min
-1
. During the initial 
investigation, it was also found that a voltage below 65 kV was unable to produce stable jet 
formation and therefore higher voltages between 65 kV and 75 kV were employed. Aluminium 
foil and SPB were used separately to collect the spun webs. Distances of 163 mm, 173 mm and 
183 mm between the collector and the spinning electrode were applied. These calculated 
distances were obtained based on the following equation (350): 
Eq.6.1 
 Distance between collector and electrode = Y + 13 
where 
Y  is the height displayed on the collection head ruler (mm) 
  
6.1.1 Preparation of PVA/MGO solutions for free surface (needleless) 
6.1.2 Free surface electrospinning 
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A summary of the free-surface electrospinning performance of each polymer solution is given in 
Table 6.1. 
 Solvent  
MGO 
concentration 
(wt %) 
PVA 
concentration 
(% w/v) 
Electrospinning 
performance 
Behaviour of polymer 
solutions 
40 wt % 
MGO 
(aqueous 
solution) 
diluted with 
distilled 
water  
  
11.22 
 
8  Beads 
Intermittent burst of 
polymer rising from the 
electrode/ some wet 
polymer on the 
collectors 
16 Fibres and beads 
Consistent polymer jets 
rising from the 
electrode/dry polymer 
web on the collectors  
20 Fibres 
Consistent polymer jets 
rising from the 
electrode/dry polymer 
web on the collectors 
 
Initial SEM micrographs were taken using a Jeol JSM-6610LV at a magnification of 2500 in 
order to assess the morphological features of the electrospun webs collected on the foil and SPB 
substrates, as shown in Fig. 6.1.  
 
For samples spun with 8% (w/v) PVA solution, the SEM micrographs showed that only beads 
were formed in the electrospun webs on both the foil and SPB collector, see Fig. 6.1A and Fig. 
6.1B respectively. During spinning it was noted that the material landing upon the collector was 
still wet at voltages between 65 kV and 75 kV and distances from 163 mm to 183 mm. This 
finding is expected, given that wet material was also observed upon the aluminium foil during 
needle electrospinning at the same concentration, resulting in merging areas which formed 
junctions within the web. However, previous papers that have explored the free surface 
electrospinning of PVA, have reported that concentrations of PVA between 6% (w/v) and 11% 
(w/v) produced fibres free from defects in a distilled water solution (266, 349).  
 
Notably, one study by Sinah et al. (349) did not report the molecular weight of the PVA used, 
and so no direct comparison can be made. In another study, the molecular weight was reported 
to be 72,000 (266). It has been previously documented that, for different molecular weights, a 
minimum polymer concentration is required to stabilise the electrospinning jets (242, 351). As 
the molecular weight of PVA in this experiment was 31-50,000, a relatively low concentration 
of 8% (w/v) provided insufficient chain entanglement to prevent the breakup of the polymer jet, 
6.2  Results and Discussion 
6.2.1 Free surface (needleless) electrospinning performance 
Table 6.1: Summary of free surface electrospinning performance. 
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resulting in wet material forming upon both substrates which lead to the formation of beads. 
However, in the study where a 72,000 Mw was used, an 8% (w/v) PVA concentration provided 
sufficient entanglement between the polymer chains to avoid the breakup of the electrospinning 
jets (266).  
 
In the present work, as the PVA concentration was increased to 16% (w/v), the morphology of 
the fibres in the spun webs improved, such that fibres together with some beads were formed on 
both the foil and SPB substrates, as seen in Fig. 6.1C and 6.1D respectively. Similar to the 
findings obtained for fibres produced via needle electrospinning, as the concentration of PVA 
was doubled from 8% (w/v) to 16% (w/v), the viscosity increased (section 5.1.4.1, Fig.5.2) and 
the polymer chain entanglement became sufficient to prevent the breakup of the electrically 
charged jet. When compared to the morphology of the fibres produced at a 16% (w/v) PVA 
concentration using needle electrospinning over a series of voltages between 7 kV and 18 kV 
and distances between 5 cm to 15 cm, no beads appeared (section 5.1.4.1, Fig. 5.6). However 
when using free surface electrospinning, some beads were apparent. Notably, the voltages used 
with free surface electrospinning were necessarily higher (65 kV to 75 kV) when compared with 
needle electrospinning (7 kV to 18 kV) to ensure continuous spinning could be maintained. This 
substantial increase in voltage can be expected to heighten the electrostatic field, leading to 
instabilities in the electrospinning jets, which has been reported to lead to an increase in bead 
formation (268, 276). It is also known that an increase in voltage can reduce the flight time of 
the polymer jets to the collector. This  results in insufficient crystallisation in the fibre as the  
molecular chains have less time to align themselves before reaching the collector (352).  
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PVA concentrations on aluminium foil and SPB substrates. A & B = 8% (w/v) PVA on foil 
and SPB respectively, C & D = 16% (w/v) PVA on foil and SPB respectively and E & F = 20 
% (w/v) on foil and SPB respectively. 
 
Owing to the formation of some beads at a 16% (w/v) PVA concentration, a 20% (w/v) PVA 
solution was also prepared, with the intention of eliminating any beads in the web due to the 
increase in viscosity (2634 cP, as seen in section 5.1.4.1, Fig.5.2). Fig. 6.1E and 6.1F present 
micrographs of the morphology of the fibres produced at a 20% (w/v) PVA concentration on the 
foil and SPB substrates respectively. No beads were observed on either substrate. Interestingly, 
when the viscosity of the polymer solutions used in needle electrospinning was increased to 
1421 cP and above, as discussed in section 5.1.4.1, the polymer was found to dry at the needle 
tip and subsequently there was no initiation of an electrospinning jet. A possible explanation as 
to why such a comparatively high viscosity of 2634 cP was capable of producing fibres using 
free surface electrospinning, may be due to the constant agitation of the polymer solution (6 r 
A B 
C D 
E F 
Figure 6.1: SEM micrographs of free surface (needleless) electrospun webs produced from different 
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min
-1
). The continuous agitation of the fluid allowed the polymer chains to move freely, 
maintaining the viscoelastic nature of the polymer solution, which can be easily stretched via 
the electrostatic attraction between rotating electrode and collector.  
 
When using needle electrospinning, the relatively slow flow rate of 0.1 ml hr
-1
 allows only a 
small volume of polymer solution to be exposed at the needle tip to the ambient conditions. The 
relatively slow flow rate at the point of electrification of the polymer allowed sufficient time for 
the solvent to evaporate, allowing the polymer to dry out quickly at the needle tip. However if 
the flow rate of the polymer from the needle tip was increased, this may give less time for the 
solvent to evaporate and allow the stretching of the polymer solution to elongate and form fibres 
on the collector (267).  
 
Notably, after one hour of spinning time when using free surface electrospinning, the 20% (w/v) 
PVA solution in the polymer bath visually began to thicken as a result of solvent evaporation. 
This led to infrequent and intermittent formation of the polymer jets forming along the spinning 
electrode, at which point free surface electrospinning was inhibited. 
 
In Fig 6.2 and 6.3, the morphology of the fibres produced from a 20% (w/v) PVA concentration 
over the series of voltages between 65 kV and 75 kV and distances of 163 mm to 183 mm are 
shown. In all cases, no beads were observed in the collected webs. The mean fibre diameter in 
each electrospun web produced at different voltages and distances is given in Table 6.2. 
Examples of the fibre distributions on both collector substrates are given in Fig 6.4.  
 
The smallest mean fibre diameter (155 nm) and lowest standard deviation (35 nm) was achieved 
on the foil substrate at a voltage of 65 kV and a distance of 183 mm. The mean fibre diameters 
of the electrospun webs produced on the aluminium foil were all lower than any of the mean 
diameters fabricated on the SPB substrates. The increased electrical field when using a 
conductive aluminium foil collector compared with a non-conducting fibrous SPB material may 
explain this. A conductive collector allows the electrical charges on the fibres to be dissipated, 
thus allowing an increased electrical field, which may act upon the stretching and elongation of 
the polymer jet (353). In the case where a non-conductive SPB collector was used, the electrical 
charges on the polymer jets will accumulate on the non-conducting material and exert a 
repulsive force on the subsequent fibres landing on the collector. These repulsive forces may be 
inclined to reduce the stretching of the polymer solution (353, 354) such that there could be an 
increase in the mean fibre diameter of the collected fibres.  
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A previous study, which evaluated the morphology of PVA fibres on up to seven different 
substrates, when using free surface electrospinning, also reported a smaller mean fibre diameter 
using an aluminium foil substrate when compared to a polypropylene SPB substrate. The 
previous work related to experiments conducted at a lower voltage (60 kV) and distance (130 
mm) (266) compared with that studied herein. 
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Figure 6.2: SEM micrographs of free surface (needleless) electrospun webs produced on an aluminium foil substrate from a 
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Figure 6.3: SEM micrographs of free surface electrospun webs on a SPB substrate from a 20% (w/v) PVA concentration over a 
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both an aluminium foil and SPB substrate from a 20% (w/v) PVA concentration, over a 
series of voltages (kV) and distances (mm). 
Substrate Aluminium foil Spunbond 
Voltage (kV) 65 65 
Distance (mm) 163 173 183 163 173 183 
Mean (nm) 211 195 155 402 427 219 
STD (nm) 93 66 35 160 131 113 
Voltage (kV) 70 70 
Distance (mm) 163 173 183 163 173 183 
Mean (nm) 161 172 175 226 247 239 
STD (nm) 47.3 50.1 47.0 77.6 87.1 60.2 
Voltage (kV) 75 75 
Distance (mm) 163 173 183 163 173 183 
Mean (nm) 249 161 167 251 242 226 
STD (nm) 74 47 61 107 81 57 
  
deviations (nm) of the free surface electrospun fibres on the aluminium foil and SPB 
substrates, produced from a 20% (w/v) PVA solution. A = 65 kV, 183 mm Foil, B = 75 kV, 
163mm Foil, C = 65kV, 183mm SPB & D = 65kV 173mm SPB.  
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Table 6.2: Mean fibre diameters and standard deviation (nm) of electrospun webs produced on 
Figure 6.4: Examples of the fibre diameter distributions and mean fibre diameters and standard 
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PVA/MGO fibres  
Both Fourier transform infra-red spectroscopy (FTIR) and proton nuclear magnetic resonance 
(¹H-NMR) were employed to determine the presence of MGO within the PVA/MGO fibres, as 
described in sections 3.2.6 and 3.2.7 respectively. Electrospun fibres produced from a spinning 
solution with a concentration of 20% (w/v) PVA in an 11.22 wt % synthetic MGO solution were 
assessed to verify the presence of MGO within the fibres after free surface electrospinning. The 
electrospun webs were produced at a voltage of 65 kV and a distance of 183 mm on an 
aluminium foil substrate, using a wire cylindrical electrode at a speed of 6.0 r min
-1
, as these 
parameters were previously found to produce the smallest mean fibre diameter. 
(FTIR)  
Fig 6.5 displays the FTIR results obtained for the free surface (needleless) electrospun 
PVA/MGO fibres. As previously reported in section 5.2.1 the detection of MGO in the needle 
electrospun fibres was shown to have two small peaks which could be attributed to the two 
distinct carbonyl groups in MGO, a ketone and an aldehyde group. In Fig. 6.5 the detection of 
these two small peaks was also observed. A peak at 1717 cm
-1
 is attributed to the C=O 
stretching vibration in the aldehyde carbonyl and the small peak at 1345 can be assigned to CH3 
bending in the methyl group of MGO (275). The larger peaks in the spectra are attributed to the 
PVA. The broad band centred at 3410 cm
-1
 is due to hydrogen-bonded O–H stretching vibration 
and the peak at 2929 cm
-1
 is attributed to C–H stretching in the polymer backbone. The peak at 
1438 cm
-1
 is the result of in-plane O–H bending, while the peak at 1094 cm-1 is indicative of C–
O stretching.   
6.2.2  Identification of MGO in the free surface (needleless) electrospun 
6.2.2.1 Identification of MGO using Fourier transform infra-red spectroscopy 
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KBr pellets and measured with 16 repeat scans. 
1
NMR) 
Fig 6.6 displays the 
1
H-NMR spectra obtained. As previously reported in section 5.2.2 (Fig 
5.9A) the chemical formulas of MGO, MGO mono-hydrate and di-hydrate are shown. The 
hydrogen protons, which are detectable for each chemical formula are indicated. In Fig. 6.6, the 
two singlet peaks at 1.335 ppm and 2.144 ppm can be assigned to the methyl protons present in 
the MGO di-hydrate and monohydrate respectively. The peak observed at 4.998 ppm is 
attributed to the alkyl proton of MGO monohydrate. The resonance peaks observed at 1.560 
ppm and 3.886 ppm can be assigned to the protons of CH2 and the CH proton of the PVA 
respectively (347). This data gives further confirmation that MGO was encapsulated within the 
free surface electrospun PVA fibres, with solvent evaporation having a limited effect.  
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6.2.2.2 Identification of MGO using proton nuclear magnetic resonance ( H-
Figure 6.5: FTIR spectra of the free surface (needleless) electrospun PVA/MGO webs ground into 
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1
1ml of deuterium oxide (99.9 % atom) recorded with 1024 repetitions 
 
PVA/MGO fibres were prepared for antibacterial testing via free surface (needleless) 
electrospinning. An electrospinning solution containing 20% (w/v) PVA in an 11.22 wt % 
synthetic MGO solution was prepared. The electrospinning solution was spun onto an 
aluminium foil substrate at a voltage of 65 kV and a distance of 183 mm using a wire 
cylindrical electrode, as these parameters were previously found to provide the smallest mean 
fibre diameter. To determine the minimum concentration of MGO required to produce an 
antibacterial effect, free surface electrospinning was carried out for various lengths of time 
between 2.5 and 30 min. Similar to the results found in section 5.1.8, it was expected that as the 
spinning time was increased, there would be an increase in the amount of MGO available within 
the spun web. However, as there is no control over the flow rate or the amount of jets produced 
along the spinning electrode, the weight of the spun webs was recorded after spinning. Initial 
experiments revealed that with an increasing spinning time, the weight of the spun webs did not 
increase proportionally. This may be due to the variable amount of electrospinning jets forming 
along the wire electrode during spinning, resulting in variable deposition of fibres on the 
collector. Therefore, electrospun samples were prepared with an increasing collected weight 
Figure 6.6: H-NMR spectra’s of PVA/MGO free surface (needleless) electrospun webs dissolved in 
6.2.3 Antibacterial Evaluation of PVA/MGO fibres 
6.2.3.1 Free surface (needleless) electrospinning and calculated mass of MGO 
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from 10 mg to 150 mg. To determine the mass of MGO in the spun webs, a calculation was 
made using the initial ratio of PVA and MGO in the spinning solution as follows:  
    Mass of MGO in spun web = Mass of sample x RMGO 
 
where RMGO is the ratio of MGO to MGO + PVA in the spinning solution, which in this 
experiment was 0.369. 
 
In order to validate this assumption, three PVA/MGO webs produced via free surface 
electrospinning were dispersed in distilled water at 37ºC for 30 min, 3 days and 1 week. The 
samples were shown to disintegrate on direct contact with the water, due to the poor stability of 
PVA without the addition of any crosslinking. Therefore, it was of interest to understand if all 
the MGO was released instantaneously with no change over 1 week. Measurements of the water 
containing the dispersed PVA/MGO were assessed using reverse phase high performance liquid 
chromatography (RV- HPLC), as described in section 3.2.9 to determine the mass of MGO in 
each sample and can be seen in Table 6.3. The amount of MGO released from the electrospun 
of the MGO remained in the spinning bath or that not all of the MGO was released from the 
fibres during dispersion. Based on this result the mass of MGO available for release, in an 
probably only valid for samples with the exact spinning specifications outlined in section 
6.2.3.1.  
 
Dispersion 
time 
Weight of 
spun web (mg) 
Calculated Mass of 
MGO in fibres based on 
Mass of MGO found 
in dispersion test (mg) 
Proportion of 
MGO found by 
HPLC 
Eq. 6.2 
30 min 173.00 63.85 59.8 0.937 
3 days 154.00 56.84 51.3 0.903 
1 week 67.20 24.80 24.1 0.972 
 
  
Mean 0.937 
 
Eq.6.3   
MGO
Table 6.3: Amount of MGO released during dispersion test (mg), assessed via HPLC. 
 Mass of MGO available in spun web = Mass of sample x R  x 0.937  
Eq. 6.2  
webs was found to be 93.7% of that assumed from Eq. 6.2. The reason for this may be that some 
aqueous environment was calculated using Eq. 6.3. It should be noted that this equation is 
Eq. 6.2 (mg) compared to 
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The delicate and frail nature of the electrospun webs prepared in section 6.2.3.1, presented a 
difficult task when preparing the samples to the same diameter in each case. A circular tube 
with a diameter of 20 mm was used to prepare the samples. All samples were prepared in line 
with the standards specifications of 25 ± 5 mm diameters, with the exception of one, which had 
a mean diameter of 32 mm. This was due to the fibrous webs overhang after removal of the 
tube. Four measurements were taken across the diameter of each sample to determine the mean 
diameter. From the mean diameter, the area of the sample was established. Based on the sample 
-2
seen in Table 6.4. 
 
area (mg cm
-2
) for the samples tested against E.coli and S.aureus. 
Weight of spun web 
(mg) 
Mass of MGO in 
the spun web (mg) 
Mean sample 
diameter (mm) 
Concentration of 
MGO (mg cm
-2
) 
E.coli 
10 3.46 26.0 0.65 
20 6.92 25.0 1.41 
50 17.29 24.0 3.82 
100 34.58 29.0 5.24 
150 51.87 30.0 7.34 
S.aureus 
10 3.46 23.0 0.83 
20 6.92 20.0 2.20 
50 17.29 28.5 2.71 
100 34.58 32.0 4.30 
150 51.87 30.0 7.34 
  
6.2.3.2 Sample preparation for antibacterial testing 
Table 6.4: Calculated mass of MGO in the spun webs (mg) and the concentration of MGO per unit 
area and Eq. 6.3, the concentration of MGO per unit area (mg cm ) was calculated and can be 
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Table 6.5 displays the results achieved for the PVA/MGO webs tested against E.coli and 
S.aureus. The zones of inhibition and the effect of the sample on the growth of each bacteria 
species as per the standard requirements are shown. Fig 6.7 shows a visual representation of the 
PVA/MGO samples on the growth of E.coli and S.aureus after 24 h in-vitro. The dotted black 
line indicates the original mean sample size before testing. In all cases the PVA/MGO samples 
have decreased in size during the test, as seen in Fig. 6.7. This occurrence can be explained by 
the hydrophilic nature of the PVA fibres (65, 355). During incubation at 37ºC the fibres would 
have absorbed any moisture available from the agar and the surrounding environment, forming a 
hydrogel, which was then dissolved into the agar, releasing the MGO.  
 
In Fig. 6.7A, 6.7E & 6.7F, where the concentration of MGO ranged from 1.41 mg cm
-2
 to 2.71 
mg cm
-2
, the original mean diameter of the sample was found to be slightly larger than the zone 
created by the shrunken hydrogel PVA/MGO fibres. In these cases no zone of inhibition was 
actually formed and is referred to here as zero in Table 6.5. However it is still apparent that the 
growth of bacteria was inhibited where the original sample was laid and no growth was 
observed upon removal of the remaining sample from the agar. In accordance with the standard 
requirements, a good antibacterial effect was still achieved at concentrations between 1.14 mg 
cm
-2
 to 2.71 mg cm
-2
.  
 
At MGO concentrations between 0.65 mg cm
-2
 and 0.83 mg cm
-2
 the majority of the sample had 
dissolved and moderate to heavy growth was apparent upon removal of the samples from the 
agar. In all other cases where the concentration was 3.92 mg cm
-2
 or above, a zone of inhibition 
was apparent. Upon removal of these samples from the agar, no growth was observed and a 
good antibacterial effect was achieved.  
6.2.4 Results of Antibacterial testing 
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-2
on the growth of E.coli and S.aureus. 
MGO 
concentration 
(mg cm²) 
 
Mean inhibition 
zone (mm) 
 
Growth under 
sample 
Assessment 
E.coli 
0.65 
0 Moderate  Insufficient 
1.41 
0*
1
 No growth Good effect 
3.82 
0.63 No growth Good effect 
5.24 
2.25 No growth Good effect 
7.34 
3.25 No growth Good effect 
S.aureus 
0.83 
0 
Slight to 
moderate 
Insufficient 
2.20 
0*
1
 No growth Good effect 
2.71 
0*
1
 No growth Good effect 
4.30 
1.25 No growth Good effect 
7.34 
2.00 No growth Good effect 
*
1
 The absence of growth, even without an inhibition zone, may be regarded as a good effect, as the 
formation of such an inhibition zone may have been prevented by a low diffusion of the active substance 
(315). However, in this case the original sample size was larger than the apparent zone of inhibition, 
indicated by the dotted lines in Fig.6.7. 
Table 6.5: Effect of MGO concentration (mg cm ), in the free surface (needleless) electrospun webs 
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A B C D 
E.Coli 
S.aureus E F G H 
2.20 mg cm
-2
 2.71 mg cm
-2
 4.30 mg cm
-2
 7.34 mg cm
-2
 
 
 
   
1.14 mg cm
-2
 3.82 mg cm
-2
 5.24 mg cm
-2
 7.34 mg cm
-2
 
-2
lines indicate the original sample size before incubation for 24 h. 
Figure 6.7: The effect of MGO concentration (mg cm ) on the growth of E.coli (A to D) and S.aureus (E to H). The dotted 
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When comparing the electrospinning ability of PVA/MGO webs using needle and free surface 
(needleless) electrospinng techniques, it was found that different conditions were required to 
initiate the formation of electrospinning jets and produce fibres of differing morphology. Table 
6.6 shows the parameters required for each electrospinning technique to produce fibres with the 
smallest mean fibre diameter.  
 
A range of synthetic MGO solution concentrations between 40 wt % 11.22 wt %, with varying 
PVA concentrations between 8% (w/v) and 16% (w/v) were initially prepared and trialled using 
needle electrospinning. It was found that an 11.22 wt % MGO solution and a PVA 
concentration of 16% (w/v) were favoured for producing fibres free from beads. At lower PVA 
concentrations of 8% (w/v) and 12% (w/v), wet polymer was shown to land upon the collector, 
resulting in merging fibres. In contrast, a larger PVA concentration of 20% (w/v) for free 
surface electrospinning was required to produce fibres free from beads, when compared with 
16% (w/v) where beads were observed in the as-spun webs over a series of voltages and 
distances. The viscosity of the polymer solutions was shown to increase with increasing PVA 
concentration for all synthetic MGO solutions. At a viscosity of 605 cP, the polymer solution 
moved freely through the needle at a speed of 0.1 ml h
-1
 and was found to initiate an 
electrospinning jet, resulting in dry bead free fibres on the collector. At a viscosity of 1421 cP 
and above, the polymer solution was found to dry at the needle tip and no fibres were formed. 
However, at a viscosity of 605 cP when using free surface electrospinning, beads were observed 
in the electrospun webs. At a higher PVA concentration of 20% (w/v) with a viscosity of 2634 
cP, no beads were apparent in the free surface electrospun webs. The rotation of the wire 
electrode during free surface electrospinning, was able to maintain the viscoelastic nature of the 
polymer solution.  
 
Notably, a larger voltage was used for free surface electrospinning of 65 kV in order to initiate 
electrospinning jets along the wire electrode, when compared with 15 kV for needle 
electrospinning, where sparks were shown to occur between the collector and the needle tip at a 
voltage above 18 kV. This may be attributed to the conductive nature of the bare metal needle 
tip when compared with the wire electrode, which is immersed in the less conductive polymer 
solution, allowing greater voltages to be used without sparking.  
 
When using needle electrospinning, distances between the needle and collector showed that an 
increase in distance resulted in a finer mean fibre diameters for each voltage with the exception 
of 13 kV. No correlation was found between distance and fibre diameter for free surface 
electrospinning over a series of voltages. However, at a larger distance of 183 mm and a voltage 
6.2.5 Comparison between needle and free surface electrospinning 
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of 65 kV, a small mean fibre diameter was achieved when compared with a lower distance of 
163 mm at the same voltage. 
the smallest mean fibre diameter (nm) on an aluminium foil collector. 
Parameters 
Needle electrospinning 
(smallest mean diameter =  
157 nm) 
Free surface (needleless) 
electrospinning (smallest 
mean fibre diameter = 
 155 nm) 
PVA concentration (% w/v) 16 
20 
Viscosity (cP) 605 
2634 
Surface tension mN m
-1
 45.96 
40.43 
Conductivity mS cm
-1
 1.234 
1.033 
Voltage (kV) 15 
65 
Distance (mm) 150 
183 
Flow rate (ml h
-1
) 0.1 
n/a 
Speed of electrode (r min
-1
) n/a 
6.0 
   
In this chapter it was found that a spinning solution containing 16% (w/v) PVA in a synthetic 
MGO solution with a concentration of 11.22 wt %, produced fibres with some beads via free 
surface (needleless) electrospinning. When the polymer concentration was increased to 20% 
(w/v), fibres free from beads were produced over a series of voltages between 65 kV to 75 kV 
and distances from 163 mm to 183 mm. The smallest mean fibre diameters were found in all 
cases when using the aluminium foil substrate. The lowest mean fibre diameter of 155 nm and 
standard deviation of 35 nm was achieved at a voltage of 65 kV and distance of 183 mm. The 
presence of MGO within the PVA fibres was confirmed using both FTIR and 
1
H
-
NMR. The 
antibacterial study revealed that MGO concentrations between 0.65 mg cm
-2
 and 0.83 mg cm
-2
 
were unable to inhibit the growth of E.coli and S.aureus and slight to moderate bacteria growth 
was observed, resulting in limited antibacterial efficiency. As the MGO concentration was 
increased to 1.14 mg cm
-2
 and above, the bacteria growth under the samples was inhibited and a 
good antibacterial effect was achieved. This result also corresponds with the findings of the 
antibacterial work in section 5.3.2, where a similar MGO concentration of 1.50 mg cm
-2
 and 
above was found to inhibit the growth of bacteria. At a lower concentration of 0.75 mg cm
-2
, 
slight bacteria growth was observed with a limited antibacterial efficiency.  
Table 6.6: Differing parameters required for needle and free surface electrospinning, to produce 
6.3 Summary 
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Glutaraldehyde on the Release of 
Methylglyoxal from PVA/MGO Fibres 
  
Chapter 7 Effect of Crosslinking with 
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The release behaviour and kinetics of other antibacterial agents or drugs, from electrospun PVA 
fibres or hydrogels, has been explored in numerous studies as previously discussed in sections 
2.7.1.3 and 2.8.4.2. Although PVA is able to form a hydrogel upon contact with fluid, its ability 
to retain rigidity in water remains poor, as previously shown in section 6.2.3.1. Consequently, 
all of the encapsulated MGO was quickly released from the PVA/MGO webs into the water at 
37ºC within the first 30 min, with no change in the amount of MGO detected over a period of 
one week. To overcome this problem, crosslinking techniques may be expected to assist in 
maintaining the fibrous structure as well as delay the release of the antibacterial agent, as 
discussed in section 2.7.1.3. Of these methods, crosslinking PVA with glutaraldehyde (GA) has 
been demonstrated to be effective, particularly when using GA in a vapour phase (66, 254), 
since this reduces the potential for loss of fibre morphology in aqueous conditions.  
 
Additionally, plasma technology may also offer a potential method to provide crosslinks at the 
PVA fibre surfaces. The plasma technique is described in section 3.2.10. Plasma technology in 
the textile field has become increasingly popular since the 1980s in many research laboratories 
around the world, showing encouraging results for the improvement in various functional 
properties of the fabric. The environmental and energy saving potential of plasma technology 
has many advantages over wet chemistry based textile processing, where large amounts of 
water, energy and effluent are used. Therefore plasma technology has the potential to offer 
many benefits if development to a commercial level is intended (321).  
 
A number of property enhancements can be achieved via plasma treatment, including imparting 
hydrophilic, hydrophobic or oleophobic properties, increasing adhesion, changing the electronic 
conductivity, application of antibacterial agents or fire retardants, anti-shrinkage to wool, 
sterilisation and desizing of cotton. These functions are achieved by the addition or removal of 
materials or chemistry to or from the intended sample via the plasma treatment. Where 
something may be added to a textile, activation of the surface energy may be achieved via the 
introduction of reactive species such as oxygen atoms, which can react with hydrocarbons, 
leading to the formation of chemicals such as H2O and CO2 (322, 356).  
 
Functionalisation of the textile may also be employed via the permanent grafting of functional 
groups on the surface (356). Finally, a very thin film or coating may also be deposited on the 
surface by plasma polymerisation. In this case reactive precursor gases that can polymerise can 
be introduced into the plasma chamber. These gases are broken into radicals that react with each 
other on the surface of the textile sample (322).  
 
7.1 Introduction 
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As plasma technology offers the potential to add functionalisation to the surface of a textile, 
there is a possibility that the introduction of crosslinks on the surface of PVA/MGO electrospun 
webs may also be achieved by employing a GA gas into the plasma chamber to react with the 
hydroxyl groups in the PVA. 
 
The aim of this chapter was therefore to investigate the effect of crosslinking PVA with GA 
vapour and with the aid of plasma, and to alter the release rate of synthetic MGO from the 
electrospun PVA/MGO webs. Where GA vapour crosslinking was employed, the effect of 
crosslinking time on the release of MGO over a period of 24 h was investigated for different 
crosslinking times between 1 h to 48 h.  
 
The swelling behaviour of the GA vapour crosslinked PVA/MGO webs was also investigated. 
Scanning electron microscopy (SEM) was employed to examine the effect of GA vapour 
crosslinking on the morphology of the electrospun webs. As a novel technique, a preliminary 
experimental study using GA plasma treatment on the PVA/MGO webs over a period of 1 h 
was also introduced as a potential new crosslinking system. FTIR analysis was used to confirm 
the presence of GA on the surface of PVA/MGO webs after treatment with GA plasma. In both 
crosslinking systems, the detection of MGO released from the PVA/MGO webs was confirmed 
by reverse phase-high performance liquid chromatography (RV-HPLC).  
An electrospinning solution containing 20% (w/v) PVA and 11.22 wt % synthetic MGO was 
prepared as described in section 6.1.1. Free surface (needleless) electrospinning was carried out 
using an Elmarco Nanospider Lab as described in section 3.2.4.2. A voltage of 65 kV and a 
distance of 183 mm was utilised. Spinning was carried out for 30 min each time to enable the 
sufficient build up of fibres on an aluminium foil collector.  
Crosslinking of the PVA/MGO electrospun webs was carried out via two methods of 
crosslinking described below. Prior to crosslinking with each method, all samples were 
contained within a sealed polythene bag to minimise exposure to variations in ambient moisture. 
Before the samples were subjected to GA vapour treatment, the sample weight was recorded. 
A 40 ml glass beaker was filled with a 25 wt % GA solution and placed inside the desiccator 
chamber. The chamber was then sealed with a lubricated lid to provide an air tight environment, 
and left inside a fume cupboard for 24 h at room temperature. This allowed enough time for the 
GA vapour to saturate the desiccator chamber. The electrospun webs were then attached to a 
7.1.1 Preparation of PVA/MGO electrospun webs 
7.1.2 Crosslinking of PVA/MGO electrospun webs with GA  
7.1.2.1 GA vapour crosslinking using a desiccator chamber 
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metal frame, which was placed inside the desiccator chamber and suspended above the 40 ml 
beaker of GA. Care was taken to avoid any direct contact between the sample and the GA 
solution. The desiccator chamber was sealed once again to provide an air tight environment. 
Separate electrospun webs were left exposed in the saturated chamber for 1, 8, 24 and 48 h. 
Upon removal of the sample from the desiccator chamber, the sample was placed directly into a 
vacuum oven at 50ºC for 24 h to remove any unreacted GA and then contained within a sealed 
polythene bag.   
Plasma treatment with GA was investigated as a potential new crosslinking mechanism, as 
described in section 3.2.10. Only preliminary work was carried out via this experimental 
method due to time constraints in the study. As this was a new technique, preliminary 
experiments were initially performed to decide upon suitable experimental parameters. These 
initial parameters and observations are given in Table 7.1.  
 
The initial experiments were done for 1 h. The valve connecting the GA solution with the 
plasma machine operates in a 10 s time cycle. For the initial experiments (Table 7.1), the valve 
was opened for 2 s (20 % time on) and closed for 8 s during the 10 s time cycles. After exposure 
to plasma power levels between 30 W and 150 W for 1 h, the PVA/MGO webs were shown to 
disintegrate or decrease in weight. This was due to an increase in temperature inside the plasma 
chamber at the higher power levels, causing the PVA/MGO webs to soften and deteriorate. 
From these preliminary findings, a power level of 15 W was identified as being suitable to 
permit further experiments.   
7.1.2.2 GA crosslinking using plasma treatment 
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Power 
(W) 
Time 
cycle 
(s) 
 
Time 
on (%) 
 
Sample 
weight 
prior to 
plasma 
treatment 
(mg) 
Sample 
weight after 
plasma 
treatment 
(mg) 
Percentage 
weight loss 
(%) 
Sample 
observation 
after plasma 
treatment 
150 10 20 825.1 n/a n/a 
Complete 
disintegration 
90 10 20 987.4 256.9 73.9 
Partial 
disintegration 
30 10 20 151.32 100.02 33.9 
Sample 
shrinkage 
15 10 20 243.92 232.82 4.6 
Minor decrease 
in weight (mg) 
 
To detect the presence of GA in the electrospun webs after plasma treatment, ATR-FTIR 
analysis was employed as outlined in section 3.2.6. Electrospun webs were exposed to the 
plasma treatment for 1 h. The treatment was performed with 15 W power and the vaporiser was 
opened for 4 s (in a 10 s time cycle) to allow a greater density of GA. A control sample with no 
plasma treatment was also prepared.  
The GA vapour crosslinked PVA/MGO webs and the GA plasma treated samples were placed 
in a 100ml conical flask containing 20 ml of distilled water at 37ºC. Each conical flask was then 
placed inside a Grant-Bio ES-20 orbital shaker incubator maintained at 37ºC and set to run at a 
speed of 250 r min
-1
. The conical flask was sealed with a rubber stopper to avoid any loss of 
water during shaking. Individual samples crosslinked via GA vapour were allowed to disperse 
for 2, 8 and 24 h. As only limited samples were prepared for the GA plasma treatment, a 
dispersion time of only 8 h was used for these samples. RV-HPLC was used in this study to 
detect the presence of MGO when released from the GA vapour crosslinked PVA/MGO webs 
and the GA plasma treated webs. A detailed description of the RV-HPLC technique can be 
found in section 3.2.9. A calibration curve was obtained for synthetic MGO in aqueous 
solutions by using 0.1 mg ml
-1
, 1 mg ml
-1
, 10 mg ml
-1
 and 20 mg ml
-1
 solutions. 
 
Fig. 7.1 shows the calibration curve obtained. The detectable HPLC retention times of synthetic 
MGO, PVA and GA were all confirmed and can be observed in Table 7.2. It was also important 
to determine that any unreacted GA was not present in the PVA/MGO electrospun webs after 
Table 7.1: Initial experimental parameters using plasma GA treatment. 
7.1.2.3 Characterisation of the GA plasma treated PVA/MGO webs 
7.1.3 Release study of MGO from the GA crosslinked PVA/MGO webs  
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exposure to the vacuum oven. Note that GA is employed as a disinfectant in hospital 
environments (128) and would cause unnecessary complications in a patient should this remain 
in a wound dressing material. During the HPLC analysis, any detection of GA was noted.  
 
 
 
 
Compound Retention Time (min) 
MGO 3.51 to 3.52 
PVA 5.50 to 5.55 
GA 5.17 to 5.20 
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Figure 7.1: Calibration curve of MGO using RV-HPLC. 
Table 7.2: Retention times of MGO, PVA and GA when using RV-HPLC. 
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The swelling behaviour of the GA vapour crosslinked fibres was studied, based on similar 
methods outlined in the current literature (255, 357). PVA/MGO webs crosslinked with GA 
vapour for 1, 8, 24 and 48 h were prepared and the weight of each sample was recorded. The 
sample webs were placed in separate conical flasks containing 20 ml of distilled water at 37ºC 
for 24 h. After removal from the distilled water, the samples were lightly blotted with Whatman 
blotting paper to remove any excess water on the surface. The wetted samples were then 
immediately weighed and the swelling percentage was calculated using the following equation: 
 
Eq. 7.1     
Swelling % = 100 (Ws – Wd) / Wd  
 
where  
Wd  is the weight of the fibres after crosslinking and, 
Ws  is the weight of the swollen fibres after removing any excess water on the surface with 
blotting paper.  
7.1.4 Swelling behaviour of the GA vapour crosslinked PVA/MGO webs 
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The crosslinking reaction between the GA and the PVA is shown in Fig. 7.2. Acetal bridges are 
formed between the hydroxyl groups in the PVA and the difunctional aldehyde molecule of the 
GA (254, 255). The crosslinking reaction between PVA and GA can consist of intramolecular 
and/or intermolecular crosslinks (251, 253). Synthetic MGO will not react with the PVA during 
crosslinking, as the aldehyde group of MGO reacts with water when in solution, forming two 
compounds, methylglyoxal monohydrate and methylglyoxal dihydrate (216) as seen in Fig. 7.3 
(358). Therefore the MGO will remain freely available within the crosslinked PVA fibres.  
 
 
 
methylglyoxal dihydrate (3). 
         
  
(1) (3) (2) 
7.1.5 Results and Discussion 
7.1.5.1 The effect of crosslinking with GA vapour on the PVA/MGO webs 
Figure 7.2: Reaction of PVA with GA(254) 
Figure 7.3: Chemical structure of methylglyoxal (1), methylglyoxal monohydrate (2) and 
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Fig. 7.4 shows the percentage of MGO released from the fibres over a period of 24 h after 
crosslinking times of 1, 8, 24 and 48 h. The percentage release of MGO from the crosslinked 
fibres is based on the calculated mass of MGO available in the fibres prior to crosslinking, using 
Eq. 6.3 in section 6.2.3.1. 
 
To understand the release profile of the MGO from the electrospun webs, SEM micrographs of 
the crosslinked samples before dispersion were taken using a Jeol JSM-6610LV at a 
magnification of 6000, as shown in Fig. 7.5.  
 
It can clearly be observed in Fig. 7.4 that the percentage of MGO released after all crosslinking 
times, increases over a period of 24 h. Interestingly, the sample crosslinked for 8 h showed the 
highest percentage of MGO released between 2 h and 24 h, with a maximum release of 75%. 
The sample crosslinked for only 1 h showed the lowest percentage of MGO released, 35% after 
2 h and 40% after 8 h. The release of MGO after 24 h crosslinking, showed a similar percentage 
release to 8 h crosslinking, with a slight decrease of approximately 5% over 24 h. After 48 h 
crosslinking time the percentage release of MGO has decreased to similar values to the sample 
crosslinked for only 1 h. However, the final amount released at 24 h was 6% less than the 
sample crosslinked for 1 h. 
 
This unusual release profile may be explained by the change in fibre morphology of the 
electrospun webs, as seen in Fig 7.5. Fig. 7.5A shows a PVA/MGO sample with no 
crosslinking. The mean fibre diameter was found to be 155 nm. As the crosslinking time 
increased from 0 h to 1 h the mean fibre diameter increased to 434 nm as is evident in Fig. 7.5B. 
After 8 h crosslinking time, the morphology of the PVA fibres on the surface showed 
intersecting areas where the fibres had merged together (Fig 7.5C). As the crosslinking time 
increased to 24 h, little change in the morphology was obseved (Fig. 7.5D). However, after 48 h 
crosslinking, the fibres appeared to have fused together still further and no visual pores between 
interbonded fibres could be obverved on the surface (Fig. 7.5E). 
 
The reason for this substantial change in fibre morphology, and subsequent release profile of 
MGO from the PVA fibres, may be explained by the high water content present in the 25 wt % 
gluatarldehyde solution during vapour crosslinking. As the crosslinking time increased from 1 h 
to 8 h, the hydrophilic PVA fibres softened and swelled, forming intersecting points and 
interfibre bonding (254). This created a larger surface area in contact with the water during 
dispersion, allowing an increased rate of MGO to diffuse out into the water. As there was little 
difference in the release of MGO at 24 h crosslinking and the morphology of the fibres 
remained similar to those after 8 h crosslinking, the same explanantion may be given. 
7.1.5.2 Release behaviour of MGO from the GA vapour crosslinked fibres 
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However, as the crosslinking time increased to 48 h, the percentage release of MGO was 
decreased. This may be attributed to an increase in the amount of crosslinking between hydroxyl 
groups in the PVA and the difunctional aldehyde molecule of the GA. This will restrict the 
amount of swelling and subsequently reduce the diffusion of MGO into the water.  
 
In a clinical situation, a wound dressing may be expected to sustain a controlled release of 
antibacterial agent into a bacteria critically colonised wound for up to one week . This avoids 
the unnecessary need to change the dressing (21). In this study, after 24 h the amount of MGO 
released for the sample crosslinked for 1 h, where a fibrous structure remained, showed that just 
over half of the MGO (56%) was released. Therefore further testing would need to be carried 
out in future work, in order to determine the percentage release after one week. 
 
 
different crosslinking times. 
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Figure 7.4: Percentage (%) of MGO released from the GA vapour crosslinked PVA/MGO webs for 
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times. A = no crosslinking, B = 1 h, C = 8 h, D = 24 h and E = 48 h. 
  
A B 
C D
E
Figure 7.5: SEM micrographs of PVA/MGO fibres after crosslinking with GA vapour for different 
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As described above, the morphology of the crosslinked samples for 8, 24 and 48 h showed only 
intersecting areas and inter-fibre bonding, allowing for a greater release of MGO in a quicker 
time frame and would be impractical for potential use as part of a controlled delivery system. 
For this reason the swelling of these samples was measured after only 24 h and can be seen in 
Table 7.3. The swelling of the samples crosslinked for 1 h, where the morphology of the web 
had retained a fibrous structure, were studied over a period of 10 days and can be observed in 
Table 7.4. 
 
The results presented in Table 7.3 show that the samples crosslinked for only 1 h, had a mean 
swelling of 124% after 24 h. This was the lowest swelling percentage, when compared with the 
samples crosslinked for 8, 24, and 48 h. As the crosslinking time was increased to 8 h the largest 
swelling percentage was observed with a mean of 405%. This is unusual as previous studies 
have shown that when increasing the crosslinking time, the swelling decreases, due to an 
increased amount of acetal bridges formed between hydroxyl groups in the PVA and the 
difunctional aldehyde molecule of the GA (256). However, in this case, the larger surface area 
in contact with the water after 8 h crosslinking may have facilitated an increase in the amount of 
water into the PVA fibres, allowing for a higher swelling percentage. This also correlates with 
the largest percentage release of MGO for the 8 h crosslinked sample (Fig. 7.4). After 24 h 
crosslinking time the swelling percentage was reduced to a mean of 238% and after 48 h 
crosslinking time the swelling percentage remained similar, with a mean of 256%.  
 
Interestingly the swelling of the samples crosslinked for 1, 8, 24 h, followed a similar 
relationship to the percentage release of MGO and can be seen in Fig. 7.6. This gave further 
evidence that at an increase in crosslinking time between 8 h and 48 h increased the amount of 
crosslinking, resulting in the reduced swelling. The results presented in Table 7.4, show that the 
mean swelling percentage of the PVA/MGO web crosslinked for only 1 h increased from 124% 
after 1 h in water to a mean swelling of 335% after 1 week. After 10 days the negligible increase 
in the mean swelling to 346% confirmed that the GA vapour crosslinked PVA/MGO fibres had 
reached saturation.   
7.1.6 Swelling behaviour of the GA vapour crosslinked PVA/MGO webs 
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Crosslinking 
time (h) 
Wd (Weight 
after 
crosslinking) (g) 
Ws (Weight 
after swelling 
for 24 h) (g) 
Swelling 
(%) 
Mean 
(%) 
STD 
            
1 0.08961 0.16375 82     
1 0.12475 0.2619 109     
1 0.0968 0.35094 262     
1 0.1472 0.20952 42 124 83 
            
8 0.03263 0.15694 380     
8 0.04539 0.18912 316     
8 0.0648 0.37648 480     
8 0.04783 0.25894 441 405 62 
            
24 0.05723 0.22202 287     
24 0.0537 0.1354 152     
24 0.04939 0.1646 233     
24 0.05369 0.20385 279 238 53 
            
48 0.04587 0.13841 201     
48 0.1259 0.40111 218     
48 0.15374 0.59424 286     
48 0.2064 0.86554 319 256 48 
 
  
time. 
Time in water Mean swelling (%) SD 
1 h 124 83 
3 days 291 45 
7 days 335 64 
10 days 346 66 
 
Table 7.3: Swelling % of GA vapour crosslinked PVA/MGO webs after 24 h in water. 
Table 7.4: Swelling (%) of PVA/MGO webs after 10 days in water, for 1 h GA vapour crosslinking 
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crosslinking time (h). 
 
Fig. 7.7 shows the percentage of MGO released from the GA plasma treated samples after 8 h 
dispersion in water. The plasma treatments were done for 1 h at 15 W power. The valve 
connecting the vaporiser to the plasma chamber operates at a 10 s time cycle where the opening 
time of the vaporiser could be varied. In this work, the opening time was varied from 20% (2 s) 
to 80% (8 s). The results indicate that the GA plasma treatment effectively introduced 
crosslinking to the PVA/MGO webs, as the samples did not disintegrate on direct contact with 
water, as the non-crosslinked samples did. The release of MGO from the GA plasma treated 
samples indicated a percentage MGO release of between 47% and 62% after a period of 8 h in 
water. The effect of time on, during plasma treatment had a limited effect on the amount of 
MGO released and further work would need to be carried out to study this further.  
 
Fig. 7.8 shows the FTIR spectra obtained for the PVA/MGO samples exposed to GA plasma 
treatment for 1 h (time on 40%), when compared with a non-crosslinked sample. The large 
broad band observed between 3100 cm
-1 
and 3700 cm
-1 
(region 3) is associated with the 
stretching vibration of the hydroxyl group arising from intermolecular and intramolecular 
hydrogen bonds. The decrease in intensity of this broad band is shown for the GA plasma 
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Figure 7.6: Relationship between the percentage release of MGO (%), mean swelling (%) and 
7.1.6.1 Effect of GA plasma treatment on the PVA/MGO fibres 
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treated sample, indicating the formation of acetal bridges between the hydroxyl groups in the 
PVA and the difunctional aldehyde molecule of the GA (254, 256). The bands between 1600 
cm
-1
 and 1750 cm
-1
 (region 2) can be assigned to the C=O stretching of the unreacted end of the 
aldehyde in the PVA/MGO GA plasma treated sample (256). The heightened peak observed at 
1185 cm
-1 
 (region 1) for the plasma treated sample, may be attributed to the C-O-C vibration of 
the acetal group (256). Two other studies, which looked at the crosslinking of PVA with GA 
vapour, also reported similar spectra with a decrease in band intensity observed at 3330-3350 
cm
-1 
(256) and 3200-3650 cm
-1 
(254) due to the formation of acetal bridges. Peaks were also 
observed between 1700 and 1750 cm
-1
 attributed to the C=O stretching (254) and broadening of 
peaks between1000-1140 cm
-1
 were attributed to C-O-C vibration of the acetal group (254, 
256). This FTIR spectra gave further confidence that GA was successfully introduced to the 
PVA/MGO webs during treatment with GA plasma and further confirmed the delay in the 
release of MGO from the GA plasma treated samples as seen in Fig 7.7, when compared to a 
non-crosslinked sample referred to in section 6.2.3.1.  
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Figure 7.8: FTIR spectra of the GA plasma treated PVA/MGO webs, power of 15 W, treatment 
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The stability of PVA/MGO electrospun fibre webs in water was considerably improved after 
crosslinking using two different approaches, namely a 25 wt % GA vapour and a GA plasma 
treatment. The non-crosslinked samples disintegrated instantly on contact with water, as 
reported in Chapter 6. The overall percentage release of MGO from the GA vapour crosslinked 
PVA/MGO webs progressively increased over a period of 24 h for each crosslinking time, with 
the largest percentage release after 8 h crosslinking time. The SEM images of the GA vapour 
crosslinked PVA/MGO webs revealed an increase in fibre diameter after 1 h crosslinking time 
and inter-fibre bonding and merging was apparent after 8 h crosslinking time. This was due to 
the high water content available in the 25 wt % GA vapour, allowing the fibres to swell and 
provide a larger surface area in contact with the water. The swelling studies also showed a 
similar relationship with the release study, showing the highest swelling percentage to be 
achieved at 8 h crosslinking time. As the crosslinking time was increased to 48 h, the percentage 
of MGO released and the swelling percentage was reduced due to an increase in the acetal 
bridge formation in the PVA fibres.  
 
A small number of experiments were done with the novel GA plasma treatment. The 
experiments showed promising results, with a decrease in the percentage of MGO released 
when compared with a non-crosslinked sample. FTIR analysis provided additional confirmation 
that crosslinking had occurred in the PVA/MGO webs via GA plasma treatment. Although the 
GA plasma experiment was a preliminary study, the results confirmed that this is a promising 
technique for controlling the release rate of MGO from PVA/MGO samples. It is believed that 
this is the first time crosslinking with GA plasma treatment has been employed with a 
successful outcome. Further work is required to explore the effect of different operating 
parameters using plasma technology on crosslinking and MGO release behaviour. 
 
7.2 Summary 
~ 161 ~ 
 
  
Chapter 8 Conclusions and Future Work 
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Electrospun polymeric materials possess valuable properties as potential wound healing 
materials, as a result of their nano to sub-micron fibre diameters which closely mimic the 
topographical extra cellular matrix (ECM) of the skin, while providing conformability to the 
wound site and a scaffold for cellular growth. The high surface and small interfaces promote 
haemostasis to occur naturally, and a high porosity coupled with small pore size provides a 
semi-permeable environment offering protection from external bacteria and breathability. 
Additionally the ability to incorporate antibacterial agents into a polymer matrix also exists.  
 
Manuka honey, a current antibacterial agent utilised in wound dressing materials, provides a 
well documented  antibacterial effect owing in part to one of its constituents, methylglyoxal 
(MGO). Previously, Manuka honey has been coated or impregnated on to nonwoven substrates 
for use in wound care, and this mode of application has been clinically utilised for some time. 
However, this is not a particularly convenient means of delivery given the viscosity and 
adhesiveness of the native material. It also complicates packaging during manufacture as well as 
storage, prior to use. The encapsulation of Manuka honey or MGO within synthetic fibres is 
notionally a more convenient method of delivery, since it involves topical application of a dry 
substrate during wound care, followed by diffusion or release in to the surrounding wound 
environment. The feasibility of this approach has been studied herein as a potentially new 
approach for preparing a wound dressing component. It was established that poly(vinyl alcohol) 
(PVA) a hydrophilic polymer, approved by the FDA for use in humans, has the ability to 
provide a favourable moist wound environment, due to its ability to form a hydrogel on contact 
with water. Accordingly this research investigated the antibacterial properties of synthetic MGO 
as a sole antibacterial compound, and the feasibility of incorporating MGO into polymeric 
electrospun webs using PVA as a carrier. 
 
To provide an understanding of the antibacterial properties of Manuka honey and MGO, 
experiments were first conducted in which both materials were evaluated as coatings onto a 
preformed nonwoven fabric and then after encapsulation in the form of PVA/MGO nano-
fibrous electrospun webs.  
  
Although there have been previous reports on the antibacterial activity of Manuka honey and 
MGO in liquid form or in the form of a Manuka honey dressing, none of them have expressed 
the concentration of MGO required to have an antibacterial effect in terms of unit area, which is 
particularly important in the design and development of a wound dressing material. This study 
provided the first comparison of equivalent MGO concentrations per unit area to provide an 
antibacterial effect when applied as a coating to a nonwoven fabric in the form of Manuka 
honey and synthetic MGO. The antibacterial efficiency was investigated using both BS EN ISO 
8.1 Conclusions 
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20743:2007 (314) and BS EN ISO 20645:2004 (315) to determine if synthetic MGO provided a 
comparable antibacterial effect to Manuka honey. In the first instance, the bacteria inoculated 
samples were immersed in 20 ml of simulated wound exudate fluid where a relatively high 
moisture content was available to facilitate the diffusion of MGO. It was found that an MGO 
concentration of 0.0054 mg cm
-2
 for both Manuka honey and synthetic MGO was sufficient to 
 
Experiments using bacteria seeded agar plates, found that higher concentrations of MGO 
between 0.0170 mg cm
-2
 and 0.1 mg cm
-2
 were required to produce a good antibacterial effect 
affinity of lyocell fibres for water, is believed to be responsible for the differing MGO 
concentrations needed to produce an antibacterial effect. In the case of BS EN ISO 20743:2007, 
a high moisture content is available due to the addition of 20 ml of SCDLP, which is likely to 
encourage the hydration of the lyocell fibres and facilitate MGO diffusion, when compared to 
BS EN ISO 20645:2004, where limited moisture content is available from the agar plates.  
 
The Manuka honey coated nonwovens were shown to produce zones of inhibition at relatively 
low MGO concentrations between 0.1 mg cm
-2 
and 0.2 mg cm
-2
, when compared with the 
synthetic MGO coated nonwovens, where clear zones of inhibition were not apparent until a 
-2 -2 
where the Manuka honey coating is likely to soften and allow greater diffusion into the bacteria 
seeded agar from the fibres, when compared to the less viscous synthetic MGO coating, which 
is retained by the lyocell fibres. Manuka honey also contains hydrogen peroxide, which may 
also heighten the antibacterial effect, when compared with synthetic MGO. 
 
Assessment of the minimum inhibitory concentrations (MIC) and minimum bactericidal 
concentrations (MBC) of MGO in liquid form, was achieved via a standard laboratory protocol 
in accordance with the Clinical and Laboratories Standards Institute (CLSI). Three of the most 
previously reported in the current literature when in a planktonic state. The MIC and MBC for 
S.aureus was found comparable to previous studies with the exception of one, where a 
concentration of approximately four times higher than that found in this study, had a 
reported for the first time. 
achieve 100% reduction in bacteria when tested against Gram positive S.aureus and Gram 
negative K.pneumonia.  
against E.coli and S.aureus. The variation in moisture content in each method of test and the 
concentration of 0.4 mg cm  of MGO was achieved for E.coli and 0.8 mg cm of MGO for 
S.aureus. This difference was attributed to the incubation of the samples at 37ºC during testing, 
common bacterial strains found in chronic wounds, including S.aureus, P.aeuroginosa and 
E.faecalis were assessed. Limited studies have previously been reported on the MIC and MBC 
bactericidal effect. Notably in this study, the MIC and MBC of MGO against E.faecalis was 
of MGO. In this study the MIC and MBC against P.aeuroginosa were found be lower than that 
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The production of the electrospun webs was explored using both needle and free surface 
(needleless) electrospinning technologies, where the parameters of each process was governed 
to determine the most favourable conditions in producing fibres free from defects. Synthetic 
MGO was successfully encapsulated in PVA electrospun webs using both electrospinning 
techniques. It could not be assumed that the conditions required for optimal needle-based 
electrospinning of PVA/MGO fibres could be directly translated to free surface electrospinning 
because of the substantial differences in the design of the electrodes used by each method. The 
different conditions required by each system are rarely reported in the literature. Therefore, the 
spinning of PVA/MGO was explored by both methods for the first time.  
 
A number of synthetic MGO and PVA concentrations in water were initially examined to 
determine the optimum spinning solution. In the case of needle electrospinning, an 11.22 wt % 
MGO solution with a 16% (w/v) PVA concentration was most favourable for producing fibres 
free from defects, observed via scanning electron microscopy (SEM). It was found that a 
voltage of 15 kV and a distance of 15 cm between the needle tip and an aluminium foil 
collector, produced the smallest mean fibre diameter of 157 nm. At a concentration of 20% 
(w/v) PVA, needle blockage occurred due to a high viscosity of 2634 cP and slow flow rate of 
0.1 ml h
-1
 allowing the polymer to dry at the needle tip.  
 
When using free surface needle electrospinning, a PVA concentration of 20% (w/v) was found 
to be needed to eliminate any beads in the resultant fibres when compared to a 16% (w/v) PVA 
concentration, where some beads were observed. During free surface electrospinning, unlike in 
needle based electrospinning, the 20% (w/v) PVA solution was kept under constant agitation 
because of the rotation of the electrode, allowing the polymer chains to move freely and become 
easily stretched by the electrostatic force. Larger voltages between 65 kV and 75 kV were 
required to initiate electrospinning jets from the wire electrode, when compared with needle 
electrospinning, where a voltage above 18 kV produced sparking due to the highly conductive 
nature of the aluminium collector and metal needle tip. It is thought that the larger voltage of 65 
kV, when using free surface electrospinning was achieved due to the immersion of the wire 
electrode in a less conductive polymer solution.  The smallest mean fibre diameter of 155 nm 
was produced at a voltage of 65 kV and a distance of 183 mm between the wire electrode and an 
aluminium foil collector. 
 
For practical assembly of a wound dressing component as part of a continuous process it is 
important to establish conditions that will allow fibres to be directly deposited on to a preformed 
nonwoven substrate, rather than on to metal foil, which is the most commonly used collector 
reported in the literature. Therefore, direct deposition on to a preformed nonwoven substrate 
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was also explored in the current work. It was established that use of an aluminium foil substrate 
produced fibres with a smaller mean fibre diameter due to an increased electric field when 
compared with a non-conducting nonwoven substrate (polypropylene spunbond), where 
repulsive forces act upon the resultant fibres during deposition, reducing the stretching of the 
viscoelastic jet. The findings were found to be consistent with the results of previous studies, in 
which up to eight different collector substrates were examined for their effect on resultant fibre 
morphology.  
 
FTIR and 
1
H-NMR confirmed the successful incorporation of MGO within the PVA fibres, 
which highlighted the carbonyl groups associated with MGO’s keto-aldeyde groups. The 
antibacterial evaluation of the PVA/MGO electrospun webs, further confirmed the presence of 
MGO using BS EN ISO 20645:2004 when compared to a PVA only electrospun web, where no 
antibacterial activity was observed.  
 
It was also established that the composition of the polymer substrate used to deliver the MGO or 
Manuka honey is likely to affect the concentration needed to produce an antibacterial effect. 
The antibacterial evaluation of both needle and free surface PVA/MGO electrospun webs 
confirmed that similar MGO concentrations of 1.50 mg cm
-2
 and 1.14 mg cm
-2
 respectively, 
higher when compared to the coated nonwoven samples due to the encapsulation of MGO 
within the PVA fibres allowing for a slower diffusion rate into the agar.  
 
Depending on their molecular structure, water soluble PVA fibres can dissolve within a few 
hours, or instantaneously on contact with water, as they did so in this study. It is an important 
requirement for a bioactive wound dressing material to be able to maintain a stable structure, 
while providing a controlled and sustained release of antibacterial agent into the wound bed up 
to a period of one week. To overcome the instability of PVA in water, crosslinking with GA in 
previous studies has shown the potential to control the stability of PVA and reduce the release 
of any supplementary compounds within the fibre matrix. In this study crosslinking with GA 
was successfully carried out via two different processes including vapour crosslinking and a 
novel technique with plasma technology, which to the author’s knowledge has not been 
previously reported in the literature.  
 
The percentage release of MGO from the GA vapour crosslinked PVA/MGO webs was detected 
using reverse phase high performance liquid chromatography (RV-HPLC). 93.7% MGO of that 
assumed in the PVA/MGO webs was released within 30 minutes from the non-crosslinked 
samples. A considerable reduction in the percentage release of MGO from the crosslinked 
PVA/MGO webs was observed over a period of 24 h. A noticeable change in the fibre 
provided a good antibacterial effect in-vitro. These concentrations were found to be noticeably 
~ 166 ~ 
 
morphology was shown with an increase in crosslinking time, resulting in an enlarged mean 
fibre diameter after 1 h crosslinking time when compared to a non-crosslinked sample.  
 
An increased surface area was observed between 8 h and 48 h crosslinking time where merging 
and inter-fibre bonding occurred. This was attributed to the swelling of the PVA/MGO fibres in 
the GA vapour, where a high water content was available. The swelling percentage of the 
vapour crosslinked fibres showed a similar relationship to the percentage release of MGO after 
different crosslinking times, where the highest swelling was shown to provide the highest 
percentage release of MGO.  
 
Initial experiments with GA plasma treatment were shown to effectively crosslink the 
PVA/MGO webs, where confirmation with FTIR analysis showed elevated and reduced peaks 
as a result of GA plasma treatment, when compared to a non-plasma treated sample. The 
stability of the PVA/MGO webs in water was shown to improve, slowing the release of MGO 
when compared to the non-crosslinked sample. To the authors knowledge this is the first time 
that GA plasma technology has been employed as a novel crosslinking technique, and provides 
a promising new approach to controlling the release of MGO from PVA electrospun webs. 
 
A number of additional areas of study can be identified for future work, that will help in the 
further understanding of MGO as an antibacterial agent as well as providing greater 
understanding of the release kinetics of MGO from electrospun PVA webs. 
 
 The antibacterial evaluation of MGO against multiple bacteria organisms, when applied 
as a coating to a nonwoven fabric and when incorporated within electrospun PVA webs 
would provide further insight into the bacteriostatic and bactericidal performance of 
MGO as an antibacterial agent in wound care. BS EN ISO 20743:2007 and BS EN ISO 
20645:2004 could be modified to provide this data.  
 Electrospinning of co-polymer solutions with differing mechanical and physical 
properties, suitable for wound healing applications, may provide an alternative approach 
in the controlled release of MGO into a wound site. 
 GA vapour crosslinking times between 1 h and 8 h and variations in GA concentration 
would give further insight into the conditions at which the fibrous morphology of spun 
webs transforms to merging and inter-bonding areas.  
8.2 Suggestions for future work 
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 The vapour crosslinking study provided a release profile of MGO after 24 h. Clinically, 
a dressing could potentially extend beyond the 3-4 day maximum that is often 
encountered in practice. A release profile up to 7-10 days would be valuable to explore. 
 The current study involved a preliminary experiment in which a novel GA plasma 
approach was explored. Extensive research could be employed in this area, to further 
understand the effects of different operating parameters and GA concentration on the 
crosslinking and release of MGO from PVA/MGO fibres. There is also the potential to 
assess a variety of crosslinking agents and polymeric materials.   
 A release study of MGO from the crosslinked PVA/MGO electrospun webs using BS 
EN ISO 20645:2004 or BS EN ISO 20743:2007 over a period of one week, would offer 
a useful insight into the effect of differing antibacterial conditions on the delivery of the 
MGO into a wound environment.  
 On the understanding that Manuka honey contains MGO and additional antibacterial 
compounds, such as hydrogen peroxide, a study into the electrospinning of Manuka 
honey/PVA fibres and their antibacterial properties compared to PVA/MGO fibres 
would be of interest. 
 Study the adherence properties of the PVA/MGO webs via a simulated wound model.  
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Appendix A: 
Supplementary data is given for Tables 4.4 and 4.5 in Chapter 4. 
  Zone Diameter Measurements (mm)   
Mean zone 
of 
inhibition 
(mm) 
MGO 
concentration 
on sample (mg 
cm-2) 
1 2 3 4 
Mean diameter 
across the 
sample and zone 
of inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on Eq. 
3.5 (mm) 
                
0.20 
32 32 31.5 32.5 32.0 1 
1.58 34 33 33.5 33.5 33.5 1.75 
34 34 34 34 34.0 2 
0.15 
30 30 30 30 30.0 0 
0.75 32 32 31.5 32.5 32.0 1 
32 33 32.5 32.5 32.5 1.25 
0.10 
31 31 31 31 31.0 0.5 
0.42 31 32 31.5 31.5 31.5 0.75 
30 30 30 30 30.0 0 
0.0170 ----- ----- ----- ----- N/A N/A N/A 
0.0054 ----- ----- ----- ----- N/A N/A N/A 
 
  Zone Diameter Measurements   
Mean zone 
of 
inhibition 
(mm) 
MGO 
concentration 
on sample 
(mgcm
2
) 
1 2 3 4 
Mean diameter 
across the 
sample and zone 
of inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on Eq. 
3.5 (mm) 
                
1.20 
41 38 40 39 39.5 4.75 
4.50 36 37 36.5 36.5 36.5 3.25 
41 41 40.5 41.5 41.0 5.50 
0.80 
32 33 32.5 32.5 32.5 1.25 
2.17 33 32 33 32 32.5 1.25 
38 38 37.5 38.5 38.0 4.00 
0.40 
31 31 31 31 31.0 0.50 
1.00 33 33 32.5 33.5 33.0 1.50 
31 33 33 31 32.0 1.00 
0.20 ----- ----- ----- ----- N/A N/A N/A 
0.15 ----- ----- ----- ----- N/A N/A N/A 
0.10 ----- ----- ----- ----- N/A N/A N/A 
Table A.1: Zone of inhibition measurements for the Manuka honey coated samples, against E.coli. 
Table A.2: Zone of inhibition measurements for the synthetic MGO coated samples, against E.coli. 
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Table A.3: Zone of inhibition measurements for the Manuka honey coated samples, against 
  Zone Diameter Measurements (mm)   
Mean zone 
of 
inhibition 
(mm) 
MGO 
concentration 
on sample (mg 
cm-2) 
1 2 3 4 
Mean diameter 
across the 
sample and zone 
of inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on Eq. 
3.5 (mm) 
                
0.20 
36 37 36.5 36.5 36.5 3.25 
3.08 36 35 35.5 35.5 35.5 2.75 
37 36 37 36 36.5 3.25 
0.15 
31 31 31 31 31.0 0.5 
1.58 34 33 33.5 33.5 33.5 1.75 
35 35 34.5 35.5 35.0 2.5 
0.10 
31 31 31 31 31.0 0.5 
0.17 30 30 30 30 30 0 
30 30 30 30 30 0 
0.0170 ----- ----- ----- ----- N/A N/A N/A 
0.0054 ----- ----- ----- ----- N/A N/A N/A 
 
Table A.4: Zone of inhibition measurements for the synthetic MGO coated samples, against 
  Zone Diameter Measurements   
Mean zone 
of 
inhibition 
(mm) 
MGO 
concentration 
on sample 
(mg/cm2) 
1 2 3 4 
Mean diameter 
across the 
sample and zone 
of inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on Eq. 
3.5 (mm) 
                
1.20 
38 41 39 40 39.5 4.75 
4.50 39 37 38.5 37.5 38.0 4 
39 40 40 39 39.5 4.75 
0.80 
37 38 37.5 37.5 37.5 3.75 
3.08 38 36 35.5 36.5 36.5 3.25 
34 35 35 34 34.5 2.25 
0.40 
----- ----- ----- ----- N/A N/A 
N/A ----- ----- ----- ----- N/A N/A 
----- ----- ----- ----- N/A N/A 
0.20 ----- ----- ----- ----- N/A N/A N/A 
0.15 ----- ----- ----- ----- N/A N/A N/A 
0.10 ----- ----- ----- ----- N/A N/A N/A 
 
S.aureus. 
S.aureus. 
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Appendix B: 
Supplementary data is given for Figure 5.2 in Chapter 5. 
Table B.1: Viscosity measurements of PVA/MGO solutions at different concentrations. A spindle size of 31 was used with 9ml of fluid. 
  PVA concentration (% w/v) 
  16 18 20 14 16 18 20 12 14 16 18 8 10 12 14 16 
  MGO concentration (wt %) 
  No MGO 11.22 14.76 21.57 
Speed     
(r min
-1
) 
Viscosity (cP) 
100 ---- ---- ---- 287 ---- ---- ---- 355 ---- ---- ---- 237 277 ---- ---- ---- 
60 501 ---- ---- 299 483 ---- ---- 357 ---- ---- ---- 237 280 415 ---- ---- 
50 518 ---- ---- 305 490 ---- ---- 358 719 ---- ---- 239 282 416 ---- ---- 
30 525 ---- ---- 321 512 ---- ---- 360 730 ---- ---- 240 283 419 ---- ---- 
20 563 970 ---- 334 535 1063 ---- 362 749 1387 ---- 243 286 421 ---- ---- 
12 589 1011 ---- 355 575 1127 ---- 367 763 1401 ---- 250 291 427 1213 ---- 
10 621 1030 2180 366 585 1146 2624 371 774 1415 ---- 258 295 432 1230 ---- 
6 636 1089 2193 380 605 1210 2634 374 783 1421 3147 260 301 435 1245 3864 
5 655 1131 2210 ---- 630 1242 2651 ---- 791 1441 3141 ---- 306 444 1257 3857 
4 672 1147 2217 ---- 652 1282 2662 ---- 802 1480 3162 ---- ---- 465 1261 3884 
3 ---- 1179 2240 ---- ---- 1320 2699 ---- ---- 1490 3191 ---- ---- 490 1273 3919 
2.5 ---- 1213 2250 ---- ---- 1340 2700 ---- ---- 1501 3203 ---- ---- ---- 1290 3900 
2 ---- 1245 2261 ---- ---- 1380 2710 ---- ---- ---- 3215 ---- ---- ---- ---- 3891 
1.5 ---- ---- 2266 ---- ---- ---- 2720 ---- ---- ---- 3275 ---- ---- ---- ---- 3880 
1 ---- ---- 2272 ---- ---- ---- 2730 ---- ---- ---- ---- ---- ---- ---- ---- 3840 
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Supplementary data is given for Figure 5.11 in Chapter 5. 
    Sample Diameter Measurements Zone Diameter Measurements   
Time spun 
(h) 
Mass of 
MGO 
based on 
Eq.5.1  
(mg cm
-
²) 
1 2 3 4 
Mean 
sample 
diameter 
for testing 
(mm) 
1 2 3 4 
Mean diameter 
across the 
sample and 
zone of 
inhibition  
(mm) 
Calculated zone 
of inhibition 
based on  
Eq. 3.5  
(mm) 
                          
0.5 0.75 30 30 30 30 30 30 30 30 30 30 0 
1 1.50 30 30 30 30 30 32 32.5 31.5 32 32 1 
2 3.00 30 29.5 30.5 30 30 34.5 35 35.5 37 35.5 2.75 
3 4.50 30 32.5 32.5 35 32.5 43.5 43 42.5 43 43 5.25 
4 6.00 30 30 30 30 30 49 48 48 47 48 9 
 
 
    Sample Diameter Measurements Zone Diameter Measurements   
Time spun 
(h) 
Mass of 
MGO 
based on 
Eq.5.1  
(mg cm
-
²) 
1 2 3 4 
Mean 
sample 
diameter 
for testing 
(mm) 
1 2 3 4 
Mean diameter 
across the 
sample and 
zone of 
inhibition  
(mm) 
Calculated zone 
of inhibition 
based on  
Eq. 3.5  
(mm) 
                          
0.5 0.75 30 30 30 30 30 30 30 30 30 30 0 
1 1.50 30 30 30 30 30 32 32.5 32 31.5 32 1 
2 3.00 30 29.5 30.5 30 30 38 39 37.5 39.5 38.5 4.25 
3 4.50 30 30.5 29.5 30 30 41.5 44 42 42.5 42.5 6.25 
4 6.00 30 30 30 30 30 45 46 45.5 45.5 45.5 7.75 
  
Table B.2: Needle electrospun sample measurements and zone of inhibition measurements, against Ecoli. 
Table B.3: Needle elctrospun sample measurements and zone of inhibition measurements, against S.aureus. 
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Appendix C: 
Supplementary data is given for Figure 6.7 in Chapter 6. 
  Sample Diameter Measurements Zone Diameter Measurements   
MGO in 
fibres 
based on 
Eq.6.2 
(mg) 
 MGO per 
unit area 
based on 
Eq.6.3  
(mg cm
-2
) 
Weight 
of spun 
web 
(mg) 
1 2 3 4 
Mean 
sample 
diameter 
for testing 
(mm) 
1 2 3 4 
Mean 
diameter 
across the 
sample and 
zone of 
inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on 
Eq. 3.5 
(mm) 
                            
10 24 25 27 28 26.0 ----- ----- ----- ----- No Zone ----- 3.46 0.65 
20 25 24 26 25 25.0 21.5 22 21 21.5 21.5 -1.75 6.92 1.41 
30 24 24 25 23 24.0 25.5 24.5 26 25 25.3 0.63 17.29 3.82 
40 29.5 30 28 28.5 29.0 33.5 34.5 35 31 33.5 2.25 34.58 5.24 
50 32 31 29 28 30.0 36 37 37 36 36.5 3.25 51.87 7.34 
  
Table C.1: Free surface (needleless) electrospun sample measurements and zone of inhibition measurements, against Ecoli. 
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  Sample Diameter Measurements Zone Diameter Measurements   
MGO in 
fibres 
based on 
Eq.6.2 
(mg) 
 MGO per 
unit area 
based on 
Eq.6.3  
(mg cm
-2
) 
Weight 
of spun 
web 
(mg) 
1 2 3 4 
Mean 
sample 
diameter 
for testing 
(mm) 
1 2 3 4 
Mean 
diameter 
across the 
sample and 
zone of 
inhibition 
(mm) 
Calculated 
zone of 
inhibition 
based on 
Eq. 3.5 
(mm) 
                            
10 22 23 23 24 23.0 ----- ----- ----- ----- No Zone ----- 3.46 0.83 
20 21 19 20 20 20.0 17 16 19 20 18.0 -1 6.92 2.20 
30 30 27 28 29 28.5 28 28.5 27.5 28 28.0 -0.25 17.29 2.71 
40 31 33 30.5 33.5 32.0 36.5 34 33.5 34 34.5 1.25 34.58 4.30 
50 29 30 31 30 30.0 34 33 35.5 33.5 34.0 2 51.87 7.34 
Table C.2: Free surface (needleless) electrospun sample measurements and zone of inhibition measurements, against S.aureus. 
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Appendix D: 
Supplementary data is given for Figures 7.4 and 7.7 in Chapter 7. 
Table D.1:Percentage of MGO released from the GA vapour crosslinked PVA/MGO webs for 
different crosslinking times .  
Crosslinking 
time (h) 
Dispersion 
time (h) 
Weight of 
fibres 
before 
crosslinking 
(mg) 
Amount of 
MGO in 
fibres based 
on Eq. 6.3 
(mg) 
MGO 
released 
based on 
HPLC 
analysis 
(mg) 
Percentage 
of MGO 
released 
from fibres    
(%) 
1 2 565.40 195.52 63.89 33 
1 8 1074.10 371.43 150.20 40 
1 24 750.10 259.39 144.08 56 
8 2 333.32 115.26 73.40 64 
8 8 153.58 53.11 36.62 69 
8 24 300.23 103.82 78.36 75 
24 2 324.08 112.07 66.92 60 
24 8 156.47 54.11 36.42 67 
24 24 140.53 48.60 33.64 69 
48 2 396.05 136.96 47.60 35 
48 8 171.55 59.32 28.16 47 
48 24 216.66 74.92 37.80 50 
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Table D.2:Percentage (%) of MGO release from the GA plasma treated PVA/MGO webs after 8 h in water. 
Power 
(W) 
Time 
cycle 
(sec) 
Time 
on (%) 
Crosslinking 
time (h) 
Dispersion 
time (h) 
Weight of 
fibres 
before 
crosslinking 
(mg) 
Amount of 
MGO in 
fibres based 
on Eq. 6.3 
(mg) 
MGO 
released 
based on 
HPLC 
analysis 
(mg) 
Percentage 
of MGO 
released 
from fibres 
(%) 
15 10 20 1 8 243.92 84.35 39.82 47 
15 10 40 1 8 293.19 101.39 53.70 53 
15 10 60 1 8 284.52 98.39 52.10 53 
15 10 80 1 8 354.67 122.65 75.48 62 
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